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SUMM ARY
1. The platelet responses to adenosine 5’-diphosphate (ADP) and ADP-induced 
signal transduction involved in mediating the platelet responses are reviewed. The 
current knowledge of P2 purinoceptor classification is summarised and the current 
model of platelet activation involving multiple ADP receptors is discussed.
2. The structure-activity relationships for several analogues of adenine nucleotides in 
causing aggregation and shape change were compared in washed platelets using 
an aggregometer. In general, the structure-activity relationships for both responses 
were similar, but for some analogues differences were observed. Adenosine 5’-0- 
(1-thiodiphosphate) (ADPaS) and adenosine 5’-0-(2-thiodiphosphate) (ADP{3S) 
were much more potent agonists relative to ADP for shape change than for 
aggregation and indeed ADPaS antagonized ADP-induced aggregation. 2- 
Methylthioadenosine 5’-triphosphate (2-MeSATP) also had different effects in 
aggregation and shape change, being a much higher affinity antagonist of 
aggregation than of shape change. These results support the suggestion that these 
two responses are mediated by multiple ADP receptors on human platelets, and 
are consistent with shape change being mediated via one receptor (the P2Yi 
receptor) with aggregation requiring the activation of two receptors (the P2Yi and 
the P2Y ac receptors).
3. The effects of adenosine 3’-phosphate 5’-phosphosulfate (A3P5PS) which has 
been proposed to be a selective antagonist at P2Yi receptors, were tested on the 
responses of human platelets to ADP. A3P5PS selectively antagonised in an 
apparently competitive manner ADP-induced platelet aggregation, as well as the 
ability of ADP to cause shape change and increases in [Ca2+]i in platelets, but had 
no effect on the inhibition of stimulated adenylate cyclase by ADP, confirming 
suggestions that this response is mediated by means of a different receptor 
subtype.
4. These studies using washed platelets indicated different effects of ADPaS, 
ADPpS and 2-MeSATP on aggregation between washed platelets in buffer and
2
unwashed platelets in plasma. To see whether the different responses between 
washed platelets and platelets in plasma is caused by some factors in plasma, or 
by the process of washing resulting in receptor desensitization, washed platelets 
were resuspended in plasma and the effects of ADPaS, ADPpS and 2-MeSATP 
were simultaneously compared both in unwashed platelets and in washed platelets 
in plasma. The extent of aggregation induced by ADPaS or ADPJ3S, which act as 
agonists preferentially on the P2Y i receptor, was not affected by the presence of 
plasma, but was decreased by the washing procedure, suggesting that the P2Yi 
receptor is desensitized by washing. Unlike ADPaS and ADPpS, the extent of 
response to ADP in the presence of 2-MeSATP, which acts preferentially on the 
P2YAc receptor, appeared to be affected by the presence of plasma rather than by 
the process of washing as if the plasma restores the ability of P2Yi receptor to 
induce some aggregation alone.
5. The effects of platelets on cultured human vascular smooth muscle cells were 
investigated using explant cultures of human saphenous vein vascular smooth 
muscle as the experimental material. Released products from activated and non­
activated platelets were tested for their effects on [3H]-thymidine incorporation 
into the human smooth muscle cells to see their effects on the proliferation of 
smooth muscle cells, and phosphoinositide hydrolysis was measured to see if the 
effects on smooth muscle cell proliferation involve the phosphoinositide signaling 
pathway. No marked effects on smooth muscle cell proliferation were shown by 
ADP or by adenosine 5’-triphosphate (ATP) alone, but ADP and ATP increased 
smooth muscle cell proliferation in synergy with platelet-derived growth factor 
(PDGF). Aggregated and non-aggregated platelets caused increases in the 
proliferation of vascular smooth muscle cells with aggregated platelets showing a 
greater effect than non-aggregated platelets although the stimulatory effects were 
markedly decreased by an increased density of platelets. The effect of platelet- 
derived products on smooth muscle cells was not observed for phosphoinositide 
hydrolysis, suggesting that the effect of aggregated platelets on smooth muscle 
cell proliferation is not due to phosphoinositide turnover.
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CHAPTER 1. 
GENERAL INTRODUCTION
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1.1 M orphology and functions of platelets
1.1.1 Morphology
Platelets are the smallest cells among the constituent cells in blood and are non-nucleated. 
Due to this size and simplicity of structure, platelets were the last cells among the blood 
cells to be recognised as a distinct cell type and investigated, and it has become clear that 
the mechanisms responsible for platelet activation are highly complex. Platelet 
ultrastructure has been examined utilizing various techniques (See White, 1992). Platelets 
in circulating blood and in well-prepared plasma are round or oval, biconvex discs in 
shape varying in size from about 1.5-3.5 pm in diameter. This is about 20-50% of the size 
of average erythrocytes (7.2 pm in diameter) (Burkitt et al., 1993). As shown in figure
1 .1 , the outermost features of the platelet form the peripheral zone, consisting of a 
glycocalyx and the plasma membrane itself. Platelets have a well developed cytoskeleton. 
Beneath the cell periphery is a marginal band of micro tubules which depolymerise at the 
onset of platelet aggregation. The cytoplasm is also rich in the contractile proteins actin 
and myosin and other filamentous elements, all probably involved in the functions of clot 
retraction and extrusion of granule contents. There are two internal membrane networks 
in platelets, the surface connected open-canalicular system (OCS) and the dense tubular 
system (DTS). The OCS provides an access to the deep interior of the cells for plasma- 
borne substances and greatly increases the surface area for secretion of platelet products. 
The DTS, analogous to the endoplasmic reticulum of other cell types, contains an active 
uptake system, Ca2+-ATPase, which allows it to accumulate calcium from the cytoplasm 
(Cutler et al., 1978; Kaser-Glanzmann et al., 1978) and the DTS is the most likely 
candidate for the calcium-sequestering internal organelle (Skaer et al., 1974). Platelets 
contain most of the cytoplasmic organelles of other cells including mitochondria, 
microtubules, glycogen granules, occasional Golgi elements and ribosomes as well as 
enzyme systems for both aerobic and anaerobic respiration. According to the 
electromicrographs of Burkitt et al. (1993), the most conspicuous organelles are the 
electron-dense granules which constitute about 20% of platelet volume and are of four 
types: a-granules, dense granules, lysosomes and peroxisomes. a-Granules are variable
18
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ill size and shape and contain two proteins exclusive to platelets, namely, platelet factor 
IV and (3-thromboglobulin. These granules also contain coagulation factors, such as 
fibrinogen, factor V, factor VIII, von Willebrand factor, and other proteins including 
fibronectin, thrombospondin, platelet-derived growth factor and other growth factors 
(Harrison and Cramer, 1993). Dense granules are very electron-dense and contain 5- 
hydroxytryptamine (5-HT), which is not synthesized by platelets or their precursors but is 
absorbed from the plasma having been produced by enterochromaffin cells of the gut 
(Plescher et al., 1971). They also contain adenine nucleotides (ADP and ATP), Ca2+ and 
Mg2+ (Martin et al., 1974; Meyers et al., 1982; Skaer et al., 1974). Lysosomes are 
membrane-bound vesicles distinct from the a-granules and contain lysosomal enzymes. 
The contents of lysosomes are released only after the platelets are stimulated with 
powerful aggregating agents such as thrombin and collagen. Peroxisomes are small in 
number and have peroxidase activity. In addition to these electromicrographically 
obvious organelles, mitochondria and glycogen granules are also found in platelets. 
Mitochondria with sparse cristae are responsible for the maintenance of adequate ATP 
levels, since metabolic energy is required for all stages of platelet activation. Glycogen 
granules serve as an energy reserve for glycolysis .
1.1.2 Functions
The major function of the blood platelets is in the process of haemostasis. Haemostasis is 
the prevention of bleeding from damaged blood vessels. Disc shaped platelets circulating 
in nonadhesive state do not adhere to each other or to other normal, undamaged, and 
unstimulated cells. The endothelium lining the blood vessels is nonthrombogenic and 
platelets do not adhere to it. However, when blood vessels are severed, circulating 
platelets adhere to components of the exposed subendothelium, e.g. collagen, which 
causes platelets to activate. Activated platelets release ADP, 5-HT, thromboxane A2, and 
other substances. These substances cause the platelets to expose the binding sites for 
fibrinogen, glycoprotein (GP) nb/IIIa, on their surfaces and thus to cause aggregation 
(figure 1.2). Aggregation involves links formed by fibrinogen binding to the GP Ilb/IIIa 
receptors on adjacent platelets. Platelet aggregates form a surface upon which the
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coagulation cascade can be initiated. The coagulation cascade results in the generation of 
thrombin. Thrombin is another potent platelet activator, amplifying the haemostatic 
process and is also the enzyme which converts fibrinogen into fibrin, resulting in 
consolidating the plug.
Two major results from dysfunction and malfunction of platelets are bleeding disorders 
and vascular disease. Patients with an abnormally low number of platelets, called  ^
thrombocytopenia, or whose platelets do not function properly for some reason, suffer 
from bleeding disorders. The role of platelets in vascular disease occurs through 
atherosclerosis and thrombosis. Thrombosis is the pathological formation of an unwanted 
haemostatic plug or thrombus but the mechanism is basically the same as that of 
haemostasis. It is the acute event that vascular disease leads up to. Atherosclerosis is one 
example of vascular disease, where platelets play a role both by forming arterial thrombi, 
which develop into atherosclerotic plaques, and by secreting mitogenic factors, e.g. 
platelet-derived growth factors, which stimulate the proliferation of cells in the vessel 
walls (Ross et al., 1986; Ross, 1988a,b).
ADP is known to play a major role in platelet activation. It was the first low molecular 
weight platelet aggregating agent to be identified (Gaarder et al., 1961). When platelets 
are stimulated by other aggregating agents such as thrombin or collagen, ADP, which is 
contained at very high concentrations (~1M) in the platelet dense granule, is released to 
reinforce platelet aggregation. In addition, low concentrations of ADP potentiate and 
amplify the effects of all other agents, especially weak agonists such as adrenaline or 5- 
HT (Siess, 1989). It has been reported that there is a congenital defect of platelet function 
caused by selective impairment of platelet responses to ADP (Cattaneo et al, 1992). 
Platelet aggregation by ADP is also implicated in the development and extension of 
arterial thrombosis. Specific inhibitors of the ADP activation pathway such as the 
antiaggregatory thienopyridine compounds ticlopidine and clopidogrel are clinically used 
as antithrombotic drugs (Schror, 1993). It is obvious that a further knowledge of the ADP 
platelet activation mechanism is essential for the better understanding of haemostasis and 
for pharmaceutical development of new antithrombotic drugs.
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1.2 Platelet responses to ADP
Platelets encounter a number of different aggregating agents in the circulation, such as 
thrombin, ADP, collagen, thromboxane Aa, platelet-activating factor, 5-HT, adrenaline, 
and vasopressin. ADP is released from storage granules of stimulated platelets and may 
also enter the circulation as the result of rupture of red blood cells or endothelium 
(Born et al., 1976; Born and Kratzer, 1984; Born, 1985). ADP affects other platelets, 
causing them to change shape, extend pseudopods and adhere to the platelets on the 
damaged surface, what is followed by activation of GP Ilb/IIIa so that it becomes the 
receptor for fibrinogen, which binds in the presence of Ca2+ and forms bridges between 
adjacent, stimulated platelets to cause aggregation.
Shape change
The shape change is noted at a very early stage when platelets are activated by ADP. It 
occurs in the first few seconds after platelet activation and is characterized by a change in 
the appearance of platelets in plasma. The normally discoid circulating platelets become 
spherical and throw out from their surface projections of varying shape, which then 
develop into multiple pseudopodia (O’Brien and Hey wood, 1966). The production of 
pseudopods increases the membrane area thereby enhancing cellular interactions. The 
surface-connected canalicular system provides extra area of membrane (Frojmovic and 
Milton, 1982). The changes in external shape of platelets are accompanied by 
considerable internal rearrangements, involving the assembly of a contractile 
cytoskeleton (White, 1968). During this internal rearrangement process, microtubules are 
dispersed and rearranged at the centre of the cell. Also, the phosphorylation and 
polymerization of myosin and the formation of actomyosin occurs. The creation of 
pseudopodia involves the polymerization of actin, and the involvement of a-actinin and 
actin-binding protein. The necessity of microtubules for platelet shape change as well as 
aggregation were demonstrated with the use of colchicine, which tightly binds to the 
tubulin monomer and prevents its polymerization (Menche et al., 1980). However, the
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inhibition of shape change by cytochalasin B, which prevents actin from polymerizing by 
binding to the plus end of actin filaments, does not alter platelet aggregation, suggesting 
that the shape change is not a prerequisite for aggregation (Schollmeyer et al., 1978; 
Davies, 1984). In addition, shape change occurs in the presence of 
ethylenediaminetetraacetic acid (EDTA) in concentrations sufficient to prevent 
aggregation completely, which means that shape change is not dependent on extracellular 
calcium (Peerschke, 1985). A transient drop in metabolic ATP during shape change 
suggests that metabolic energy is consumed.
Binding to fibrinogen and aggregation
Early studies on patients with congenital afibrinogenemia whose platelets aggregate 
weakly or fail to aggregate in response to ADP provided initial evidence of the major role 
of fibrinogen in aggregation (McLean et al., 1964). Since the initial observation that 
radiolabeled fibrinogen associates with aggregating platelets (Mustard et al., 1978), it has 
been further evident that specific and saturable fibrinogen receptors are induced by a 
broad range of platelet agonists. Fibrinogen plays a central role in platelet aggregation by 
forming the links between platelets, but fibrinogen itself does not aggregate platelets 
unless the fibrinogen receptor, GP Etb/IIIa, has been altered by limited cleavage (Phillips 
et al., 1988). GP nb and GP Ilia are the two most prominent glycoproteins in platelet 
membrane. These molecules form a Ca2+-dependent heterodimer, a member of the 
integrin family termed anbP3. The basic mechanism by which ADP and other agonists 
alter the GP Ilb/ffla complex, enabling it to bind fibrinogen, is unknown. The 
intracellular tail of GP Ilia seems to be the site of action of an unidentified transduction 
protein (Shattil, 1995). Fibrinogen is a dimeric glycoprotein with three pairs of 
nonidentical subunits, Aa, Bp, and y, covalently linked by disulphide bridges. Sequences 
of the fibrinogen molecule that bind to GP Ilb/IIIa on platelets have been identified as the 
RGDF (Arg-Gly-Asp-Phe) and RGDS (Arg-Gly-Asp-Ser) sequences at amino acids 95- 
98 and 572-575 on the Aa chains, and a dodecapeptide near the carboxyl termini of the y 
chains at amino acids 400-411. The importance of the RGDS sequences has not been 
established, and the RGDF and y chain sequences appear to interact with the same site, or
24
mutually exclusive sites, on GP Ilb/IIIa (Lam, 1992). Hawiger et al. (1989) suggested 
that in forming a bridge between two adjacent platelets, the dimeric fibrinogen molecule 
may bind through a total of six sites, i.e. to three GP Ilb/IIIa complexes on each of the 
platelets. Fibrinogen is not the only RGD-containing protein that binds to GP Ilb/IIIa, but 
in normal plasma, fibrinogen provides the bridging molecules between activated platelets. 
The other proteins that bind to platelets through an RGD sequence include von 
Willebrand factor, fibronectin, and vitronectin. Von Willebrand factor may substitute for 
fibrinogen in patients with afibrinogenemia. Under conditions of very high shear in 
severely narrowed blood vessels, there is evidence that von Willebrand factor may be the 
adhesive protein that binds platelets together by forming links with GP Ilb/IIIa (Ruggeri 
and Ware, 1993). Fibrinogen does not interact with resting platelets, although it has been 
found to be internalized into a  granules by receptor-mediated endocytosis in a GP 
Ilb/IIIa-dependent manner (Handagama et al.,1993). Binding to the specific binding sites 
on the stimulated platelets is time and divalent cation dependent, and saturable with 
respect to the concentrations of ADP and fibrinogen (Marguerie et al., 1979). 
Extracellular cations are not required for receptor induction but are necessary for the 
interaction of fibrinogen with its binding site.
Because of the difficulty of examining platelet aggregation in vivo, most studies have 
been carried out in vitro, using platelets in plasma prepared by centrifugation of citrated 
blood. Two types of aggregation response can be distinguished in vitro: a primary, 
reversible aggregation which does not involve the release of contents from platelets, and 
a secondary, irreversible aggregation involving the formation of thromboxane A2 and the 
secretion of granule contents. When human platelets are brought into close contact with 
each other by rapid stirring, the concentration of Ca2+ in the suspending medium 
determines the extent to which the platelets in plasma respond to agonists (Heptinstall 
and Mulley, 1977; Packham et al., 1989). With ADP as an aggregating agent, if the 
concentration of Ca2+ is approximately ImM or greater, only a reversible, primary phase 
of aggregation takes place regardless of the concentration of ADP that is used to 
stimulate the platelets. Aggregation starts 3-5s after the addition of ADP, reaches half 
maximal 10-3Os later, and reaches a maximum and then decreases within 2-3min.
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Thromboxane A2 formation does not occur, and there is negligible secretion of granule 
contents. In contrast, when aggregation induced by ADP at concentrations of 2-4 pM or 
greater is studied in citrated platelet in plasma, or in any buffered medium containing 
approximately 20 \iM Ca2+, the primary phase of aggregation is followed by an 
essentially irreversible secondary phase which involves the release reaction. The 
concentration of Ca2+ in the plasma from blood anticoagulated with sodium citrate is 40- 
50 pM, whereas it is 1-2 mM in plasma from blood that has been anticoagulated with a 
thrombin inhibitor that does not chelate calcium, such as hirudin. Therefore, it does not 
seem to be that ADP-induced aggregation of citrated platelets in plasma or in artificial 
media containing unphysiologically low concentration of Ca2+ corresponds to the 
physiological responses of platelets to ADP (Packham et al., 1989).
Platelets are desensitized to ADP very rapidly, and trace amounts of ADP are sufficient 
to render platelets refractory. To avoid ADP-induced desensitization during platelet 
isolation, ADP scavengers such as apyrase are often used (Mustard et al., 1972).
1.3 M easurement of platelet responses
Much information about platelet aggregation, shape change and secretion has been 
obtained by means of the optical aggregometry technique which was originally 
introduced by O’Brien (1962) and Bom (1962). The principal of the method is as 
follows: light shines through a cuvette which contains a platelet suspension and any 
transmitted light is detected by a photoelectric cell. When the platelets are activated by 
agonists such as ADP, there is a brief increase (3-20s) in light scattering associated with 
the shape change. Light scattering then decreases over the next 20s to about 4 min, when 
values close to those of platelet-poor plasma are reached. This phase of the platelet 
response reflects the formation of large aggregates. Also, in case of weak agonists, such 
as ADP in low concentrations of Ca2+, biphasic aggregation tracings may be seen, with 
the second phase coinciding with the formation of thromboxane A2 and the secretion 
from dense granules during the release reaction. The most widespread parameters used 
for quantitation of platelet aggregation are the maximal net increase in transmission, the
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slope of the aggregation curve, and the half-time of the aggregation curve (Frojmovic, 
1973). All of these parameters are dependent on several factors such as the optical 
geometry, wave length, and light path length of the measuring device as well as shape, 
size distribution, and concentration of the platelets (Frojmovic, 1978).
Instead of optical aggregometry, lumi aggregometry and particle counting may be used to 
measure platelet responses. Lumi aggregometers are turbidimeters which are additionally 
equipped with a photomultiplier rendering them capable of detecting chemiluminescence 
(Feinman et al., 1977; Ingerman-Wojenski et al., 1983). Thus, these aggregometers allow 
the determination of ADP release from platelet dense bodies using the lueiferin/luciferase 
system. The principal of the particle counting is that as a consequence of platelet 
aggregation, the concentration of single, free platelets and total particles (platelet 
doublets, triplets, etc.) decreases. Thus aggregation can be determined by measuring the 
concentration of single platelets and/or total particles before and after stimulation of 
platelet aggregation (Lumley and Humphrey, 1981; Gear, 1982; Frojmovic et al., 1989). 
More recently, a flow cytometric analysis has been used to quantitate the platelet shape 
change or aggregation by monitoring changes in scattering profile of platelets. (Ruf and 
Patscheke, 1993; 1995). For this measurement, the whole blood is incubated with one of 
the platelet-specific monoclonal antibodies and the fluorescence-labelled second antibody 
so that the flow cytometer can detect the labelled platelets by their fluorescence. The flow 
cytometer can also be applied to measure the formation of the aggregates between 
platelets and other types of cell (e.g. platelet-leucocyte aggregates) by directly 
conjugating one specific monoclonal antibody with fluorescence and incubating the 
whole blood with two type of cell-specific antibodies (Li et al., 1997).
In cases where the agonist affects the adenylate cyclase activity or cytosolic calcium 
concentration of platelets, the responses may also be assessed by measuring the inhibition 
(e.g. by ADP) or stimulation (e.g. by adrenaline) of adenylate cyclase, or by measuring 
the initial calcium transient induced by the agonist, respectively. Adenylate cyclase 
assays are described by Haslam and Rosson (1975). These are performed by pre-labelling 
the platelets with radiolabelled adenine, stimulating with agonist, and then extracting the
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labelled cAMP. The measurement of increases in [Ca2+]i has become simple and routine 
by the development of the now widely used fiira-2, based upon a series of 
tetracarboxylate Ca2+-indicator dyes which can be loaded into living cells easily and non- 
disruptively (Tsien, 1980; Grynkiewicz et al., 1985).
1.4 ADP-induced signal transduction
By virtue of their structural simplicity and widespread availability, platelets frequently 
have been used as a model system to study signal transduction. Also, studies of signal 
transduction in platelets have helped in elucidating the number and type of ADP 
receptors in platelets, which are not clearly characterized yet. At the intracellular level, 
platelet activation following ADP binding to its receptor leads to a transient rise in free 
cytoplasmic Ca2+, resulting from both Ca2+ influx and mobilization of internal stores 
(Sage et al, 1992), possibly from the dense tubular system (DTS). Calcium mobilization 
by ADP from intracellular stores suggests a phospholipase C (PLC)-mediated action, but 
ADP has been reported to be a weak stimulator of inositol phosphate production (Vickers 
et al., 1990; Packham et al., 1993). Recently, Vanags et al. (1998) showed a significant 
increase in inositol (l,4,5)-trisphosphate (IP3) formation after ADP stimulation in a 
stirred aggregation system using a very sensitive competitive receptor binding assay for 
IP3. Simultaneously, at a very early stage of the activation process, ADP inhibits 
stimulated adenylate cyclase although this is in itself insufficient to induce platelet 
aggregation (Haslam et al., 1978). ADP also stimulates the binding of [35S]-guanosine 5’- 
0-(3-thiotriphosphate) (GTPyS) to platelet membranes in man (Gachet et al., 1992a) and 
in rat (Gachet et al., 1992b), suggesting that the ADP receptors are coupled to G proteins, 
further identified as G-& (Ohlmann et al., 1995) and Gq (Offermanns et al., 1997). Each of 
these processes will be discussed in more detail in following sections.
1.4.1 Intracellular Ca2+
In the resting state, platelets have a very low cytosolic calcium concentration in the nM 
range, compared to the concentration in the internal calcium stores and plasma, which are
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in the mM range. Activation of platelets with ADP causes an increase in the cytosolic 
calcium concentration up to at least lpM. Ca2+ influx occurs via receptor-mediated 
events, however, ADP-induced elevation of cytosolic calcium does not appear to be 
identical with that induced by any other agonists for platelets.
Stopped-flow studies with fura-2-loaded human platelets at 17°C have shown two 
distinctly resolved phases of [Ca2+]i increase, which are poorly resolved at 37°C (Sage et 
al., 1990). At the lower temperature, a fast phase of [Ca2+]i increase occurs without 
measurable delay in the presence of external calcium, coinciding with opening of a 
plasma membrane ion channel closely coupled to the ADP-receptor, and a delayed phase 
of [Ca2+]i increase follows at 800 msec (at 200 msec at 37°C) related to discharge of 
intracellular stores.
Using patch-clamp techniques, it has been demonstrated that the calcium entry which 
occurs without measurable delay after stimulation by ADP is due to single channels 
tightly coupled to the ADP receptors (Mahaut-Smith et al., 1990, 1992). In these studies, 
ADP evoked inward currents if included in the pipette but not when added to the bath 
saline, demonstrating that this channel is activated directly by receptor activation rather 
than via a diffusible second messenger. It has been recently suggested that the Ca2+ entry 
channel responsible for the first phase of Ca2+ entry and linked directly to receptor 
activation represents P2Xi receptors in platelets (MacKenzie et al., 1996). In these 
studies, using fura-2 measurements of [Ca2+]i in stirred platelet suspensions, both ADP 
(40 pM) and the non-hydrolyzable ATP analogue a,(3-methyleneadenosine 5’- 
triphosphonate (ap-meATP) (lOpM) activated a rapid Ca2+ influx whereas only ADP 
mobilized Ca2+ from internal stores. In nystatin permeabilised whole-cell patch clamp 
recordings, ATP, ADP, aJ3-meATP and adenosine 55-0-(3 -thiotriphosphate) (ATPyS), all 
activated a cation channel permeable to both monovalent and divalent cations showing 
the characteristics of P2Xi receptors in other tissues (Mackenzie et al., 1996).
The exact mechanism by which ADP stimulates the release of intracellular Ca2+ stores in 
platelets is not clearly elucidated yet. The delay time after the first Ca2+ entry increases
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with decreasing agonist concentration, suggesting that the binding of agonists to plasma 
membrane receptors elicits the rapid release of calcium from internal stores (Sage and 
Rink, 1985, 1987). Although most aggregating agents stimulate PLC and the subsequent 
production of IP3 which is usually responsible for the mobilization of intracellular Ca2+ 
stores, it is not clear yet whether this is the case for ADP or not. The further explanation 
related to this will be dealt with in section 1.4.2. The ADP receptor which is responsible 
for Ca2+ mobilization in platelets has been suggested to be the P2Yi receptor (Jin et al., 
1998) (see section 1.7).
Since Mn2+ appeal's to pass through the same pathway as Ca2+, binding to fora-2 with 
high affinity and quenching its fluorescence, it was used as a tracer for Ca2+ 
(Grynkiewicz et al., 1985; Cobbold and Rink., 1987). ADP also induced a biphasic influx 
of Mn2+ entry, coinciding with both phases of the [Ca2+]i elevation. In Ca2+-free medium, 
ADP evoked a rise in [Ca2+]i following a 1400 msec delay and Mn2+ entry was also 
delayed by 1400 sec, due to intracellular discharge. The fact that the release of calcium 
from intracellular stores occurred with a shorter delay (at 800 msec) in the presence of 
extracellular calcium than in its absence (at 1400 msec) suggests that the timing of the 
second event is somehow modulated by [Ca2 l ]i i.e. the result of the earlier influx of Ca2+ 
in the first phase. In addition, the coincidence of the delayed Mn2+ entry with the phase of 
calcium mobilization associated with store release suggests that as well as the initial 
entry, there is a second Ca2+ entry from extracellular medium to refill the depleted 
intracellular calcium stores in platelets. There may be some kind of communication 
between the intracellular Ca2+ store and membrane to enable store discharge to signal the 
initiation of the delayed phase of ADP-evoked Ca2+ entry. The mechanism of this ‘store- 
regulated’ Ca2+ entry is often referred to as the ‘capacitative’ model, proposed by Putney 
in 1986. The capacitative model is based upon the observation that in many different cell 
types, there are two components to Ca2+ mobilization: the HVmediated discharge of the 
intracellular Ca2+ pools and a sustained phase of Ca2+ entry. The withdrawal of the 
agonist leads to the rapid degradation of IP3, but the influx of Ca2+ continues until the 
Ca2+ content of the pool reaches a sufficient level and inactivates Ca2+ entry.
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The Ca2+-ATPase of the dense tubular system appears to play a role in sequestering Ca2+ 
in the stores while the plasma membrane Ca2+-ATPase expels Ca2+ to the extracellular 
space for the maintenance and restoration of the resting cytoplasmic calcium 
concentration (Rink and Sage, 1987, 1990; Schaeffer and Blaustein, 1989; Falchetto et 
al., 1991; Tao and Haynes, 1992). Many studies of store-regulated Ca2+ entry have 
utilized inhibitors of the dense tubular system Ca2+-ATPase, e.g. thapsigargin (Thastrup 
et al., 1987a,b; Jackson et al, 1988; Takemura et al., 1989; Verma et al., 1990; Ely et al., 
1991; Lytton et al., 1991; Sagara et al., 1992; Wictome et al., 1992). In platelets, 
thapsigargin has been shown to inhibit Ca2+ uptake into the dense tubular system 
(Thastrup et al., 1989). However, more recently doubts have been raised about the 
specificity of action of thapsigargin in human platelets as Kimura et al. (1993) have 
reported multiple cellular effects of thapsigargin treatment in human platelets.
1.4.2 Inositol phospholipids
IP3 and diacylglycerol (DG) are the hydrolyzed products from phosphatidylinositol 4,5- 
bisphosphate (PIP2) of the plasma membrane, produced by the action of PLC. IP3 
mobilizes Ca2+ from intracellular stores and DG activates the protein kinase C (PKC) 
which phosphorylates other proteins. PKCa and PKC(3 isoforms are expressed in 
platelets (Watson et al., 1999). There are three major subclasses of PLC which are 
distinctly regulated. PLCfl isoforms are regulated by G proteins, PLCy isoforms by 
tyrosine phosphorylation while the mechanism of regulation of PLC8 isoforms is not 
established (Lee et al., 1996). PLCp2 and PLCy2 are expressed in platelets at higher 
levels than other isoforms of PLC (Lee et al., 1996).
IP3 recognizes a specific site, the IP3 receptor on the membrane of the dense tubular 
system, opening a calcium channel which is pH-sensitive. Although the majority of 
platelet agonists induce activation through the phosphoinositide second messenger 
pathway, conflicting results have been published with regard to ADP so far, probably due 
to the different conditions of the experiments, for example, the concentration of Ca2+ in 
the medium, the presence or absence of aspirin, the presence of fibrinogen, and the
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concentration of ADP itself. On one hand, a number of groups have reported no change 
in the [32P] labelling of PIP2 for up to 20s after ADP stimulation (Fisher et al., 1985; 
MacIntyre et al., 1985). It has also been shown from the studies using PKC inhibitor 
staurosporine and diacylglycerol kinase inhibitor, R59022 that the primary effects of 
ADP (shape change, first aggregation phase) do not require hydrolysis of the 
phosphoinositides (Kroll and Schafer, 1989; Packham et al., 1993). Packham et al. (1993) 
showed that in comparison with thrombin, ADP-induced aggregation was insensitive to 
the effects of inhibition of diacylglycerol kinase or to inhibition of PKC by staurosporine, 
and that activation of PLC does not occur during ADP-induced primary aggregation, 
suggesting that the inositol phospholipid pathway is only poorly activated by ADP. On 
the other hand, Daniel et al. (1986) showed a significant increase in the level of IP3 in 
32P-labelled, aspirinated, fura 2-loaded human platelets upon stimulation with ADP. Also, 
Heemskerk et al. (1993) have shown a transient increase in the level of IP3 induced by 
ADP in washed, aspirinated platelets. Some groups have reported variations in the 
concentrations of inositol 1,3,4,5-tetrakisphosphate (IP4), IP3, PIP2, IPi, and phosphatidic 
acid (PA) following activation by ADP (Daniel et al., 1986; Raha et al., 1993). These 
effects were transient, and this could explain why they have not been detected under the 
conditions normally used for other agonists. According to Vickers (1993), the changes 
observed in PIP2 and phophatidylinositol monophosphate (PIP) could be due to ADP- 
stimulated binding of fibrinogen and/or to the aggregation process rather than to 
activation of PLC. He showed that omitting fibrinogen from the suspending medium or 
blocking fibrinogen binding to the platelets using Arg-Gly-Asp-Ser (RGDS) inhibited the 
decreases in PIP2 and PIP, which could be seen following ADP-stimulation of washed 
platelets containing Ca2+ (2mM) and fibrinogen (0.4mg/ml). Recently, using a sensitive 
competitive receptor binding assay for IP3, Vanags et al. (1998) have detected a 
significant increase in IP3 formation at an early time (<10s) after ADP stimulation in a 
stirred aggregation system. This is in agreement with previous studies of Raha et al. 
(1993) in which an increase in IP3 occurred at 1.5-5s after the addition of ADP or 
thrombin and correlated with the mobilization of intracellular Ca2+ within 2s.
In case of the agonists which induce activation through the phosphoinositide second
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messenger pathway, nyC a2+ and DG/PKC exhibit synergistic effects with each other in 
stimulating secretion from dense granules whereas only small responses are stimulated by 
each on its own (Walter and Watson, 1993).
1.4.3 Cyclic nucleotides
Increasing the concentration of adenosine 3’,5’-cyclic monophosphate (cAMP) within 
platelets results in inhibition of most of their responses, e.g. the increase in [Ca2+]i and 
aggregation in response to weak stimuli. The intraplatelet concentration of cAMP is 
regulated by two enzymes, adenylate cyclase and phosphodiesterase. Adenylate cyclase 
which is localized on the internal surface of the platelet membrane synthesizes cAMP 
from ATP and is activated by the a s-subunit of G proteins (Sunahara et al., 1996). 
Among nine subtypes of adenylate cyclase, subtype VII and IV appear to exist in 
platelets, with the former as the predominant form. The cAMP level is reduced by the 
activity of phosphodiesterase. This enzyme catalyzes the hydrolysis of the 3 ’ phosphate 
bond of cAMP to yield free 5’-adenylate (5’-AMP). Seven homologous 
phosphodiesterase families are identified so far, of which three distinct 
phosphodiesterases exist in the human platelet; guanosine 3’,5’-cyclic monophosphate 
(cGMP)-stimulated phosphodiesterase type II, cGMP-inhibited phosphodiesterase and 
cGMP-specific phosphodiesterase (for review, see Butt and Walter, 1997).
cAMP modulates platelet function by a multitude of mechanisms. Initially, cAMP 
activates cAMP-dependent protein kinase (PKA) which phosphorylates a number of 
proteins including myosin light chain, actin binding protein, a 21kD G protein, tubulin, 
and GP lb (Gerrard et al., 1987; Lapetina et al., 1989; Berry et al., 1989; Fox and Brendt, 
1989) and it is through the action of these phosphoproteins that cAMP elicits all its 
responses. In addition, elevation of cAMP is associated with marked inhibition of 
activation of PLCj3 isoforms by G protein receptor-coupled agonists, an action mediated 
by inhibition of py-regulation of PLC (Park et al., 1993). There are two ways in which 
PLC)3 can be activated: one by the a q subunit of G proteins, the other by the py subunits 
of G proteins, and both are responsible for hydrolysis of PIP2 to IP3 and DG. The
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inhibited PLCP results in a decrease of the cytosolic calcium concentration by inhibiting 
the exit of calcium from the dense tubular system and by stimulating its resequestration 
(Zavoico and Feinstein, 1984; Feinstein et al., 1985). A study of isolated dense tubules 
has shown that cAMP inhibits the D^-operated channel of the dense tubules (Quinton and 
Dean, 1992). In addition, cAMP inhibits activation of the fibrinogen receptor GP Ilbllla, 
preventing aggregation by all extracellular agonists (Van Willing and Akkermann, 1991). 
Other pathways are also implicated in the inhibition of platelet function by cAMP but 
most of these are secondary to inhibition of PLC.
Platelet adenylate cyclase is activated through receptor-dependent mechanisms via Gs 
proteins as intermediaries by adenosine, PGD2, PGEi, PGI2 (prostacyclin) and adrenaline 
(p2 receptor), and inhibited through receptor-dependent mechanisms via Gi proteins (e.g. 
thrombin, ADP) (Aktories and Jakobs, 1984) and adrenaline (a2 receptor) (Jakobs et al.,
1976), ADP is a strong inhibitor of adenylate cyclase, and this inhibition is also 
dependent on a Gi protein (Cole et al., 1971; Haslam, 1973; Cooper and Rodbell, 1979). 
The inhibition of adenylate cyclase by ADP does not induce any reduction in the basal 
concentration of intraplatelet cAMP, but limits it instead when the enzyme is activated by 
PGEi or PGI2 or adenosine. Although this action of ADP on adenylate cyclase is 
insufficient to cause platelet aggregation on its own (Haslam et al., 1978), it is important 
in understanding the stimulus-response coupling mechanism for ADP in platelets.
In addition to adenylate cyclase, platelets contain guanylate cyclase activity (Glass et al.,
1977) which is activated by nitric oxide or any system which generates it. Activated 
guanylate cyclase produces cGMP. The action of cGMP is mediated through cGMP- 
dependent protein kinase (PKG), exhibiting inhibitory effects on platelet activation like 
cAMP (Mellion et al., 1981). Many aspects of the action of cGMP are similar to those of 
cAMP, including inhibition of PLCp, and thereby Ca2+ influx to the cytosol, inhibition of 
activation of GP Ilbllla, and phosphorylation of a number of common substrates 
(Koesling and Numberg, 1997). The inhibitory effects on calcium fluxes of both cAMP 
and cGMP may contribute to the termination of the agonist-evoked calcium signal by a 
feedback mechanism. cGMP can elevate cAMP levels by activating cGMP-inhibited
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phosphodiesterase (Butt and Walter, 1997), and has also been reported to be involved in 
inhibition of tyrosine phosphorylation by ADP in platelets (Oda et al., 1992). The nitric 
oxide which is released from endothelial cells and activated platelets increases cGMP and 
strongly inhibits platelet function (Coller, 1992). It has been shown that in human washed 
platelets, a selective inhibitor of nitric oxide synthesis reduces the increase in cGMP and 
enhances aggregation (Radomski et al., 1990). Together with prostacyclin (PGI2) which 
is made within endothelial cells from PGH2 liberated by the activated platelets and 
stimulates adenylate cyclase, nitric oxide and cGMP play a role in preventing the 
platelets from activation under normal condition (Radomski et al, 1987; Kroll and 
Schafer, 1989).
1.4.4. G proteins
Receptor-mediated G protein activation is one of the most general mechanisms for 
transducing signals in cells. The G protein complex exists as a heterodimer in the resting 
state, composed of a guanosine 5’-diphosphate (GDP)-bound a  subunit complexed with a 
tightly associated py dimer. G protein-effector activation is initiated by the receptor- 
mediated GTP/GDP exchange. When the G protein is activated by the receptor-catalyzed 
GTP/GDP exchange reaction, both the a  and py subunits can proceed to regulate a 
number of effectors, including adenylate cyclase, phospholipases and ion channels. The 
efficiency of these G protein-effector interaction is controlled by the rate of hydrolysis of 
GTP bound to the a  subunit, affecting a downstream process of effector activity and a 
reassociation of the a  subunit with the Py dimer.
There are four subgroups of a  subunits comprising 20 or more family members: (i) the Gs 
subgroup which stimulates adenylate cyclase, (ii) the Gj subgroup which attenuates 
adenylate cyclase and modulates ion channel function (originally identified as substrates 
for pertussis toxin) and (iii) the Gq subgroup which activates PLCp isoforms and (iv) the 
G12 subgroup, for which specific target effectors have not been unequivocally identified 
yet. Multiple forms of the P (6 isoforms) and y (11 isoforms) subunits are also known. In 
platelets, in addition to a s, a  subunit members of the Gi subclass (an, 0,12, (Xi3, a z), the Gq
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subclass (aq), and the G12 subclass (0C12, an ) have been identified (for review, see ref. 
Brass et al., 1993). In most cases, a given receptor has been known to show a preferential 
affinity for one type of G protein. However, it appears to be possible that receptors can 
interact with more than one type of G protein as seen for one of the thrombin receptors 
which interacts both with Gq, thereby stimulating PLCp, and with Gi, thereby inhibiting 
adenylate cyclase (Vu et al., 1991; Coughlin et al., 1992; Hollenberg, 1999). In this case, 
the predominant effect of an agonist is determined by the relative abundance of the 
subtypes in a particular region or type of cells.
By studying the binding of [35S]-GTPyS to platelet membranes stimulated with ADP, it 
was suggested that the platelet ADP receptor might belong to the G protein-coupled 
receptor family (Strader et al., 1994). At the result of an approach combining 
photolabelling and immunoprecipitation to identify the activated G proteins, it was found 
that ADP stimulated labelling of the Gi2 immunoprecipitate, suggesting that ADP inhibits 
cAMP formation by activation of Gj2 proteins (Laugwitz et al., 1994; Ohlmann et al.,
1995). However, Offermanns et al. (1997) demonstrated using Gq-deficient mice that Gq 
is essential for the signalling processes used by different platelet activators, including 
ADP, and that it can not be replaced by Gi or the Py subunits of the heterotrimeric G 
proteins. More recently, the existence of two distinct G protein-coupled ADP receptors 
was suggested on platelets, one coupled to PLC, and the other to inhibition of adenylate 
cyclase (Daniel et al., 1998; Jin et al., 1998). In addition, Jin and Kunapuli (1998) 
showed that intracellular signalling from both G protein-coupled ADP receptors is 
essential for ADP-induced platelet aggregation using specific antagonists, which will be 
discussed in section 1.7. As for the relation to calcium signalling, it was shown by 
Pulcinelli et al (1998) that concomitant activation of Gi and Gq protein-coupled receptors 
does not require an increase in cytosolic calcium for platelet aggregation, suggesting that 
an increase in cytosolic calcium concentration preferentially activates G proteins 
downstream signalling pathway.
1.5 P2 purinoceptor family
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Since ADP receptors are classified within the group of purine receptor family, it is 
necessary to know how purine receptors are classified and characterized in order to 
discuss the nature of the ADP receptor(s). According to the first suggestion by Burnstock 
in 1978, the two main categories of purine receptors were divided into ‘PI receptors’ 
which recognize adenosine, and CP2 receptors’ which recognize primarily ATP and ADP 
(table 1.1). This classification has set the stage for further subdivision.
PI receptors have been further subdivided into four subtypes, Ai, A2a, A2b, and A3, 
according to convergent molecular, biochemical, and pharmacological evidence (for 
review, see Ralevic and Burnstock, 1998). All of these couple to G proteins. An earlier 
system of subclassification of P2 receptors identifying endogenous P2x, P2y, P2U, P2T, and 
P2z receptors was principally based on their pharmacological profiles. Moreover, when 
P2 receptors were cloned, there was an apparent mismatch between pharmacological data 
in biological tissue and the P2 receptor subtypes classified on the basic of molecular 
structure. It is considered acceptable to base receptor subclassification on amino acid 
sequencing where differences of 30 to 40% are generally regarded as justification for 
subtyping, although even less than 5% differences in sequence can result in substantial 
differences in pharmacological profile. Also, interpretation of pharmacological responses 
in some tissues may be complicated by receptor heterogeneity among species, receptor 
coexpression, the possible expression of new receptor subtypes that have not yet been 
cloned, and breaskdown of nucleotides (Ralevic and Burnstock, 1998).
The original subdivision by Burnstock and Kennedy (1985) described “P2x-” and “P2y- 
purinoceptors” with distinct pharmacological profiles and tissue distributions: the “P2x- 
purinoceptor” was shown to be most potently activated by the stable analogues of ATP, 
a,{3-methylene ATP (a,(3-meATP or AMPCPP), and (3,y-methylene ATP ((3,y-meATP or 
AMPPCP), while at the “P2y-purinoceptor” a,f3-meATP
and p,y-meATP were weak or inactive. Other P2 receptors that were identified in 
biological tissue, according to their different pharmacological profiles, are the P2u 
receptor which is activated equally by ATP and UTP, the P2t receptor (the platelet ADP 
receptor) and the P2z receptor which is found on mast cells and
37
Ta
bl
e 
1.1
 
C
la
ss
ifi
ca
tio
n 
of 
Pu
rin
e 
R
ec
ep
to
rs
38
lymphocytes (Gordon, 1986; O’Connor et al., 1991). The revision of P2 receptor 
nomenclature was prompted by evidence that extracellular ATP works through two 
different transduction mechanisms, namely intrinsic ion channels and G protein-coupled 
receptors (Benhan and Tsien, 1987; Dubyak, 1991), and by the cloning of the first two P2 
receptors, P2Yi (corresponding to the “P2Y-purinoceptor”) (Webb et al., 1993) and P2Y2 
(corresponding to the “P2u-purinoceptor”) (Lustig et al., 1993). In 1994 it was formally 
suggested that P2 receptors should be divided into two broad groups termed P2X and 
P2Y according to whether they are ligand-gated ion channels or are coupled to G protein, 
respectively, with subtypes defined by the different structure of mammalian P2 receptors 
(Abbrachio and Burnstock, 1994; Barnard et al., 1994; Fredholm et al., 1994). So far 
seven mammalian P2X receptors, P2Xi.7, and five P2Y receptors, P2Yi, P2Y2, P2Y4, 
P2Y6, and P2Yn have been cloned, characterized pharmacologically and accepted as 
valid members of the functional P2 receptor family (references listed in table 1.2, table 
1.3). The gap between numbering of the P2Y receptor family is caused by the recognition 
that certain receptors had been erroneously identified as belonging to this family, leading 
to the subsequent withdrawal of P2Y5 (Webb et al., 1996b) and P2Y7 (Akbar et al., 
1996). The cloned receptors P2Y9 and P2Yio are also probably not nucleotide receptors. 
A P2Y receptor cloned from Xenopus neural plate (previously called P2Y8) (Bogdanov et 
al, 1997) is not included in the definitive P2Y receptor family recognized by the 
IUPHAR committee, based on the rationale that this is a non-mammalian receptor (King 
et al., 1998). The proposed P2Y3 is also not included because the origin is non­
mammalian (cloned from chick) (Webb et al., 1995, 1996a). This receptor may be the 
avian homologue of the human P2Ye receptor, but it has not been confirmed yet. P2Yi is 
characterized by higher selectivity for ADP than for ATP and does not respond to UTP, 
therefore it corresponds to the old P2Y. P2Y2 responds equally well to ATP or UTP, 
therefore it corresponds to the old P2U. P2Y4 (the human but not the rat receptor) and 
P2Ye are uridine nucleotide-specific receptors (receptors not activated or only weakly 
activated by purines) that have been cloned and shown to be sensitive preferentially to 
UTP and UDP, respectively. However, the rat P2Y4 receptor is also activated potently by 
ATP, making it similar to the P2Y2. The P2Yn receptor is so far the only P2Y receptor 
selective for ATP versus other purine and pyrimidine nucleotides (Ralevic and
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Burnstock, 1998).
In the last 10 years, some important facts have been discovered which demand a re- 
evaluation of characterizations drawn from earlier studies on P2 receptors. These include: 
a) P2X receptors are multisubunit receptors that may exist as heteromers with different 
pharmacology, and multiple P2X receptor proteins are often coexpressed in different 
proportions in different tissues; b) cations such as Mg2+, Ca2+, Na+, K+ can profoundly 
affect P2X channel activity; c) antagonists previously used as P2 receptor blockers are 
non-selective, can inhibit ecto-nucleotidase activity and may have allosteric effects on P2 
receptors. The general lack of selective agonists and antagonists, together with 
complications introduced by coexistence of different P2 receptors and the widespeard use 
of impure solutions caused by purine and pyrimidine degradation and interconversion, 
also has significantly hindered advances in P2 receptor characterization. Studies of P2 
receptors on cells in culture may add another potential complication because of the 
emerging evidence that the expression of P2 receptors may alter in culture conditions. For 
example, astrocytes studied in situ, or after acute isolation from rat brain, are mostly 
insensitive to ATP, whereas in primary cultures, there is a profound increase in the 
number of cells responding to ATP (Jabs et al., 1997; Kimelberg et al., 1997).
P2 receptors have broad natural ligand specificity, recognizing ATP, ADP, UTP, and 
UDP. At present there are no agonists or antagonists that discriminate adequately 
between subtypes of receptors within each groups. Some of the most useful agonists are 
the stable ATP analogues a,p-meATP and (3,y-meATP, which if effective, strongly imply 
actions at P2X receptors, especially at P2Xi and P2X3 subtypes, and are generally 
inactive at P2Y receptors. Also useful are ADP, ADPpS and UTP, as these are agonists at 
some P2Y receptors, but are weak or inactive at P2X receptors. Agonist potency orders, 
important in the characterization of cloned and native P2 receptors, are profoundly 
influenced by the different stability’s of P2 receptor ligands in the presence of ecto- 
nucleotidases (Crack et al, 1994; Dubyak and El-Moatassim, 1993). Thus, greater 
caution is advised in interpreting the order of agonist potency where ecto-nucleotidase 
activity might have been involved. This is a particularly important consideration in the
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pharmacology of P2X receptors because of the wide range of stability of commonly used 
P2X agonists, but seems to have less impact on P2Y receptor profiles, probably because 
many of the commonly used P2Y agonists are similarly unstable (Ralevic and Burnstock, 
1998).
At the following sections of this thesis, in agreement with the recent review by Ralevic 
and Burnstock (1998), the name of the clone is preferentially used to refer to P2 
receptors. When it is not certain how the previous nomenclature corresponds to the 
current classification, which is true for the majority of cases, the term “-like” is used as in 
“P2Xi-like receptor”. Thus, “P2Xi-like receptor” is used to replace the previous “P2X- 
purinoceptor” of smooth muscle, “P2X7-like receptor” is for the previous “P2z- 
purinoceptor”, “P2Yi-like receptor” is for the previous “P2Y-purinoceptor’’, and “P2Y2- 
like receptor” is for the previous “P2U-purinoceptor”.
1.5.1 P2X receptors
P2X receptors are ATP-gated ion channels which mediate rapid (within 10 ms) and 
selective permeability to cations (Na+, K+ and Ca2+) (Bean, 1992; Dubyak and El- 
Moatassim, 1993). Because this transduction mechanism does not depend on the 
production and diffusion of second messengers within the cytosol or cell membrane, the 
response time is very rapid. This contrasts with the slower onset of response (less than 
100 ms) to ATP acting at metabotropic P2Y receptors, which involve coupling to G 
proteins and second messenger systems. Most of these P2X receptors are distributed on 
excitable cells (smooth muscle cells, neurones, and glial cells) and have a role as 
mediators of fast excitatory neurotransmission to ATP in both the central and peripheral 
nervous system. Cloned P2X receptor proteins (P2Xi to P2X7) have been reconstituted 
from homomeric association of the subunits to form ion channels when expressed in 
Xenopus oocytes or in mammalian cells in order functionally to characterize and 
investigate distinct pharmacological profiles. P2X receptors consist of 379 to 472 amino 
acids. Structural features of P2X receptors have been predicted from the amino acid 
sequences of cloned P2X receptor subunits, but they might not represent the actual
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receptor structure. The protein comprises two hydrophobic transmembrane domains and 
seems to insert into the cell membrane, with much of the protein occurring extracellularly 
as an intervening, hydrophilic loop. Most of the conserved regions are in the extracellular 
loop, with the transmembrane domains being less well conserved (Brake et al., 1994).
Cations can modulate ATP-activated currents through recombinant and endogenous P2X 
receptors. Mg2+ and Ca2+ generally inhibit P2X receptor currents, probably by decreasing 
the affinity of the ATP binding site by an allosteric change in the receptor (Honore et al., 
1989; Nakazawa et al., 1990; Li et al., 1997). Zn2+ potentiates the cation conductance 
induced by ATP at most P2X receptors, however, the P2X7 receptor is an exception in 
this respect because it is inhibited by Zn2+ and Cu2+ (Virginio et al., 1997). Extracellular 
protons also modulate the affinity of the ATP-binding site; acid pH causes an increase, 
and alkaline pH causes a decrease in currents, as shown for the recombinant P2X2 
receptor and endogenous P2X receptors in rat dorsal root and nodose ganglion cells 
(King et al., 1996; Li et al., 1996, 1997; Wildman et al., 1997).
According to the extent of desensitization, P2X receptors can be divided into two broad 
groups: those which desensitize rapidly (within 100 to 300 ms), and those which 
desensitize slowly if at all (Ralevic and Burnstock, 1998). As a general rule, all rapidly 
desensitizing P2X receptors, including recombinant P2Xi and P2X3 receptors, are 
activated by a,(3-meATP as well as by ATP, while non-desensitizing P2X receptors, 
including P2X2, P2X4, P2Xs, P2X6 are either sensitive to a,p-meATP or insensitive to 
a, p-meATP (Evans and Suprenant, 1996). The mechanism of P2X receptor 
desensitization is not well understood.
There are no subtype-selective P2X receptor agonists. ATP and diadenosine 
polyphosphates with a phosphate chain length greater than or equal to three are naturally- 
occurring agonists at P2X receptors (Hoyle et al., 1989; Hoyle, 1990; Bo et al., 1994; 
Schliiter et al., 1994; Bailey and Hourani, 1995; Ralevic et al., 1995, Usune et al., 1996). 
The greater potency of the longer chain diadenosine polyphosphates (Ap4A-Ap6A) 
compared to ATP at endogenous P2Xi-like receptors may be caused by their greater
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resistance to breakdown (Hoyle, 1990; Ogilvie, 1992, 1996; Hourani et al., 1998a). a,p- 
meATP is an agonist at recombinant P2Xi, P2X3, as well as at endogenous P2Xi-like 
receptors in smooth muscle, platelets (MacKenzie et al., 1996) and HL60 cells (Buell et 
al., 1996b), P2X3-like receptors in neonatal nodose and dorsal root ganglia (Krishtal et 
al., 1988a,b; Li et al., 1993; Robertson et al., 1996) and P2X receptors in guinea-pig 
coeliac ganglion (Evans et al., 1992; Khakh et al., 1995a). a,p-MeATP generally does 
not bind to P2Y receptors; it is weak or inactive at recombinant P2X2 and P2X4.7 
receptors and at their likely endogenous P2X receptor counterparts (Collo et al., 1996; 
Evans and Suprenant, 1996). a,P-MeATP-sensitive P2X receptors are sensitive to ATP, 
and a,p-meATP with EC50 values of approximately 0.5 to 5 pM, whereas a,p-meATP- 
insensitive P2X receptors are generally less sensitive to ATP and (Collo et al., 1996; 
Evans and Suprenant, 1996). ATPyS is an agonist at recombinant P2X2 and P2X4 
receptors (Brake et al., 1994; Bo et al., 1995). It is a partial agonist at recombinant P2Xi 
and P2X2 receptors, as well as at endogenous receptors in vas deferens, 
pheochromocytoma cells (PC 12 cells), and nodose and coeliac ganglia with a potency 
generally less than of ATP except for vas deferens (Suprenant, 1996).
In physiological solution, Ca2+ and Mg2+ ions form complexes with the free acid ATP4', 
such that the solution contains a mixture of ATP4', MgATP2', and CaATP2'. Thus, in this 
condition, ATP4' is a minor component of the total ATP concentration and decreases with 
increasing cation concentration and with acidic pH. About the question of which is the 
active form of ATP, Cockcroft and Gomperts (1980) suggested that ATP4' causes an 
increase in mast cell plasma membrane permeability. Since then, this form of ligand has 
been shown to be likely to be responsible for pore-forming actions in mast cells, 
macrophages, and lymphocytes as well as a number of other cell types expressing a 
receptor termed the P2Z or P2X7 receptor, and then extending to P2X receptors in general 
(Fedan et al., 1990; McMillan et al., 1993; Kim and Rabin, 1994; Choi and Kim, 1996; 
Honoreetal., 1989).
The seven cloned P2X receptors are as follows:
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Cloned P2Xi receptor
The P2Xi receptor has been cloned from rat vas deferens, human and mouse urinary 
bladder (Valera et al., 1994, 1995, 1996). The recombinant receptor is activated by 
ATP>a,P-meATP»ADP, and inward currents evoked by these compounds are 
reversibly blocked by suramin and pyridoxalphosphate-6-azophenyl-2,,4’-disulfonic acid 
(PPADS) (Valera et al, 1994). The receptor desensitizes very rapidly (in hundreds of 
milliseconds). The P2Xi receptor mRNA is expressed in urinary bladder, smooth muscle 
layers of small arteries and arterioles, vas deferens, dorsal root ganglia, trigeminal 
ganglia, coeliac ganglia, spinal cord, and rat brain (Valera et al., 1994; Webb et al., 1995; 
Collo et al., 1996). The P2Xi receptor seems to be the most significant P2X subtype in 
vascular smooth muscle, although P2X4 receptors may also be expressed (Soto et al., 
1996). ATP-gated ion channels in platelets and megakaryocytes have a similar 
pharmacology to the recombinant P2Xi receptor, suggesting that these ion channels are 
P2Xi receptors (Somasundaram and Mahaut-Smith, 1994; MacKenzie et al., 1996).
Cloned P2X2 receptor
The P2X2 receptor was first cloned from rat PC 12 cells (Brake et al., 1994). At the 
recombinant P2X2 receptor ATP, ATPyS and are approximately equipotent at causing 
non-selective inward cation currents, whereas a,p-meATP and P,y-meATP are inactive as 
agonists or antagonists (Brake et al., 1994). It is different from P2Xi receptor in that it 
undergoes little or no desensitization and it is less permeable to Ca2+ and shows much 
higher sensitivity to inhibition by extracellular Ca2+ (Evans et al., 1996).
Cloned P2X3 receptor
The P2X3 receptor has been cloned from rat dorsal root ganglion (Chen et al., 1995a; 
Lewis et al., 1995). The P2X3 receptor is activated by agonists with a potency order of 
ATP>a,P-meATP and undergoes rapid desensitization. The P2X3 receptor has a very 
restricted distribution; it is expressed only by a subset of sensory neurones such as
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trigeminal, nodose, and dorsal root ganglia. The human P2X3 receptor transcript is 
limited to spinal cord and heart (Garcia-Guzman et al., 1997a).
Cloned P2 X4 receptor
The P2X4 receptor has been cloned from rat hippocampus (Bo et al., 1995), dorsal root 
ganglion cells (Buell et al., 1996b), rat (Seguela et al., 1996; Garcia-Guzman et al., 
1997a) and human brain (Soto et al., 1996; Garcia-Guzman et al., 1997b), as well as rat 
endocrine tissue (Wang et al., 1996). The recombinant P2X4 receptor is most potently 
activated by ATP, but a,|3-meATP is weak or inactive (Bo et al, 1995; Seguela et al, 
1996). The P2X4 receptor does not desensitize rapidly, although reversible rundown of 
the current occurs during prolonged exposure to ATP (Seguela et al., 1996). It has been 
reported that the human P2X4 receptor desensitizes more rapidly compared to the rat 
P2X4 receptor (Buell et al., 1996a).
Cloned P2Xs receptor
This P2X receptor was first cloned from rat coeliac ganglia (Collo et al., 1996). Human 
homologues of the P2Xs receptor have tentatively been identified (Tokuyama et al., 
1996a, 1996b). Rapid inward currents are activated by ATP»ADP, whereas a,|3-meATP 
is ineffective as an agonist. The receptor does not readily desensitize.
Cloned P2X6 receptor
This clone was isolated from a rat superior cervical ganglion cDNA library (Collo et al.,
1996). Rapid currents are mediated by ATP»ADP, but a,(3-meATP has no effect. P2X6 
mRNA is heavily expressed in the central nervous system (Collo et al., 1996).
Cloned P2 X7 receptor
The P2X7 receptor cloned from rat macrophages and brain by Suprenant et al. in 1996
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was previously called the “P2z receptor” and described in mast cells, macrophages, 
fibroblast, lymphocytes, erythrocytes, and erythroleukemia cells. The agonist potency 
order for eliciting inward currents is 2’,3’-0-(4-benzoyl)benzoyl ATP 
(BzATP)>ATP»ATPyS>ADP (Suprenant et al., 1996). The human homologue has been 
cloned and shows a lower sensitivity to agonists (Rassendren et al., 1997). The cloned 
P2X7 as well as endogenous P2X7 receptors is selectively permeable only to small cations 
under physiological conditions, but can convert to a pore, permeable to small molecules 
as well as ions when divalent cation levels are low or in the continued presence of ATP.
1.5.2 P2Y receptors
P2Y receptors are purine and pyrimidine receptors, coupled to G proteins. Currently this 
includes the cloned mammalian receptors P2Yi, P2Y2, P2Y4, P2Yb, and P2Yn. Among 
these, two cloned receptors are activated specifically by pyrimidine, specially by uridine 
nucleotides, but not by adenine nucleosides or nucleotides. These two are P2Y4 and 
P2Yg, showing preference for UTP and UDP, respectively (Communi et al., 1996a,b). 
P2Y2 receptors are activated by ATP, as well as UTP, and are distinct from receptors that 
are activated selectively by pyrimidines. The potency orders for agonists of human P2Y 
receptors (except P2Yn) and rat P2Y4 receptors are based on the studies where 
nucleotides were purified either by high performance liquid chromatography (Leon et al.,
1997) or enzymatically (Nicholas et al., 1996). Other functional P2Y receptors (including 
human P2Yn receptors) were characterized using adenine and uridine nucleotides 
without purification and thus the precise potency orders of agonist for these remain to be 
further determined.
P2Y receptors are proteins of 308 to 377 amino acids with a mass of 41 to 53 kDa after 
glycosylation. They have typical features of G protein-coupled receptors with a seven 
transmembrane domain tertiary structure (Van Rhee et al., 1995). Most P2Y receptors act 
via G protein coupling to activate PLC leading to the formation of IP3 and mobilazation 
of intracellular Ca2+, as well as coupling to adenylate cyclase in the case of P2Yn. Their 
involvement in second messenger systems and/or ionic conductance mediated by G
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protein coupling makes the response time of P2Y receptors longer than that of the rapid 
responses by P2X receptors.
Cloned P2Yi and endogenous P2Yi receptors
The P2Yi receptor is a receptor for the endogenous ligands, ADP, and ATP, but not for 
UDP and UTP. The first cloned P2Yi receptor was from chick brain and was activated by 
agonists with a potency order of 2-MeSATP>ATP>ADP, although a,p-meATP, p,y- 
meATP, UTP and UDP are inactive (Webb et al., 1993). Homologues of the chick brain 
P2Yi receptor have been cloned from a variety of species. Recombinant P2Yi receptors 
from different species and tissues show different relative potencies to ATP and ADP as 
do endogenous P2Yi receptors.
Activation of the recombinant P2Yi receptor and endogenous P2Yi-like receptors causes 
IP3 formation and an increase in intracellular Ca2+ but no change in cAMP levels (Simon 
et al., 1995). The main signal transduction pathway is activation of PLC. From the studies 
of the P2Yi-like receptor in turkey erythrocytes, the G protein has been identified as a Gq 
protein, Gn, which activates PLCp isoenzymes via its a  subunit and is insensitive to 
pertussis and cholera toxin (Waldo et al., 1991a,b; Maurice et al., 1993). Insensitivity or 
partial sensitivity to pertussis toxin is characteristic of most endogenous P2Yi-like 
receptors coupled to PLC, indicating the involvement of Gq/n proteins as for the turkey 
erythrocyte P2Yi receptor. IP3 formation and Ca2+ mobilization can stimulate a variety of 
signalling pathways including PKC, PLA2, Ca2+-dependent K+ channels, and nitric oxide 
synthase. Activation of PKC and subsequent rapid tyrosine phosphorylation of mitogen- 
activated protein kinase (MAPK) seems to be the pathway by which P2Yi-like (and 
P2Y2-like) receptors on endothelial cells mediate prostacyclin production (Bowden et al, 
1995; Patel et al., 1996). A second signalling pathway of endogenous P2Yi-like receptors 
may be inhibition of adenylate cyclase. This has been described in a clonal population of 
rat brain capillary endothelial cells (BIO cells) (Webb et al., 1996a). P2Yi-like receptors 
coupled to inhibition of adenylate cyclase are typically blocked by pertussis toxin, 
indicating an involvement of Gi proteins (Boyer et al., 1995; Berti-Mattera et al., 1996;
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Webb et al., 1996c). These two pathways are expressed independently, that is, P2Yi-like 
activation of PLC is not related to P2Yi-like inhibition of adenylate cyclase. It is not clear 
whether this involves differential G protein coupling or is caused by heterogeneity of 
P2Yi-like receptors (Webb et al., 1996a). P2Y receptor-mediated adenylate cyclase 
inhibition was originally described for P2Yi-like receptors in rat C6 glioma cells and the 
clonal cell line C6-2B (Pianet et al., 1989; Valeins et al., 1992; Lin and Chuang, 1993; 
Boyer et al., 1993, 1994, 1995). However, the decrease in cAMP in C6 cells is not 
blocked by selective antagonists of the P2Yi receptor, which suggests that these receptors 
are distinct from P2Yi receptors coupled to activation of PLC (Boyer et al., 1996).
In some cells, P2Yi-like receptors are colocalized with P2Y2-like receptors. The 
biological significance of this is not clear, particularly where ATP is a common agonist, 
but makes more sense in cases where the P2Yi-like receptor is selective for ADP, and 
ATP acts only at the P2Y2-like receptor. The receptors have similar signalling pathways, 
although the P2Yi-like receptor seems to be more sensitive than the P2Y2-like receptor to 
activation of PKC activity (Gallinaro et al., 1995; Purkiss et al., 1994; Communi et al., 
1995; Chen et al., 1996).
In general, P2Yi and P2Yi-like receptors do not readily desensitize. When this occurs, as 
with other G protein-coupled receptors, desensitization may involve receptor 
phosphorylation by protein kinases and uncoupling from the associated G protein. Studies 
of the P2Yi-like receptor in turkey erythrocyte membranes showed that desensitization 
involves multiple mechanisms, and does not involve PKC or intracellular Ca2+ (Galas and 
Harden, 1995). In cultured bovine aortic endothelial cells, preincubation with 2-MeSATP 
or UTP caused partial desensitization of IP3 formation by P2Yi and P2Y2-like receptors, 
respectively (Wilkinson et al., 1994). P2Yi-like receptor desensitization has also been 
reported in rat muscularis mucosae (Hourani et al., 1993), and rabbit mesenteric arterial 
smooth muscle (Ziganshin et al., 1994).
The P2Yi receptor is generally more sensitive to ADP than ATP. 2-MeSATP is a potent 
and selective agonist at P2Yi and P2Yrlike receptors versus other cloned P2Y receptors,
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but is also a potent agonist at most P2X receptors (reference in table 1.3). Responses to 
ATP and 2-MeSATP are antagonized by suramin (Dunn and Blakeley, 1988) and reactive 
blue 2 (Burnstock and Warland, 1987). a,(3-meATP, p,y-meATP, and UTP are inactive 
and thus are useful as negative evidence in the characterization of this receptor. As 
previously mentioned, the potency of ATP differs widely among endogenous P2Yi-like 
receptors. However, molecular evidence does not support a subdivision of the P2Yi 
receptor. 2-Thioether derivatives of adenine nucleotides, including 2-hexylthio ATP and 
2-cyclohexylthio ATP, are potent agonists at P2Yi-like receptors coupled to adenylate 
cyclase, but are significantly less potent at the PLC-coupled P2Yi receptor (Boyer et al., 
1995). The charge carried by the molecule may influence agonist potency, the more 
acidic analogues being more potent. For example, it has been suggested that ATP 
uncomplexed with divalent cations, ATP4', is the preferred agonist of the P2Yi-like 
receptor expressed on bovine aortic endothelial cells (Motte et al., 1993b).
For human P2Yi receptors, ATP has been proposed to be a pure antagonist when used 
after purification (Leon et al., 1997). In this study, when the human P2Yi receptor was 
expressed in Jurkat cells and the effects of HPLC purified nucleotides were investigated 
on calcium movements, ATP, Sp-ATPaS and (3,y-meATP were competitive antagonists 
while ADP and 2-methylthioadenosine 5’-diphosphate (2-MeSADP) were potent 
agonists. Adenosine 3’,5’-and 2’,5’-bisphosphates act as competitive antagonists at the 
human recombinant P2Yi receptor coupled to PLC; A3P5PS and adenosine-3 
phosphate-5’-phosphate (A3P5P) block responses at this recombinant P2Yi receptor 
(Boyer et al., 1996). These compounds are inactive at the adenylate cyclase-coupled 
P2Yi-like receptor of C6 glioma cells and at recombinant P2Y2, P2Y4, or P2Y6 receptors. 
Interestingly, A3P5PS and A3P5P are partial agonists at the turkey P2Yi-like receptor 
but not the human P2Yi receptor (Boyer et al., 1996).
P2Yi and P2Yi-like receptors are widely distributed, including in heart, vascular, 
connective, immune, and neural tissues (Ralevic and Burnstock, 1998). The transcript for 
chick brain P2Yi mRNA is distributed in brain, spinal cord, gastrointestinal tract, spleen, 
and skeletal muscle, but not in heart, liver, stomach, lung, or kidney (Webb et al., 1993).
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Cloned P2Y2 and endogenous P2Y 2 receptors
The P2Y2 receptor and its endogenous counterpart, formerly called the P2U receptor, is 
activated by ATP and UTP with approximately equal potency and is insensitive or is only 
weakly activated by ADP and other nucleoside diphosphates, 2-MeSATP and a,{3- 
meATP. The first cloned P2Y2 receptor was from mouse NG108-15 neuroblastoma cells 
(Lustig et al., 1993). Cloned P2Y2 and endogenous P2Y24ike receptors couple via both 
Gi/0 and Gq/n proteins to mediate phospholipid breakdown and phosphoinositides as well 
as Ca2+ mobilisation via PLCp, and their effects may accordingly be pertussis toxin- 
sensitive, -partially sensitive, or -insensitive (Dubyak and El-Moatassim, 1993). PLCp2 is 
activated by the Py subunits of G proteins, which further stimulates IP3 formation, Ca2+ 
mobilisation, and a variety of signalling pathways including PKC, PLA2, Ca2+-dependent 
K+ channels (Park et al., 1993; Fields and Casey, 1997). The specific downstream 
signalling pathway seems to be partially dependent on the cell type in which the P2Y2- 
like receptor is expressed. A P2Y2-Hke receptor has been shown to mediate inhibition of 
adenylate cyclase in some cells, e.g. NCB-20 cells (Garritsen et al., 1992), cultured renal 
mesangial cells (Schulze-Lohoff et al., 1995), MDCK-D1 cells (Post et al., 1996) 
although as shown in C6-2B rat glioma cells, this may occur secondary to an increase in 
cytosolic free Ca2+ (Munshi et al., 1993).
P2Y2 and endogenous P2Y2-like receptors do not readily desensitize. However, 
tachyphylaxis of a P2Y2-like response has been reported in UMR-106 rat osteoblasts 
(Sistare et al., 1994), human term placental (trophoblastic) cells (Petit and Belisle, 1995), 
rat cultured pituitary cells (Chen et al., 1994, 1995b), C6-2B rat glioma cells (Munshi et 
al., 1993), and in cultured endothelial cells (Motte et al., 1993a; Wilkinson et al., 1994; 
Nobles et al., 1995).
UTP and ATP are natural ligands at P2Y2 and P2Y2-like receptors, and are approximately 
equipotent. 2-MeSATP and a, p-me ATP are weak or inactive, which provides useful 
negative evidence in the characterization of this receptor. Uridine 5’-0-(3-
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thiotriphosphate) (UTPyS) is equipotent with UTP and ATP at recombinant P2Y2 and 
endogenous P2Y2-like receptors, but has the advantage of being resistant to hydrolysis 
(Lazarowski et al., 1996). ATPyS has been shown to be an agonist at recombinant P2Y2 
receptors, but is less potent than UTP and ATP (Lustig et al., 1993; Lazarowski et al.,
1995). p1,p4-diadenosine tetraphosphate (Ap4A) is a potent agonist at recombinant P2Y2 
receptors with a potency greater than ATPyS and within the same range as UTP and ATP, 
raising the possibility that it is an endogenous regulator of these receptors (Lazarowski et 
al., 1995). It has been suggested that endogenous P2Y2-like receptors are preferentially 
activated by the fully ionized forms of ATP and UTP, ATP4', and UTP4' in bovine aortic 
endothelial cells (Lustig et al., 1992; Motte et al., 1993), human neutrophils (Walker et 
al., 1991), a cultured neuroblastoma cell line (NG108-15 cells) (Lin et al., 1993), rat 
lactotrophs (Carew et al., 1994), mouse pineal gland tumour cells (Suh et al., 1997), and 
MDCK cells (Yang et al., 1997). According to these results, the UTP and ATP responses 
were shown to correlate with the concentration o f the fully ionized form of these agonists 
and not with the concentration of their cation complexes or other ionized forms. Although 
the agonist profile at recombinant P2Y2 has been studied extensively, less is known about 
antagonism. It has been reported that suramin is a competitive, but weak antagonist at 
human P2Y2 whereas PPADS has no effect on UTP responses (Charlton et al., 1996). 
There are no equivalent data for mouse P2Y2 and rat P2Y2 homologues. Endogenous 
P2Y24ike receptors show two types o f responses with respect to antagonism by suramin 
and PPADS; sensitive or insensitive. In rat, P2Y2 and P2Y4 have the same agonist profile 
(equally sensitive to ATP and UTP), but different sensitivity to antagonist; P2Y2, a 
suramin-sensitive, and P2Y4, a suramin-insensitive. Thus, there are two structurally 
distinct subtypes of the previous P2u receptor in rat according to the current classification 
of P2 receptors.
P2Y2 receptors are widely distributed, but little is known about their physiological 
significance. It is particularly intriguing that a receptor can be activated equally by purine 
and pyrimidines. To understand if this is physiologically relevant it is important to know 
more about whether there are different sources 01* differential release of UTP and ATP. In 
the vasculature, P2Y2-like receptors are generally present on the endothelium where they
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stimulate the synthesis and release of prostacyclin and nitric oxide, leading to 
vasodilation (Ralevic and Burnstock, 1991a,b; 1996a,b). Release of UTP from a variety 
of cells has been shown, including from endothelial cells (Saiag et al., 1995), human 
astrocytoma cells (Lazarowski et al., 1997; Lazarowski and Harden, 1999) and human 
platelets (Lazarowski and Harden, 1999). Smooth muscle contraction mediated 
equipotently by UTP and ATP may indicate P2Y2-like receptors, although the G protein 
coupling of these receptors remains to be confirmed. As mentioned already in this 
section, it has been shown recently that, unlike the human P2 Y4-like receptor, which is 
selective for UTP, the rat P2Y4 homologue is equisensitive to ATP and UTP; that is, in 
agonist profile it is identical with rat P2Y2 (Bogdanov et al., 1998).
Cloned P2Y4 receptors
This uridine nucleotide-specific receptor has been cloned from human placenta 
(Communi et al, 1996c), human chromosome X (Nguyen et al., 1996), and rat heart 
(Bogdanov et al., 1998). The human P2Y4 receptor is highly selective for UTP over ATP 
and is not activated by ADP. ATP can act as an antagonist and partial agonist. The human 
P2Y4 receptor has been reported to couple to two distinct G proteins: a Gi protein at the 
early stage and a Gq/u protein at a later stage of signalling to activate PLC and IP3 
formation (Communi et al., 1996a). The human P2Y4 receptor is not blocked by suramin, 
but both blocked by PPADS (IC50 approximately 15 p,M) (Communi et al., 1996a) and 
relatively insensitive to block by PPADS (used at 30pM) (Charlton et al., 1996). Human 
P2Y4 is expressed almost exclusively in placenta with low levels of expression in lung, 
and absent in most other tissues (Communi et al., 1996c), P2Y4 mRNA has been detected 
in vascular smooth muscle (Erlinge et al., 1998). The recent cloning of a rat receptor 
which has shown to be activated equipotently by ATP and UTP (Bogdanov et al., 1998), 
suggests that some P2Y2-like responses may be mediated by a P2Y4 receptor, at least in 
rat tissues.
Cloned P2 Y6 receptors
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This uridine nucleotide-specific receptor has been cloned from rat aortic smooth muscle 
(Chang et al., 1995) and human placenta and spleen (Communi et al., 1996b). The 
receptor is activated most potently by UDP but weakly or not at all by UTP, ATP, ADP, 
or 2-MeSATP (Communi et al., 1996b; Nicholas et al., 1996). The response is pertussis 
toxin insensitive, indicating the involvement of Gq/n proteins in stimulation of PLC and 
in the formation of IP3 (Nicholas et al., 1996).
P2Ye mRNA is found abundantly in various rat tissues including placenta, thymus, lung, 
stomach, intestine, spleen, mesentery, heart, and aorta (Chang et al., 1995; Communi et 
al, 1996b). It has been suggested that the P2Y6 receptor accounts for uridine nucleotide- 
specific responses in C6-2B cells (Nicholas et al., 1996),
The more widespread distribution of the P2Ye receptor, compared with the P2 Y4 
receptor, suggests that this receptor is more likely to account for endogenous uridine 
nucleotide-specific responses (Ralevic and Burnstock, 1998).
Cloned P2Yu receptors
The P2Y n  receptor was cloned from human placenta (Communi et al., 1997). The 
receptor couples to the stimulation of both the phosphoinositide and the adenylate cyclase 
pathways; in this respect, it is unique among the P2Y family. This receptor seems to be 
the only P2Y receptor selective for ATP because it is stimulated by agonists with a rank 
order of potency of ATP>2-MeSATP»ADP, with UTP and UDP inactive (Communi et 
al., 1997). Northern blot analysis detected mRNA corresponding to the P2Yn receptor in 
spleen and HL-60 cells (Communi et al., 1997). Recently, Communi and his colleagues 
reported the pharmacological characterization of the recombinant human P2Y n  receptor 
using two distinct cell lines stably expressing the P2Yn receptor gene: the 1321N1 
astrocytoma cells for IP3 measurements and the CHO-K1 cells for cAMP assays 
(Communi et al., 1999). They showed almost identical rank order of potency of a series 
of nucleotides for the two pathways: ATPyS«BzATP>ATP>ADPpS>2-MeSATP 
(Communi et al., 1999).
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1.6 Structure-activity relationships of the platelet ADP receptor
Agonists
Accumulated data on the relative activities of a large number of ADP analogues 
effectively define the characteristics of the ADP receptor. The ADP receptor for 
aggregation has a quite remarkable degree of structural specificity. The only structural 
analogues that have a similar potency to ADP are those which are substituted in the 2- 
position of the purine ring such as 2-chloroadenosine 5’-diphosphate (2-C1ADP) and 2 - 
MeSADP; these are somewhat more active than ADP (Maguire and Michal, 1968; Gough 
et al., 1972) and 2-MeSADP is the most active nucleotide aggregating agent known to 
date. A striking characteristic of the 2-substituted ADP analogue is their relatively 
powerful effect on adenylate cyclase; whereas 2-MeSADP is 10-fold more active than 
ADP as an aggregating agent, it is 150 to 200-fold more active as an inhibitor of 
adenylate cyclase (Macfarlane et al., 1983). Both ADP and 2-MeSADP cause increased 
levels of intracellular Ca2+, presumably by a combined effect on influx from the medium, 
and on mobilization from intracellular stores. 2-MeSADP is a full agonist and 20-fold 
more active than ADP for causing increases in [Ca2+]i (Hall and Hourani, 1993).
Small changes in other parts of the purine ring, or in the D-ribofuranosyl group cause 
marked reduction of activity (Gaarder et al., 1961). Modification of the pyrophosphate 
group produces some strange effects. Substitution of S for OH on the P phosphate 
(ADPpS) gives a partial agonist for both platelet aggregation and inhibition of adenylate 
cyclase (Cusack and Hourani, 1981a). The maximum response obtained with ADPpS is 
less than with ADP for both effects, and high concentrations of ADPpS inhibit the effect 
of ADP. The Rp- and Sp- diastereoisomers of ADPaS are both partial agonists for 
platelet aggregation (Cusack and Hourani, 1981b). Neither compound inhibits adenylate 
cyclase, though both competitively inhibit the effect of ADP. For both actions the Sp 
isomer is 5-fold more active than Rp isomer. Adenosine 5’-(a,P- 
methylene)diphosphonate (AMPCP or a,p-meADP) is weak (Horak and Barton, 1974) or
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inactive (Cusack and Petty, 1996) as an aggregating agent as well as for inhibition of 
adenylate cyclase and the corresponding difluoro- and dichloro-methylene derivatives are 
weak inhibitors (Cusack and Petty, 1988).
Antagonists
Several compounds structurally related to ADP inhibit aggregation, including adenosine 
and 2 -substituted adenosine analogues (Born, 1965; Kikugawa et al., 1973). AMP, with 
one less phosphate than ADP, is neither an agonist nor except at very high 
concentrations, an antagonist (Packham et al., 1972), suggesting a significant role for the 
(3 phosphate group in the ligand-receptor interaction. ATP, with one additional phosphate, 
is a competitive inhibitor with the IQ value of ~ 2 0  pM against aggregation (Macfarlane 
and Mills, 1975). The inhibitory action of ATP applies to ADP-induced aggregation, 
increase in [Ca2+]i and inhibition of adenylate cyclase (Cusack and Hourani, 1982b; Hall 
and Hourani, 1993; Hall et al., 1994). The effect is immediate and specific for ADP as 
shape change and primary aggregation induced by 5-HT, vasopressin, adrenaline and low 
concentration of thrombin are not inhibited (Mills, 1996). ATP also competitively 
inhibits the effects of 2-substituted ADP analogues including 2-MeSADP, 2-azido-ADP 
and 2-C1ADP (Cusack and Hourani, 1982a). Several other competitive antagonists of 
ADP have been found, including adenosine 5’-(3-fluorotriphosphate)(ATPyF), AMPPCP, 
p1,p5-diadenosine pentaphosphate (ApsA), 2 -chloroadenosine 5’-0 - 
monophosphorothioate (2-C1AMPS), 2 -chloro-ATP (2-C1ATP) and the Sp- and Rp- 
diastereoisomers of adenosine-5 ’-O-(l-thiotriphosphate) (ATPaS). The relative potency 
order of a series of diadenosine polyphosphates to inhibit ADP-induced aggregation is 
ApsA > Ap4A(p1,p4-diadenosine tetraphosphate) »  Ap3A(p1,p3-diadenosine 
triphosphate) > Ap2A(p1,p2-diadenosine diphosphate) (Harrison et al., 1975; Zamecnik et 
al., 1992). Most of compounds described above competitively inhibit the effect of ADP 
on PGEi-stimulated adenylate cyclase activity, as well as aggregation (Hourani and Hall, 
1996; Mills, 1996; Geiger et al., 1998). The Sp-isomer of ATPaS is the most potent 
antagonist in this group with the Kb value of 4 pM against aggregation and 4.6 pM 
against inhibition of adenylate cyclase (Cusack and Hourani, 1982b).
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The structural requirements of antagonists appear similar to those of agonists, in that 2- 
substituted analogues are more potent than the parent nucleotide whilst the methylene- 
phosphonate analogues are less so. Other inhibitors of ADP-induced aggregation which 
act non-competitively are 2-MeSATP, 2-ethylthio-ATP (2-EtSATP), 2-methylthio-AMP 
(2-MeSAMP) and 2-(pentan-l-yl)-thioAMP. Their actions are not completely reversed by 
increasing the concentration of ADP, with ~50% inhibition as a maximum in platelets in 
plasma (Gough et al., 1978; MacIntyre et al., 1977a; Cusack and Hourani, 1982c). 
Similar results were reported for 2-methylthioadenosine 5’-(P,y- 
methylene)triphosphonate (2-MeS-AMP-PCP). 2-MeS-AMP-PCP is a stable analogue of 
2 -MeSATP in which |3,y-methylene linkage confers resistance to dephosphorylation. This 
compound inhibited ADP-induced maximal aggregation only by ~50%, whereas it was 
able to completely inhibit the effect of ADP on adenylate cyclase (Hourani et al., 1986; 
1996). Furthermore, 2-MeS-AMP-PCP inhibited aggregation induced by ADPpS, a 
partial agonist of adenylate cyclase inhibition in a similar manner to its inhibition of 
ADP-induced aggregation, but it was not able to inhibit aggregation induced by ADPaS 
which does not inhibit adenylate cyclase but act as an antagonist for this effect (Cusack 
and Hourani, 1982d; Hourani et al., 1996). These observations give important clues for 
understanding the mechanism of platelet activation which will be further discussed in 
next section 1.7.
The recently developed compounds ARL 67805 (2-propylthio-f3,y-dichloromethyiene-D- 
adenosine 5’-triphosphate) and ARL 66096 (2-propylthio-p,y-difluoromethyiene-D- 
adenosine 5’-triphosphate) are derivatives of 2-MeS-AMP-PCP with the methylthio 
group on adenine ring replaced by methylpropyl group and the py anhydride bond 
replaced by a dichloromethylene or a difluoromethylene bridge, respectively (Humphries 
et al., 1995 a,b). These compounds, with improved stability relative to ATP, are powerful 
inhibitors of platelet aggregation in vitro, and ARL 67805 is antithrombotic in vivo in 
dogs and rats (Humphries et al., 1994; 1995b). More recently, ARL 66096 was reported 
to block ADP-induced inhibition of adenylate cyclase, but not to affect ADP-mediated 
intracellular calcium increases or shape change, and this was used as one of the pieces of
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evidence distinguishing ADP-induced intracellular events (Daniel et al., 1998).
Another compound which should be mentioned here is a chemically unrelated 
trypanocidal drug, suramin. This compound is a inhibitor of ADP-induced aggregation 
with slightly lower pA2 than ATP (Hourani et al., 1992), increases in cytosolic calcium 
and inhibition of adenylate cyclase activity induced by ADP in washed platelets, though 
it is inactive in platelet rich plasma and acts non-specifically (Hourani et a l, 1993; Hall 
and Hourani, 1994).
1.7 Models of platelet activation involving multiple ADP receptors
Various models for ADP-induced platelet activation have been developed but are still the 
subject of some controversy. Several observations initially suggested the possibility that 
two receptors are involved for ADP, one in initiation of aggregation and shape change, 
seemingly closely related phenomena, and another in inhibition of adenylate cyclase, 
apparently quite different. This suggestion arose from studies using the affinity analogue 
probe 5 ’-p-fluorosulfonylbenzoyl adenosine (FSBA) which inhibits platelet aggregation 
without inhibiting the effects of ADP on adenylate cyclase (Bennet et al., 1978). 
Although a 100 kDa protein labelled by FSBA (“aggregin”) has been claimed to be the 
receptor by which ADP induces aggregation (Colman, 1992), the incorporation of [3H] 
from labelled FSBA into platelet membranes is only inhibited at very high concentrations 
of ADP and ATP (lOmM) and is also blocked by similar concentrations of adenosine, 2 - 
chloroadenosine, GDP, and UDP (Bennet et al., 1978), none of which are ADP receptor 
ligands. The incorporation of FSBA into platelet membrane proteins is not therefore 
consistent with the known pharmacology of the ADP receptor. More evidence against 
this first model of two ADP receptor was based on investigations using a series of 
competitive antagonists. There is a good correlation between their ability to inhibit both 
effects of ADP, e.g. aggregation and inhibition of adenylate cyclase activity, suggesting 
that they are mediated by a single receptor (Cusack and Hourani, 1982b; Hourani and 
Hall, 1994, 1996).
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Even if all observable responses to ADP from pharmacological studies appear to be 
mediated by a single receptor, studies of signal transduction in platelets have not always 
been consistent with a single receptor model. The inhibition of adenylate cyclase suggests 
a Gi protein coupled receptor, and indeed ADP has been shown to activate Gi2 in 
platelets, consistent with such an effector system (Ohlmann et al., 1995). At the same 
time, ADP mobilizes calcium from intracellular stores (Sage et al., 1992), suggesting a 
phospholipase C-mediated action which is another G protein coupled response although 
ADP is a very weak stimulator of inositol phosphate production (Gachet and Cazenave,
1991). This indicated that these two effects might be mediated either by coupling of a 
single receptor to two different G proteins or by two different types of receptor.
A model involving two ADP receptors has been supported by studies with the 
antiaggregatory thienopyridine compounds, ticlopidine and clopidogrel. Under conditions 
in which ADP-induced aggregation and inhibition of adenylate cyclase are completely 
blocked by thienopyridine treatment, low concentrations of ADP or 2-MeSADP still 
promote platelet shape change and elevation of intracellular Ca2+ concentrations (Gachet 
et al., 1990b). Using intact rat platelets, Gachet and colleagues showed that the 
thienopyridine clopidogrel led to a dose-dependent reduction in the number of [33P]-2- 
MeSADP binding sites, up to 70% of control values at the highest doses given to the 
animals (25-100 mg/kg). These findings point to the existence of another ADP receptor 
on platelet, insensitive to clopidogrel and responsible for shape change and Ca2+ entry. In 
the platelets of a patient with a congenital deficiency of ADP-induced platelet 
aggregation thought to be related to a receptor defect, a reduction of 70% in the number 
of 2-MeSADP binding sites was observed as compared to control platelets without 
modification of binding affinity (Gachet et al., 1995). The clinical profile and platelet 
function of this patient are the same as when thienopyridine compounds are administered 
to human or animals. The main feature is a strong and selective inhibition of aggregation 
induced by ADP despite conserved shape change.
More recently, the following findings have significantly contributed to the further 
characterization of a model for ADP-induced platelet activation. These include the
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development of hydrolysis resistant derivatives of ATP, e.g. ARL 66096 (Humphries et 
al., 1993, 1994a). ARL 66096 is, like ticlopidine, a potent inhibitor of ADP-induced 
platelet aggregation, blocking ADP-induced inhibition of adenylate cyclase, but failing to 
inhibit ADP-mediated [Ca2+]i increases and shape change. Similar findings were 
previously reported with 2-MeS-AMP-PCP to which ARL 66096 is structurally related 
(Hourani et a l, 1986, 1996). As mentioned in section 1 .6 , 2-MeS-AMP-PCP completely 
abolished ADP-induced inhibition of adenylate cyclase, whereas it achieved only 50% 
inhibition of ADP-induced aggregation. In addition, it inhibited platelet aggregation 
induced by ADPpS, which inhibited stimulated adenylate cyclase activity, but did not 
inhibit aggregation induced by ADPaS, which does not inhibit stimulated adenylate 
cyclase. These results imply that 2-MeS-AMP-PCP acts by inhibiting only one 
component of ADP-induced aggregation and that the inhibition of adenylate cyclase by 
ADP may be necessary for the full aggregation induced by ADP. From these observation, 
it has been suggested that ADP may induce aggregation by interacting with two forms of 
the ADP receptors, one of which is coupled to inhibition of adenylate cyclase, and the 
other is coupled in an as yet undefined way to calcium mobilization. Furthermore, Boyer 
and colleagues identified some of ATP analogues which have a phosphate in the 25- or 
3’-position of a ribose ring, e.g. A3P5PS as specific, competitive antagonists at the P2 Yi 
in studies with the human P2Yi receptor stably expressed in 132INI human astrocytoma 
cells (Boyer et al., 1996). Jin and colleagues further demonstrated that these compounds 
inhibit ADP or 2MeSADP-induced intracellular calcium increases or the shape change 
but did not affect ADP-induced inhibition of adenylate cyclase (Jin et al., 1998). Overall, 
these results from at least three types of compound, e.g. ticlopidine/clopidogrel, 2-MeS- 
AMP-PCP, and ARL 66096, and A3P5PS support the idea that multiple P2 receptors are 
involved in platelet-response coupling (figure 1.3).
ADP also causes a rapid calcium influx consistent with the opening o f a ligand-gated 
cation channel in platelets (Sage et al., 1992), and recently this receptor has been 
suggested by MacKenzie and colleagues to correspond to a P2Xi receptor, activated by 
ATP as well as ADP (MacKenzie et al., 1996). According to this group, the P2Xi 
receptors have been desensitized in previous studies, a situation which they avoided by
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carrying out their experiments in the presence of apyrase to degrade extracellular ATP. 
ADP is approximately 100-fold less potent than ATP as an agonist at the cloned and 
native P2Xi receptor, suggesting that ATP acts as an agonist for the P2Xi receptor 
instead of acting as an antagonist (Suprenant, 1996).
On the basis of all these observations, a three-receptor model was proposed (Daniel et al.,
1998): one receptor (P2Yi) coupled to PLC via Gq and responsible for shape change, the 
second (tentatively called P 2 Y ac)  coupled to G i mediating inhibition of adenylate 
cyclase, with both receptors being required to be activated for aggregation, at least in 
washed platelets (Jin et al., 1998; Jin and Kunapuli, 1998; Kunapuli, 1998; Hechler et al., 
1998a) and the third (P2Xi) mediating rapid Ca2+ influx. Leon and colleagues reported 
the pharmacological profile of the human P2Yi receptor expressed in Jurkat cells using 
HPLC purified nucleotides demonstrating that this receptor is not a nucletide triphosphate 
receptor but a nucleotide diphosphate receptor and that this P2Yi receptor strikingly 
resembles the platelet ADP receptor with triphosphate nucleotides antagonizing the 
diphosphate nucleotides effects (Leon et al., 1997). They also identified mRNA for the 
P2Yi receptor in platelets as well as megakaryoblastic cell lines (Leon et al., 1997).
1.8 Other pharmacological receptors on platelets
In addition to ADP, many substances have been identified which bind the platelets via 
their own receptors and play a role in platelets functions. Among these, thrombin, 
collagen, thromboxane A2, platelet-activating factor (PAF), 5-HT, adrenaline, and 
vasopressin act as aggregating agents while adenosine and prostaglandins act as 
inhibitory agents for platelet functions.
Thrombin
Thrombin has two major roles in platelet function: first, as a clotting factor that has an 
important role in blood coagulation, converting fibrinogen to fibrin which then forms the 
fibrillar basis of the clot: second, as the most potent aggregating agent, causing shape
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change, aggregation and release of granule contents without any contribution from ADP 
or thromboxane A2 (Packham, 1991). Thrombin is formed during coagulation by the 
action of factor Xa on the plasma precursor, prothrombin, and is a serine protease with a 
molecular weight of 36 kDa (Hourani and Cusack, 1991).
The thrombin receptor is a member of the family of protease-activated receptor (PAR). 
The mechanism for activating this receptor has been intensively investigated with the 
cloning of the G protein-coupled receptor for thrombin in 1991 (Vu et al., 1991; 
Rasmussen et al., 1991). These protease-activated receptors are activated in unique way. 
After the ligand binds the receptor, it cleaves an Arg-Ser bond in the receptor at the point 
41 amino acids away from the amino terminus. This new amino terminus acts as a 
‘anchored ligand’ and activates the receptor (Vu et al., 1991; Coughlin et al., 1992). So 
far, four members o f the PAR family have been cloned, all of which have G protein- 
coupled proteinase-activated receptor activity, two of which are activated by thrombin 
(PARi and PAR3), one of which (PAR2) can be activated by trypsin but not by thrombin, 
and the fourth family member, PAR4 is activated equally well by either thrombin or 
trypsin (See Hollenberg, 1999 for recent review).
As the result of ligand binding studies aimed at identifying the thrombin receptor on 
platelet membranes, both high (Ko<10nM) and moderate (KolOnM) affinity thrombin 
binding sites were identified (Harmon and Jamieson, 1986; DeMarco et al., 1994). More 
recently, since a short synthetic peptide representing the new N terminal of the receptor 
after cleavage by thrombin was reported to be able to mimic the effects of thrombin 
including the activation of its receptors, and has been used to identify the thrombin 
binding sites on platelets (Vu et al., 1991). The data from the binding studies with these 
PAR-activating peptides and with anti-PAR antibodies to localize the thrombin binding 
sites on platelet membrane suggests that PARi probably represents the major G  protein 
(Gi and Gi2/i3)-coupled receptor for thrombin in human platelets. PAR3 is present as a 
minor component and the presence of PAR4 is not clearly confirmed yet (Brass et al.,
1992).
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Collagen
Adhesion of platelets to the connective tissue protein collagen, causes platelet activation. 
Compared to type IV and V collagen in subendothelium, type I and III which exist deeper 
in vessel walls and type III found in atherosclerotic plaques strongly stimulate platelets, 
causing the release of secondary agonists, e.g. thromboxane A2 and ADP. Therefore, 
collagen plays a role both as a solid to which platelets adhere and as a primary agonist. 
The secondary agonists, thromboxane A2 and ADP act synergistically to amplify the 
responses o f platelets (for review, see Santoro and Cunningham, 1981).
Two types of glycoprotein complexes, GP Ialla (Sixma et al., 1995; 1997) and GP VI 
(Sugiyama et al., 1987; Moroi et al., 1989) are known as major collagen receptors on 
platelets. Collagen-platelet interaction mechanisms are explained by a series of events 
called as ‘two-site, two-step’ model (Santoro et al., 1991). According to this model, 
platelet adhesion and activation occur at two sites, and in two steps involving two 
receptors, GP Ialla and GP VI. GP Ialla acts as the first point of attachment of collagen 
to the platelets, arresting platelets under flow conditions, and bringing the collagen 
molecule into the vicinity of the other receptor, GP VI on the platelet surface. Collagen- 
platelet adhesion is followed by platelet activation via GP Vl-collagen binding. It has 
been reported that the interaction between collagen and its receptors, GP Ialla and GP VI, 
is mediated by distinct epitopes in the adhesion molecules (Morton et al., 1989, 1995).
Signalling by collagen involves stimulation of tyrosine phosphorylation of PLGy2 (Blake 
et al, 1994; Daniel et al., 1994), and thus activation of phosphoinositide pathway, 
resulting in aggregation and secretion in platelets (Watson et al., 1985). Interestingly, it 
has been proposed that this tyrosine phosphorylation pathway shares a common features 
with that used by receptors for immune complexes, FcyRIIA, involving two tyrosine 
kinases, src and syk (Weiss and Littman, 1994), suggesting collagen as the first example 
of a non-immune receptor to signal through a pathway that was thought to be used only 
by immune receptors.
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Thromboxane A2
Arachidonic acid liberated from one of phospholipid components in plasma membranes 
by the action of cytosolic PLA2 can be converted by cyclooxygenase to the endoperoxide, 
PGG2, which gives rise to PGH2, and then to thromboxane A2. Thromboxane A2 is a 
major metabolite of arachidonic acid in platelets causing shape change, aggregation and 
release of granule contents. Endoperoxides and thromboxame A2 activate the same 
receptor which is now called thromboxane-prostanoid (TP) receptor, but it will be 
referred to as the thromboxane A2 receptor, because thromboxame A2 is the most potent 
natural agonist. TP receptor is a seven transmembrane protein, coupled to Gq stimulating 
breakdown of phophoinositides, to Gj2 inhibiting adenylate cyclase and to Gi2 and G13 
(for review, see Halushka et al., 1997). Aspirin which is widely used as an antiplatelet 
agent to reduce the occurrence of thrombotic disease is an inhibitor of cyclooxygenase, 
resulting in inhibition of thromboxane A2 synthesis and it shows well the physiological 
importance of thromboxane A2. Thromboxane A2 has a half-life as short as seconds 
(Hourani and Cusack, 1991; Packham, 1994), so long-lived analogues such as 9,11- 
dideoxy-lla,9a-epoxymethanoprostaglandin F2a (U46619) are used for experiments. In 
TP receptor-deficient mice, bleeding times were prolonged and their platelets did not 
aggregate after exposure to thromboxane A2 agonist U46619 (Thomas et al., 1998).
Platelet-activating factor (PAF)
PAF was named from the finding that the basophils of rabbits stimulated with antigen 
released a very potent agent to cause strong platelet activation (Benveniste et al., 1972). 
Now it is known that other cells, including platelets, can release PAF, causing shape 
change, aggregation, and release of granule contents from platelets, although its existence 
and the effects are very species-dependent. For example, as an aggregating agent, PAF 
produces only weak aggregation of human platelets, compared to rabbit or guinea pig, 
whereas rat and mouse platelets are unresponsive (Chignard et al., 1987). In human 
platelets, the release of granule contents in response to PAF is dependent on arachidonate 
metabolism (Chignard et al., 1987). PAF is present only in very low levels within resting
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platelets and at sites of damage so it does not appear to have a physiologically significant 
role in regulating platelet function. It rather appears to have synergistic effects with other 
platelet activating agents. PAF release occurs following stimulation by A23187, 
thrombin, or collagen but not by ADP, arachidonic acid, or PAF itself (Chignard et al., 
1980). Only one subtype of PAF receptor is known which is a G protein-coupled seven 
transmembrane receptor, inducing inositol phospholipid metabolism and Ca2+ 
mobilization (MacIntyre and Pollock, 1983; Hallam et al., 1984), as well as inhibiting 
adenylate cyclase activity (Haslam and Vanderwel, 1982; Williams and Haslam, 1984).
5-Hydroxytryptamine (5-HT)
Platelets contain high levels of 5-HT, also called ‘serotonin’, in their dense granules and 
release them at sites of tissue damage, causing platelet aggregation. However, unlike 
other aggregating agents, the response is weak or variable, generally reversible, and 
species dependent. Among four main types of 5-HT receptors, platelets have the 5-HT2A 
receptor type which is coupled to G proteins, activating PLC, phosphoinositide 
breakdown (De Chaffoy de Courcelles et al., 1985, 1987; Vanags et al., 1998) and an 
increase in intracellular Ca2+ concentration (Affolter et al., 1984). It does not appear 
either to stimulate or to inhibit adenylate cyclase (Haslam, 1975; Laubscher and 
Pletscher, 1980). 5-HT is found to potentiate other aggregating agents such as ADP when 
added together with or soon before and the release of 5-HT during platelet activation is 
obviously one of the amplification mechanisms by which aggregation is enhanced. 
Therefore, the synergistic or amplification effect of 5-HT with other stimuli may have 
more physiological significance than that of 5-HT alone.
Adrenaline
Adrenaline has been known for many years as one of the weak agonists for platelet 
activation, inducing only aggregation, not accompanied by shape change or elevation of 
Ca2+ (O’Brien, 1963; Glusa and Markwardt, 1980). This is distinct from other agonists. 
The a 2-adrenoceptor, the adrenaline receptor which mediates activation, is a seven
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transmembrane, G protein-coupled receptor but it is different from other receptors on the 
platelets surface in that it couples only to Gi, not to the Gq. The absence of Gq coupling 
may explain the inability of adrenaline to increase Ca2+ because of lack of Gq-dependent 
activation of PLC (Watson et al., 1999). It also suggests that Gq, not Gi, is involved in 
shape change, being consistent with the present ADP receptor model. Platelets have only 
low number of c^-adrenoceptors, around 300/platelet according to the binding studies 
with either the nonselective a-antagonist, [3H]-dihydroergocryptine or the selective a 2- 
antagonist, [3H]-yohimbine (Kerry and Scrutton, 1985). The physiological importance of 
the action of adrenaline on platelets appears rather to be in synergistic interactions with 
other platelet activating agents, especially ADP, than on its own (Vanags et al., 1992).
Vasopressin
Vasopressin is a weak agonist, being capable of inducing irreversible aggregation and the 
release of dense granule contents (Haslam and Rosson, 1972). The Vi receptor, a seven 
transmembrane-domain vasopressin receptor, is coupled in platelets to the 
phosphoinositide metabolism pathway, but does not inhibit adenylate cyclase in intact 
platelets. However, in platelet particulate fractions, it can inhibit adenylate cyclase by a 
receptor-mediated, GTP-dependent process, suggesting involvement of a G protein 
distinct from Gi (Vittet et al., 1988). The weak action of vasopressin corresponds to the 
low density o f receptors on the platelet surfaces, ~ 95/platelet (Thibonnier and Roberts, 
1985). The significance of the role of vasopressin for the platelet activation is unclear 
because of its weak action and its requirement of much higher concentration than are 
found in human blood (Haslam and Rosson, 1972; Scrutton et al., 1987). As ADP and 
adrenaline can potentiate the effects of vasopressin (Launay et al., 1987), vasopressin 
may have an effect in combination with other platelet agonists.
Adenosine
Adenosine inhibits platelet aggregation induced by ADP (Bom and Cross, 1963), 
thrombin (Clayton and Cross, 1963), adrenaline (Clayton and Cross, 1963), 5-HT
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(O’Brien, 1964), and vasopressin (Haslam and Rosson, 1975). The inhibitory effect of 
adenosine on platelet aggregation is mediated by increasing the intracellular 
concentration of cAMP and potentiated by inhibitors of cAMP phosphodiesterase and by 
inhibitors of its uptake into platelets (Haslam and Rosson, 1975). The adenosine receptor 
on platelets is an A2a  receptor, coupled to adenylate cyclase via a Gs protein (Hourani 
and Cusack, 1991). The level o f adenosine in vivo is normally very low (20-200 nM), but 
it is increased by hypoxia and ischemia (Belardinelli et al., 1989), also by 
dephosphorylation of ATP and ADP, rendering platelets less responsive to the effects of 
activating agents as well as causing vasodilation (Hourani amd Cusack, 1991). Platelet 
aggregation to ADP was increased in A2a receptor-knockout mice (Ledent et al., 1997).
Prostacyclin (PGI2)
Prostacyclin is a major metabolite of arachidonic acid produced by cyclooxygenase 
activity from the endoperoxide PGH2 It is made within endothelial cells lining the vessel 
wall (for review, see Hourani and Cusack, 1991). The prostacyclin receptor, called IP 
receptor (recognising PGI2), is coupled to the Gs protein, giving rise to activation of 
adenylate cyclase and increasing the concentration of intracellular cAMP (Watson et al.,
1999). This receptor is also activated by other prostanoids PGEi which is also a potent 
platelet inhibitor, but its affinity for the IP receptor is lower than prostacyclin. 
Prostacyclin is the most potent endogenous inhibitor of platelet aggregation, and together 
with nitric oxide, plays an important role in maintaining a nonthrombogenic status in 
undamaged site of blood vessel (for review, see Moncada, 1982). However, its instability 
and pronounced vasodilation activity limit the use of prostacyclin as an antiplatelet drug. 
The prostacyclin receptor-deficient mice showed the increased susceptibility to 
thrombosis (Murata et al., 1997) .
1.9 Aims of this thesis
The aims of this thesis were to characterize further the responses of the human platelets 
to ADP. To distinguish the multiple ADP receptors which may mediate the different
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responses of platelets, a range of agonists and antagonists were used to compare the 
structure-activity relationships of the major responses to ADP in human platelets: 
aggregation, shape change, inhibition of adenylate cyclase and increase in intracellular 
calcium concentrations.
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CHAPTER 2.
STUDY ON AGGREGATION AND SHAPE CHANGE
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2.1 Introduction
ADP causes multiple effects on human platelets such as aggregation, shape change, 
increase in cytosolic calcium concentration and inhibition of stimulated adenylate 
cyclase. Although all these responses are stimulated by ADP, whether these responses are 
mediated by a single receptor subtype has not been clearly explained for many years and 
a number of models have been suggested by different groups, which include two or more 
ADP receptors on platelets (Colman, 1992; Hourani and Hall, 1994, 1996; Mills, 1996; 
Gachet et al., 1996; Hourani et al., 1998b; Kunapuli, 1998) to explain the platelet 
activation. However the recent results from molecular cloning have given clues about 
these models of the ADP receptors on platelets and allowed further characterization of 
the mechanisms of action. Recently two families of P2 receptors have been cloned, the 
P2Y (G protein-coupled) and the P2X (ion channel) types. Of these the P2Yi and the 
P2Xi have been shown to be present on platelets, with the P2Yi being involved in 
aggregation while the P2Xi was shown to be involved in ADP-induced rapid calcium 
entry, although this contributes only a little to the functional responses of platelets (Leon 
et al, 1997; Vial et al., 1997). There have been efforts to find or synthesize any adenine 
nucleotide derivatives which differentiate these two receptors by many groups. A3P5PS 
which was introduced by Boyer and his group in 1996 as a specific P2Yi antagonist is 
one of those compounds. This compound has been shown to inhibit competitively the 
effects of ADP in causing aggregation, shape change and intracellular Ca2+ mobilization, 
but not the ability of ADP to inhibit adenylate cyclase, suggesting that this response 
occurs independently of the P2Yi receptor while the others are mediated via the P2Yi 
receptor (Hechler et al., 1998b; Savi et al., 1998; Jin and Kunapuli, 1998; Jin et al., 
1998). This suggests the existence of another platelet ADP receptor, tentatively called 
P 2 Y ac (sometimes called P2t  or P 2 Y adp) , coupled to Gi-mediated inhibition of adenylate 
cyclase. The 2-alkylthio-substituted analogues 2-MeS-AMP-PCP and 2 - 
ethylthioadenosine 5’-monophosphate (2-EtSAMP) both competitively inhibit the effect 
of ADP on adenylate cyclase but only partially inhibit aggregation (Hourani et al., 1986, 
1996). In addition, the structurally related compound 2-propylthioadenosine 5 ’- (P ,y -  
difluoromethene)triphosphonate, which is commonly called ARL 66096, is a potent
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inhibitor of ADP-induced platelet aggregation (Humphries et al., 1995a), and also blocks 
ADP-induced inhibition of adenylate cyclase, but does not inhibit ADP-mediated 
intracellular Ca2+ mobilization, IP3 formation, or shape change (Sanderson et al., 1996; 
Daniel et al., 1998). All of these reports suggest that there are two components required 
to cause aggregation, only one of which is associated with inhibition of adenylate 
cyclase. Based on these and other complementary results, a model has been proposed in 
which there are two separate G protein-coupled receptors for ADP on platelets, in 
addition to the P2 Xi receptor, one coupled to inhibition of adenylate cyclase ( P 2 Y ac) and 
the other responsible for shape change and coupled to PLC and Ca2+ mobilization (P2Yi), 
and that coactivation of these two receptors is essential for full expression of ADP- 
induced platelet aggregation (Jin et al., 1998; Jin and Kunapuli, 1998; Kunapuli 1998; 
Hechler et al., 1998a).
A wide range of nucleotide derivatives have been tested for their effects on ADP induced 
aggregation, intracellular Ca2+ mobilization and inhibition of stimulated adenylate 
cyclase activity in human blood platelets (Cusack and Hourani, 1981a,b; 1982a,b; Hall et 
al., 1994; Hall and Hourani, 1993, 1994; Hourani et al., 1992; Hourani and Hall, 1996; 
Geiger et al., 1998). However, the effects of these derivatives on shape change have not 
been compared to the other responses of platelets and quantitatively investigated. For this 
purpose, the effects of a range of nucleotides (figure 2 .1, figure 2 .2 ) on the two functional 
responses, aggregation and shape change were investigated in human washed platelets 
and compared to allow further characterization of the platelet ADP receptors mediating 
these responses.
2.2 Materials and methods
2.2.1 Materials
ADP, ATP, AMPCP, ApsA, AMPCPP, UTP, bovine serum albumin (BSA), [ethylene- 
bis(oxyethylenenitrilo)]tetraacetic acid (EGTA), prostacyclin,
tris(hydroxymethyl)aminomethane (Tris), PGEi, AL2-hydroxyethylpiperazine-7V’-2-
73
0 o
II II
■ O P -O -P -O - I1 Io- o-
ADP
-O
OH OH
AMPCP
0ii-o-p-o1
o-
OH OH
NH2
ADPaS ADPPS
2-Methylthio-ADP
Figure 2.1 The structures of some platelet ADP receptor agonists
74
o-
■0-P-I
0II
o—p-1o-
0IIo-p-o—i1o-
n h2
<";6
N— y\
OH OH
■o-p-I
o-
p-o—
OH OH
ATP AMPCPP
O O O
n ii n
■O-P-O— P-O -P-O -1
2-Methylthio-ATP
-O
o o o
HN
cA nII 1 1p-o—P-O -P-O -1  1 1 1 ^ o ^o- o- o- 1— Y
OH OH
UTP
Ap5A
suramin
Figure 2.2 The structures of some platelet ADP receptor antagonists
75
ethanesulfonic acid (HEPES) and isobutylmethylxanthine (IBMX) were obtained from
Sigma Chemicals Company (Poole, UK). ADPpS was obtained from Boehringer
Manheim (Germany) and Sp-ADPaS was obtained from BIOLOG Life Science Institute
(Bremen, Germany). 2-MeSATP and 2-MeSADP were purchased from Research
Biochemicals Incorporated (Natick, MA, USA). Suramin was a generous gift from Bayer,
UK, HPLC solvents, triethylamine, perchloric acid and aluminum oxide were obtained
from Fisher Scientific (Loughborough, UK). AG50W-X8[H+] was purchased from Bio
Rad. [U-14C]-Adenine (270mCi/mmol) in 2% aqueous ethanol and [2 ,8 -3H]-cAMP,
ammonium salt (41.5 Ci/mmol) in 2% aqueous ethanol were from Amersham 
International, pic. Prostacyclin was dissolved at 100 pg/ml in 10 mM NaOH, PGEi was
dissolved at 1 mM in 50% aqueous ethanol, IBMX was dissolved in HEPES-saline and
all others were dissolved in water. Fibrinogen and IBMX were made up fresh each day
while the nucleotides were stored frozen at -20°C. Most of the analogues were used as
they were purchased, except for 2-MeSATP, which contained about 20% 2-MeSADP as
an impurity when it was analyzed by HOPLC. It was therefore purified before use by ion-
exchange chromatography.
2.2.2 Preparation of human washed platelets
Venous blood from healthy human volunteers, who had not taken any drugs for the 
previous 10  days was drawn into one sixth of the volume of acid-citrate-dextrose 
anticoagulant (25g/l tri-sodium citrate dihydrate, 15g/l citric acid monohydrate, 20g/l 
glucose) and centrifuged at 260g for 20min. The supernatant platelet-rich-plasma was 
removed and centrifuged at 680g for 20 min in the presence of 1 pM of prostacyclin to 
precipitate the platelets. The supernatant plasma was discarded and the platelets were 
resuspended in 10 ml of HEPES-saline (145 mM NaCl, 5 mM KC1, 10 mM glucose, 10 
mM HEPES, 2 mg/ml BSA adjusted to pH 7.4 with 1M NaOH). The platelets were again 
collected by centrifugation at 680g for 20min in the presence of prostacyclin (1 pM) and 
resuspended at 2 x 108/ml in HEPES-saline. The second centrifugation step aimed at 
removing residual plasma proteins which could affect the platelet responses.
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2.2.3 Aggregation and shape change
Aliquots (250pi) of washed platelets were taken into siliconized glass aggregometer tubes 
containing 2.5 pi CaCl2 solution (final concentration 1 mM) and maintained at 37°C for 3 
min prior to transfer to a Chronolog lumi-aggregometer (Chronolog Corp., Havertown, 
PA, USA). Aggregation was quantified as the maximal rate of increase in light 
transmission (in arbitrary units per min) through the stirred sample, relative to HEPES- 
saline, on addition of agonist. Each aliquot of washed platelets was maintained at 37°C 
within the aggregometer and was stirred at 1 ,0 0 0  r.p.m. Agonists were added in 10 pi of 
water. Antagonists, where used, were added simultaneously with the agonist to avoid 
possible complicating effects of pharmacologically active degradation products. Calcium 
was added to the platelets at ImM final concentration 3 minutes before addition of 
agonist and fibrinogen was added to the platelets at 0.3 mg/ml final concentration 10 
seconds before the agonist.
To quantify the shape change, the maximal decrease (in arbitrary units) in light 
transmission through the stirred sample at 37°C on addition of the agonist was measured. 
A 50% dilution of the platelet suspension (i.e 1 x 10s platelets/ml) was used as the 
reference rather than HEPES-saline to magnify the responses. Calcium was added in the 
same way as for aggregation, but fibrinogen was not added. Under this condition, 
aggregation in responses to ADP was negligible as measured in the aggregometer.
2.2.4 HPLC separation of adenine nucleotides
To examine the purity of the adenine nucleotides used in this study, nucleotides were 
separated by ion-paired reversed-phase HPLC (Shimadzu) on a Techsphere 5 pm ODS, 
C18 column (25cm x 4.6 mm i.d). The injection volume was 40 pi, and column 
temperature was maintained at 37°C while running. The mobile phase consisted of two 
buffers : 100 mM KH2P0 4 , 8 mM tetrabutylammonium hydrogen sulphate, pH 6 .0  
(buffer A) and a mixture of buffer A and acetonitrile (60:40, v/v), pH 6.73 (buffer B). 
The column was eluted at a flow rate of 1.3 ml/min with the following gradient: 2.5 min
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at 100% A, 2.5 min up to 20% B, 5 min up to 40% B, 3 min up to 1 0 0 % B. The column 
was held at 100% B for a further 7 min and then returned to 100% A over 5 min. UV 
detector was used to read the absorbance at 259nm for nucleotides with unmodified 
adenine moieties and 273nm for 2-methylthio substituted adenine nucleotides (figure 
2.3).
2.2.5 Nucleotide purification
2-MeSATP needed to be purified before use. It was purified by ion-exchange 
chromatography on a 30 cm x 1.5 cm DEAE-sephadex A25 column. 25 mg of 2 - 
MeSATP was dissolved with 1 ml o f distilled water and loaded on to the column. The 
column was washed with low ionic strength buffer (1 mM triethylammonium 
bicarbonate) overnight to remove uncharged species, and then eluted with a 2L linear 
gradient of 1-800 mM triethylammonium bicarbonate, collecting 10 ml fractions which 
were collected and analyzed spectrophotometrically at 273nm, the maximal absorbing 
wavelength of 2-MeSATP (table 2 .1, figure 2.4). Fractions containing the required 2- 
MeSATP were pooled and rotary evaporated to dryness in a 1L flask at a temperature not 
greater than 30°C. Under these conditions the triethylammonium bicarbonate dissociates 
into its components, triethylamine, carbon dioxide and water, all o f which were 
evaporated from the sample. The residue was redissolved in HPLC grade methanol 
(50ml), and the rotary evaporation and dissolving in methanol were repeated three times. 
The residue was transferred to a 25 ml flask in 5 ml of methanol and evaporated to 
dryness followed by a second 5 ml methanol in water (5 ml) and evaporating to dryness. 
Finally the nucleotide was dissolved in water and the concentration was determined 
spectrophotometrically.
2.2.6 Measurement of adenylate cyclase activity
The method of Haslam and Rosson (1975) was used with a modification to measure the 
extent of intracellular cAMP formation after treatment of platelet-rich-plasma for 30 sec 
with adenine (Cusack and Hourani, 1982b). To label platelet adenine nucleotides,
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Table 2.1 Optimum wavelength and extinction coefficient for adenine nucleotides
Extinction coefficient at
Adenine nucleotide Optimum wavelength their optimal wavelength
(nm) pH 6-7 ExlO'3M-1cm-1
ATP 259 15.4
ADP 259 15.4
AMP 259 15.3
Adenosine 259 14.9
2-MeSATP 273 14.5
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platelet-rich-plasma which was obtained as in section 2.2.2, was incubated with 0.5 mM 
[U-14C] adenine for 45 min at 37°C. The platelets were then collected by centrifugation at 
680g for 20min in the presence of prostacyclin (1 pM) to prevent activation and 
resuspended at 2 x 108/ml in HEPES-saline. Aliquots (450 pi) of platelet suspension, 
which had been incubated for 3min at 37°C in the presence of 1 mM CaCL, were treated 
with solutions (50 pi) of ADP which contained PGEi (1 pM final concentration) to 
stimulate adenylate cyclase, IBMX (0.1 mM final concentration), to inhibit 
phosphodiesterase activity, and an appropriate concentration of agonist in the presence 
and absence of antagonist. After a further 30 seconds incubation at 37°C, the reaction was 
terminated by addition of 100 pi of ice cold 3 M perchloric acid with [3H]-cAMP 
(-20,000 d.p.m) to estimate recovery, followed by cooling on ice. After at least 30min on 
ice, the samples were centrifuged in a microfiige for 5min and an aliquot (450 pi) of the 
supernatant was placed on a column containing a packed volume of 1.3 ml of BioRad 
AG50W-X8 resin (H+ form) to remove the adenine and adenosine. cAMP was eluted in 
the 6-15 ml fraction with 1 mM KH2PO4 adjusted to pH 7.3 with KOH. This fraction of 
eluate containing cAMP was applied to a column packed with 1 g of aluminum oxide to 
remove the adenine nucleotides other than cAMP. Most of the cAMP was eluted in the 2- 
3 ml fraction with 100 mM Tris adjusted to pH 7.5 with HC1. The eluate was counted for 
3H and 14C by scintillation counting. The adenylate cyclase activity was expressed as 
d.p.m derived from [14C]-cAMP in the samples, corrected for the recovery of [3H]-cAMP 
during the extraction procedure. The log-concentration curves were obtained in platelets 
from at least three different donors in triplicate and these results from different donors 
were pooled.
2.2.7 Data analysis
All values were expressed as mean ± s. e. mean. Agonist concentrations giving 50% 
maximal response were determined from the midpoint drawn through the linear parts of 
the individual log concentration-response curves and expressed as the negative log of the 
concentration (p[A]so). For antagonist studies the concentration-ratios were calculated 
from the shift in the [A]5o values, and the inhibitor concentration divided by
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(concentration-ratio - 1) was taken as the apparent dissociation constant of the inhibition 
and expressed as a negative logarithm (pKB). All lines were drawn by linear regression 
analysis. The significance of differences between mean p[A]5o or pKB values for the two 
effects was assessed by unpaired Student’s t-test, and P  <0.05 was considered statistically 
significant.
2.3 Results
ADP and its analogues, 2-MeSADP, AMPCP, ADPaS and ADPPS were used as 
agonists. ATP (lOOpM) and its analogues, ApsA, AMPCPP and 2-MeSATP, as well as 
UTP and suramin were used as antagonists. For ADPaS, its antagonism was also 
measured. Except for 2-MeSATP and ADPaS, all the antagonists were used at 100pM 
concentrations.
ADP concentration-dependently induced aggregation and shape change and had a slightly 
higher potency for shape change (figure 2.5-2.16, table 2.2). 2-MeSADP also induced 
aggregation and shape change with a similar potency and was approximately ten times 
more potent than ADP both for aggregation and shape change (figure 2.6a and b). 
AMPCP acted as a very weak agonist for aggregation and appeared to be a low efficacy 
partial agonist, causing a response at 1 pM  but achieving less than 25% of the response to 
ADP at 100 pM (figure 2.7a). For shape change, no agonist effect was seen at 
concentrations of AMPCP up to 100 pM (figure 2.7b). Two ADP analogues, ADPPS and 
ADPaS, showed an obviously different potency for aggregation and shape change. 
ADPPS was a much more potent agonist for shape change than for aggregation (figure 
2.8). It caused shape change with 8 fold less potency than ADP, but was almost inactive 
in causing aggregation, achieving at 100 pM  only 26% of the maximum aggregation 
induced by ADP. ADPaS also showed differential effects on the responses, being almost 
as potent as ADP for shape change (figure 2.9b), whereas it was almost inactive in 
causing aggregation (figure 2.9a). When ADPaS was used together with ADP to see its 
effect on ADP-induced aggregation, ADPaS (10 pM ) antagonized the effect of ADP as
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Figure 2.5 Effects of ADP on aggregation (a) and shape 
change (b) of human washed platelets. Each point is the 
mean of at least 3 determinations and vertical bars show the 
s.e.mean.
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Figure 2.6 Effects of 2-MeSADP on aggregation (a) 
and shape change (b) of human washed platelets. Each 
point is the mean of at least 3 determinations and 
vertical bars show the s.e.mean.
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Figure 2.7 Effects of AMPCP on aggregation (a) and 
shape change (b) of human washed platelets. Each point 
is the mean of at least 3 determinations and vertical bars 
show the s.e.mean.
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Figure 2.8 Effects of ADPpS on aggregation (a) and shape 
change (b) of human washed platelets. Each point is the 
mean of at least 3 determinations and vertical bars show the 
s.e.mean.
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Figure 2.9 Effects of ADPaS on aggregation (a) and 
shape change (b) of human washed platelets. Each point 
is the mean of at least 3 determinations and vertical bars 
show the s.e.mean.
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an aggregating agent in an apparently competitive manner with an apparent pKB of 
5.4+0.1 (figure 2.10). Overall, the potency order of agonists used was 2- 
M eSA D P»A D P»A M PCP, ADPpS for aggregation with ADPaS being an antagonist, 
and 2-M eSADP»ADP>ADPaS>ADPpS»AM PCP for shape change (see table 2.2).
Both aggregation and shape change of ADP were inhibited by ATP (100 pM), which 
caused parallel shifts to the right of the log concentration-response curve to ADP to a 
similar extent for both responses (figure 2.1 la  and b). The effects of ADP on aggregation 
and shape change were also inhibited to a similar extent by ApsA (100 pM) in an 
apparently competitive manner (figure 2.12a and b). However, AMPCPP (100 pM) 
(figure 2.13a and b) and UTP (100 pM) (figure 2.14a and b) showed very little 
antagonistic effect on either aggregation or shape change induced by ADP. Suramin (100 
pM), which has been reported to be a non-selective P2 antagonist, acted as an antagonist 
for shape change (figure 2.15). It has an apparent pKB value of 5.0+0.1 and this is similar 
to the previously reported pKB for aggregation of 4.6 (Hourani et al., 1992). 2-MeSATP 
showed differential effects on the responses. It was a much higher affinity antagonist of 
aggregation than of shape change, being inactive as an antagonist for shape change at 1 or 
10 pM (results not shown) while at 100 pM it caused a parallel shift to the right of the 
concentration-response curve with an apparent pKB value of 5.2+0.2 (figure 2.16b). 
However, 2-MeSATP almost abolished the ADP-induced aggregation at 10 or 100 pM 
(figure 2.16a), and an apparent pKB value of 7.0+0.2 was calculated for this effect. This is 
highly significantly different from the apparent pKB value for inhibition of shape change 
(P<0.005). In addition 2-MeSATP (1 pM) antagonized the inhibition by ADP of PGEi- 
stimulated adenylate cyclase in an apparently competitive manner with an apparent pKB 
value of 7.2+0.2, which is not significantly different from the apparent pKB value for 
inhibition of aggregation (figure 2.16c). Overall, the apparent affinity order for 
antagonists was 2-MeSATP»ADPaS>ATP=Ap5A>suramin>AMPCPP, UTP for 
aggregation, and 2-MeSATP>suramin>ATP=Ap5A>AMPCPP, UTP for shape change 
(table2.2).
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Figure 2.10 Aggregation of washed platelets induced by 
ADP alone or in the presence of 10 jiM ADPaS. Each point 
is the mean of at least 3 determinations and the vertical bars 
show the s.e.mean.
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Platelet Responses 
(p[A]So or apparent pKB)
Aggregation Shape change
Agonists (p[A]5o± s.e.mean)
ADP 5.7+0.1 6.2+0.1*
2-methylthio-ADP 7.0+0.4 7.2+0.2
AMPCP < 4  1 < 4  1
ADPPS < 4  1 5.2+0.1
ADPaS _ l 5.9±0.2
Antagonists (apprent pKB± s e.mean)
ADPaS 5.4±0.1 -
ATP 4.9+0.1 4.6+0.1
ApsA 4.8+0.2 4.6+0.1
AMPCPP < 4  2 < 4  2
UTP < 4 2 A io
2-methylthio-ATP 7.0+0.2 5.2+0.2*
Suramin 4.6 3 5.0+0.1
Table 2.2. p[A]so values for agonists and apparent pKB values 
for antagonists for ADP-induced aggregation and shape change 
of human washed platelets. For abbreviations see text. Each 
value is the mean±s.e.mean of results obtained from three 
experiments using three donors, except for ADP where the 
results are the mean+s.e.mean of results from at least 20 
experiments using blood from at least 20 donors. * Significant 
difference between mean values for aggregation and for shape 
change, P<0.005, unpaired Student’s 7-test. 1 very weak agonist - 
response at lOOpM less than 30% of the response to A D P.2 very 
weak antagonist - concentration ratio at lOOpM less than 2. 3 see 
Hourani et al.(1992).
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Figure 2.11 Effects of ATP on ADP-induced aggregqation 
(a) and shape change (b) of human washed platelets. 
Responses to ADP are shown alone or in the presence of 
lOOpM ATP. Each point is the mean of at least 3 
determinations and the vertical bars show the s.e.mean.
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Figure 2.12 Effects of Ap5A on ADP-induced aggregation 
(a) and shape change (b) of human washed platelets. 
Responses to ADP are shown alone or in the presence of 
lOOpM Ap5A. Each point is the mean of at least 3 
determinations and the vertical bars show the s.e.mean.
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Figure 2.13 Effects of AMPCPP on ADP-induced 
aggregation (a) and shape change (b) of human washed 
platelets. Responses to ADP are shown alone or in the 
presence of lOOpM AMPCPP. Each point is the mean of at 
least 3 determinations and the vertical bars show the 
s.e.mean.
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Figure 2.14 Effects of UTP on ADP-induced aggregation (a) 
and shape change (b) of human washed platelets. Responses 
to ADP are shown alone or in the presence of lOOpM UTP. 
Each point is the mean of at least 3 determinations and the 
vertical bars show the s.e.mean.
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ADP concentration (pM)
Figure 2.15 Effects of suramin (lOOpM) on ADP-induced shape 
change of human washed platelets. Each point is the mean of at least 
three determinations and the vertical bars show s.e.mean.
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ADP concentration (pM)
ADP alone
ADP+O.lpM 2-MeSATP 
ADP+lpM  2-MeSATP 
-A- ADP+lOpM 2-MeSATP 
ADP+lOOpM 2-MeSATP
ADP alone
ADP+lOOpM 2-MeSATP
ADP alone
ADP+lpM  2-MeSATP
ADP concentration (pM)
Fig 2.16 Effects of 2-MeSATP on ADP-induced aggregation (a), shape 
change (b), and adenylate cyclase activity (c) of human washed 
platelets. Responses to ADP are shown alone or in the presence of 
0.1,1,10 or 100 pM 2-MeSATP. The dotted line on (c) shows the 
adenylate cyclase activity in the presence of IBMX (0.1 mM) alone. 
Each point is the mean of at least three determinations, and the vertical 
bars show the s.e.mean.
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2.4 Discussion
The results in this study represent the first detailed comparison of the structure-activity 
relationships of a group of nucleotide analogues at the human platelet ADP receptors 
mediating aggregation and shape change in platelets. Various adenine nucleotide 
analogues have already been tested for their structure-activity relationships on 
aggregation, increases in calcium and inhibition of adenylate cyclase to investigate ADP 
receptor and these results have been reported by several groups so far (See Mills, 1996; 
Hourani and Hall, 1996; Geiger et al., 1998, for review). As shape change is also another 
response of platelets which is stimulated by ADP simultaneously with aggregation and it 
is still not clear whether both these functional responses are mediated by one common 
ADP receptor or separate receptors, it is important to compare directly the structure- 
activity relationships for shape change and for aggregation. In these studies, all the 
procedures and conditions were kept the same both for aggregation and shape change 
measurements, which were carried out in parallel on the same platelet preparations in 
buffer. This is important especially for calcium concentration as the calcium 
concentration has been shown to affect both ADP-induced shape change and the effect of 
ADP on adenylate cyclase, as there was a significant leftward shift in the log 
concentration-response curve to ADP in the presence of EGTA compared to that in the 
presence of calcium (Hall et al., 1994). The only difference of experimental conditions 
between aggregation and shape change in the present studies was the presence and 
absence of fibrinogen which was necessary for aggregation but not for shape change. It 
should be noted that for most of the antagonists only a single concentration was tested so 
only an apparent pKB could be calculated, and that the antagonists were not preincubated 
with the platelets to avoid breakdown. In addition, the measure of aggregation used was 
the initial rate of aggregation and there is some evidence that different conclusions can be 
drawn when using different measures, at least in plasma (Jarvis et al., 1998). This group 
demonstrated that among three indices of aggregation such as maximal extent (the 
maximum degree of aggregation), final extent (the degree of aggregation after >8min), 
and rate (initial rate of aggregation), maximum and final extents differed when 
aggregation was transient, i.e. at low concentrations of ADP, whereas maximum and final
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extents were the same when aggregation was sustained, i.e. at higher concentrations of 
ADP. It was also shown that the extent of effects of some antagonists (ARL 67085 and 
A3P5P) can be different depending on the measure used. For example, ARL 67085 
caused competitive rightward displacement of final extent of ADP-induced aggregation 
and had minimal effect on rate, whereas A3P5PS produced parallel rightward 
displacement of all three indices.
ADP dose-dependently caused both aggregation and shape change (figure 2.3), having a 
slightly higher potency for shape change than for aggregation (p[A]50 value of 5.7+0.1 for 
aggregation versus 6.2+0.1 for shape change). 2-MeSADP was much more potent than 
ADP in inducing both aggregation and shape change and had similar potencies for each 
effect, whereas AMPCP caused only very weak aggregation as previously reported to 
platelet in plasma (Horak and Barton, 1974; Hall and Hourani, 1993) and was virtually 
inactive as an agonist for shape change. Among the agonists tested in these study, the 
phosphorothioate analogues of ADP, ADPaS and ADPPS, showed obviously different 
effects for aggregation and shape change. ADPPS caused shape change with a much 
higher potency than aggregation while ADPaS showed an even greater difference, being 
as potent as ADP for shape change (p[A]so value of 5.9+0.2 for ADPaS versus 6.2+0.1 
for ADP), but acting as an antagonist for ADP-induced aggregation. The extent of 
aggregation caused by these two analogues were much lower in washed platelets than 
previously reported in platelets in plasma, where they were both partial agonists 
achieving approximately 50% of the maximal response to ADP (Cusack and Hourani, 
1981a,b). The following suggestions may possibly explain these results: first, some 
unknown factors are lost from the plasma when they are washed; second, different 
conditions e.g., calcium concentrations, make the responses different; third, the process 
of washing the platelets may selectively desensitize some components of the aggregation. 
A different calcium concentration is caused by using citrate as an anticoagulant to 
prepare platelets in plasma (Heptinstall and Mulley, 1977). The concentration of Ca2+ in 
this plasma is 40-50 pM whereas it is 1 mM in the HEPES buffer suspending platelets in 
the present studies, and the concentration of Ca2+ in the suspending medium has been 
known to determine the extent to which the platelets respond to agonists (Packham et al.,
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1989; Hall et a l, 1994). This will be further discussed in chapter 4. ADPPS has also been 
shown to act as a partial agonist for inhibition of PGEi-stimulated adenylate cyclase and 
for increases in cytosolic calcium concentration (Cusack and Hourani, 1981a; Hall and 
Hourani, 1993). However, ADPaS acts as an antagonist for inhibition of PGEi- 
stimulated adenylate cyclase, whereas it acts as a partial agonist for increases in cytosolic 
calcium concentration (Cusack and Hourani, 1981b; Hall and Hourani, 1993). The results 
presented in this thesis clearly show that the two compounds exhibit different effects with 
respect to shape change and aggregation, supporting the idea that these two responses of 
platelets are mediated by multiple ADP receptors (Jin et al., 1998; Jin and Kunapuli, 
1998; Kunapuli, 1998; Hechler et al., 1998a). Based on this model of multiple ADP 
receptors, the actions of ADPaS can be explained by it being an antagonist at the P2YAc 
receptor but an agonist at the P2Yi receptor, as its apparent pKB value calculated here for 
inhibition of aggregation, 5.4 is very similar to that previously reported for its antagonism 
of the effect of ADP on adenylate cyclase, 5.13 (Cusack and Hourani, 1981b).
Most of ATP analogues tested in this study showed apparently similar affinities for ADP- 
induced aggregation and shape change as antagonists, causing the log concentration- 
response curve to shift to the right in a parallel fashion. ATP (100 pM) acted as an 
antagonist not only for ADP-induced aggregation as previously reported (MacFarlane and 
Mills, 1975), but also for shape change. The effects of ATP (100 pM) were apparently 
competitive for both responses which were inhibited to a similar extent (pKB values of 
4.9+0.1 for aggregation and 4.6+0.1 for shape change). ApsA and suramin also inhibited 
both responses to a similar extent and were similar to or a slightly stronger than ATP 
(table 2.2), whereas AMPCPP and UTP were essentially inactive as inhibitors for both 
aggregation and shape change. These results are in agreement with the previously 
published studies about aggregation, i.e. methylene phosphonate analogues are less 
potent than ATP and the a , (3 bridging oxygen appears to be essential for nucleotides to 
bind to the ADP binding site, thus modification to this region of ADP results in very 
weak agonists or antagonists (Horak and Barton, 1974; Cusack and Petty, 1988).
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However, like ADPaS and ADPPS, 2-MeSATP is another compound which can 
pharmacologically discriminate aggregation and shape change, showing much higher 
affinity antagonism of ADP-induced aggregation than of shape change. As mentioned 
earlier in the previous chapter, similar discrimination between ADP-mediated platelet 
responses has been observed for the structurally related analogue 2-MeS-AMP-PCP, 2- 
EtSAMP (Hourani et al., 1986, 1996) and ARL 66096 (Sanderson et a l, 1996; Daniel et 
al., 1998). 2-MeS-AMP-PCP and 2-EtSAMP competitively inhibited the effect of ADP 
on adenylate cyclase but only partially inhibited aggregation. ARL 66096 inhibited ADP- 
induced aggregation and ADP-induced inhibition of adenylate cyclase, but did not affect 
the ADP-mediated [Ca2+]i and shape change. In the present study, 2-MeSATP inhibited 
the effect of ADP on adenylate cyclase activity in an apparently competitive manner, and 
its apparent pKB for this (7.2) is very similar to its apparent pKB value for inhibition of 
aggregation (7.0). This is similar to results with 2-MeS-AMP-PCP, 2-EtSAMP and ARL 
66096. From previous work, 2-MeSATP (50 pM) also inhibited ADP-induced increases 
in cytosolic calcium concentration and an apparent pKB value of around 5.3 was 
calculated (Hall and Hourani, 1993). This is similar to its pKB value of 5.2 for inhibition 
of shape change in this study, although some depression of the maximal response to ADP 
was observed for inhibition of ADP-induced increases in cytosolic calcium concentration. 
In addition, these values are similar to the pKi value of 5.2 reported for inhibition of 
calcium mobilization in Jurkat cells transfected with the human P2Yi receptor (Hechler et 
al., 1998c). Again, these results can be explained based on the model of multiple ADP 
receptors being required for platelet aggregation, with 2-MeSATP having a higher 
affinity for the P2YAc receptor than for the P2Yi receptor. However, it should be noted 
that as with ADPaS and ADPpS different results were reported for platelets in plasma 
(Cusack and Hourani, 1982c). In platelets in plasma, 2-MeSATP inhibited ADP-induced 
aggregation in a non-competitive manner, which means that a component of the response 
was clearly resistant to inhibition by 2-MeSATP.
According to this study, ADP-induced responses of washed platelets appear to be well 
explained by a model involving two G protein-coupled receptors, with one (P2Yi) 
coupled to PLC via Gq and responsible for shape change, and other (P2YAc) coupled to
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Gi mediating inhibition of adenylate cyclase, with both receptors being required to be 
activated for aggregation, at least in washed platelets (Jin et al., 1998; Jin and Kunapuli, 
1998; Kunapuli, 1998; Hechler et al., 1998a). In this model 2-MeSATP has a higher 
affinity for P2Y Ac than P2Y i, ADPpS has a higher potency at P2Y i than P2Y AC, and 
ADPaS acts as an agonist at the P2Y i but an antagonist at P2Y Ac. Furthermore, if both 
receptors need to be activated simultaneously to cause aggregation, then for any agonists 
which have a different potency for P2Yi and P2Y Ac, the extent of aggregation will be 
determined by the lower potency receptor. However, for antagonist effects, binding to 
only one receptor, P2Yi or P2Y Ac, is enough to inhibit aggregation, so the pKB for 
inhibition of aggregation reflects the higher of the two pKB values.
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CHAPTER 3.
A3P5PS EFFECTS ON HUMAN PLATELETS
10 3
3.1 Introduction
The recent results from molecular cloning of a number of P2 receptors have led to great 
advances in the understanding of the mechanism of action of adenine nucleotides on 
platelets. G protein-coupled receptors termed P2Y and the ligand gated ion channel 
receptors termed P2X are the two main groups of P2 receptors. So far, seven subtypes of 
P2X and five subtypes of P2Y receptors have been identified (Burnstock and King,
1996). Stimulation of platelets by ADP causes aggregation, shape change, transient 
increase in calcium concentration and inhibition of adenylate cyclase activity. The 
question of whether these effects of ADP are mediated by one receptor or separately by 
more than one receptors has been debated for a long time and still under controversy 
(Mill, 1996; Gachet et al., 1996; Hourani and Hall, 1996). A good correlation between 
the effects of agonists and antagonists on aggregation, [Ca2+]i increases and inhibition of 
adenylate cyclase suggested a single ADP receptor (Hourani and Hall, 1996). However, 
studies using the thienopyridines, ticlopidine and clopidogrel, which block ADP-induced 
aggregation and inhibition of adenylate cyclase, but inhibit only partially the binding of 
radiolabelled 2-MeSADP to intact platelets without any affect on shape change or [Ca2+]i 
increases, strongly suggested the existence of two separate receptors mediating [Ca2+]i 
increases and inhibition of adenylate cyclase (Gachet et al., 1990b). Recently, the human 
P2Yi receptor was cloned and its pharmacological profile was characterized in Jurkat 
cells heterologously expressing human P2Yi mRNA (Leon et al., 1997). It was also 
demonstrated that ATP, 2-MeSATP, and 2-C1ATP, when they were freshly purified, 
acted as antagonists of ADP-induced Ca2+ mobilization instead of agonists (Hechler et 
al., 1998c). In addition, using reverse transcriptase-polymerase chain reaction (RT-PCR) 
amplification, the P2Yi receptor was found to be expressed in human platelets and 
megakaryoblastic cell lines (Leon et al., 1997). Thus, all these studies suggested that the 
P2Yi receptor probably represents the platelet ADP receptor (previously called £P2t 
receptor’). Further characterization has been slowed by the lack of availability of P2Yi- 
selective antagonist. More recently, Boyer and colleagues reported that A3P5PS (figure 
3.1), a cofactor for sulfotransferase enzymes, and A3P5P, a metabolite of A3P5PS, 
behaved as weak partial agonists at the P2Y receptor of turkey erythrocytes, and were 
competitive P2Yi receptor antagonists at both turkey and human
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Figure 3.1 The structure of adenosine 3’-phosphate 5'-phosphosulfate(A3P5PS)
1 0 5
P2Yi receptors expressed in 1321N1 human astrocytoma cells, with pKB values in the 
micromolar range (Boyer et al., 1996). The isomeric adenosine 2’,5’-bisphosphate 
(A2P5P) had similar antagonistic effects (Boyer et al., 1996). The importance of these 
compounds is in the observations that the effects of these bisphosphate analogues were 
specific for the PLC-coupled P2Yi receptor, since neither agonist nor antagonist activities 
were observed at the yet to be cloned adenylate cyclase-coupled P2Y receptor of C6 
glioma cells or at recombinant P2Y2, P2Y4, or P2Y6 receptors (Boyer et al., 1996). While 
the present study was being performed, it was reported that in human platelets, these 
compounds inhibit the effects of ADP in causing shape change and intracellular Ca2+ 
mobilization, but not its ability to inhibit adenylate cyclase (Jin et al., 1998). Although 
this study gave further support to the idea that several P2 receptors are involved in the 
different aspects of platelet stimulus-response coupling, it did not investigate the ability 
of these compounds to inhibit platelet aggregation induced by ADP. A recent study in 
rabbit platelets showed inhibition of ADP-induced platelet aggregation by A3P5PS (Savi 
et al, 1998). However, neither of these studies directly compared the apparent KB of the 
antagonist for the various responses in human platelets with that previously calculated for 
the cloned P2Yi receptor (Boyer et al., 1996).
The present study, therefore, was aimed at carrying out more detailed pharmacological 
studies of the effects of A3P5PS on the responses of human washed platelets to ADP to 
allow quantitative comparison to be made. The effects of A3P5PS on ADP-induced 
aggregation, shape change, increases in [Ca2+]i and inhibition of adenylate cyclase were 
investigated and quantitatively compared to the previously reported results for cloned 
P2Yi receptors. It confirms this compound, A3P5PS, to be a P2Yi-selective antagonist 
and supports the idea that the P2Yi receptor contributes to the characteristics of the 
platelet ADP receptor.
3.2 Materials and methods
3.2.1 Materials
10 6
ADP, A3P5PS, BSA, EGTA, prostacyclin, Tris, PGEi, HEPES, IBMX, and U46619 were 
obtained from Sigma (Poole, UK). AG50W-X8[H+] was purchased from Bio Rad. 
Aluminum oxide and perchloric acid were obtained from Fisher Scientific 
(Loughborough, UK). [U-14C]-adenine (270 mCi/mmol) in 2% aqueous ethanol and [2,8- 
3H]-cAMP, ammonium salt (41.5 Ci/mmol) in 2% aqueous ethanol were from Amersham 
International, pic. Fura-2/acetoxymethyl ester (fura-2/AM) was purchased from 
Molecular Probes and dissolved at 1 mM in dimethylsulphoxide. Prostacyclin was 
dissolved at 100 pg/ml in 10 mM NaOH, and PGEi was dissolved at 1 mM in 50 % 
aqueous ethanol. IBMX was dissolved in HEPES-saline and all other drugs were 
dissolved in distilled water. Fibrinogen and IBMX were made up fresh for each 
experiment while ADP, and A3P5PS, were stored at -20°C. Fura-2/AM was stored at - 
20°C with protection from light.
3.2.2 Aggregation and shape change
Venous blood was taken from healthy human volunteers who had not taken any drugs at 
least 10 days, and the platelets were isolated, were washed by centrifugation as 
previously described at section 2.2.2, and were resuspended at a density o f 2 x 108/ml in 
HEPES-saline buffer (145mM NaCl, 5 mM KC1, 1 mM MgCL, 10 mM glucose, 10 mM 
HEPES, 2 mg/ml BSA, adjusted to pH 7.4 with 1 M NaOH). Aggregation was quantified 
photometrically using Chronolog lumi-aggregometer as the maximal change in light 
transmission through a warmed (37°C), stirred (1000 rpm) aliquot of the washed platelet 
suspension, 3 min after addition of Ca2+ (1 mM) and 10 sec after addition of fibrinogen 
(0.3 mg/ml). Shape change was quantified by using the same apparatus but as the 
maximal decrease in light transmission, and in the absence of fibrinogen to eliminate 
aggregation.
Log concentration-response curves were obtained in triplicate in blood obtained from at 
least three donors. Agonist concentrations giving 50% maximal response were 
determined from the midpoint of lines drawn through the linear parts of the individual log 
concentration-response curves and expressed as the negative log of the concentration
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(p[A]so). For antagonist, the concentration-ratio was calculated from the shift in the [A] 50 
values, and the inhibitor concentration divided by (concentration-ratio-1) was taken as the 
apparent dissociation constant of the inhibitor and expressed as a negative logarithm 
(pKs). All lines were drawn by linear regression analysis.
3.2.3 Measurement of adenylate cyclase activity
Adenylate cyclase activity was measured as previously described at section 2 .2 .6  by 
measuring levels of [14C]-cAMP present after stimulation of platelets preincubated in 
plasma for 45 min at 37°C with [14C]-adenine. The labeled platelets were washed as 
before and resuspended in HEPES-saline buffer (pH 7.4), and aliquots (450 pi) were 
taken and preincubated for 3 min with CaCl2 (1 mM). Adenylate cyclase was stimulated 
for 30s at 37°C by addition of PGEi (1 pM final concentration) in the presence of the 
phosphodiesterase inhibitor IBMX (0.1 mM final concentration) and in the presence or 
absence of ADP, A3P5PS, or both, at various concentrations, all added simultaneously in 
a volume of 50 pi. For termination of the reaction, [3H]-cAMP (~20,000 d.p.m) was 
added together with ice-cold 3M perchloric acid to estimate recovery. The adenylate 
cyclase activity was expressed as d.p.m. derived from [14C]-cAMP in the samples and 
corrected for the removal of [3H]-cAMP, and then the baseline level o f [14C]-cAMP (i.e. 
that in the presence of EBMX alone) was subtracted. Inhibition of adenylate cyclase was 
expressed as a percentage relative to the level of [14C]-cAMP in platelets stimulated with 
PGEi alone. All values were expressed as mean ± s.e.mean. Log concentration-response 
curves were obtained in platelets from three different donors in triplicate and pooled. The 
EC50 value for agonist was calculated by linear regression of the linear portion of the 
pooled log concentration-response curves and p[A]so was expressed as the negative 
logarithm of the EC50. For antagonist, the concentration-ratios were calculated from the 
shift in the [A] 50 values, and the inhibitor concentration divided by (concentration-ratio - 
1) was taken as the apparent dissociation constant of the inhibition and expressed as a 
negative logarithm (pKB).
3.2.4 Fura-2/AM loading into platelets
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This is a modification of the method of Rink and Sage (1987). Venous blood was taken 
from healthy volunteers who had not taken any drugs at least 10 days, collected into one- 
sixth of the volume of acid-citrate-dextrose anticoagulant, and centrifuged at 260g for 
20min. The supernatant, platelet-rich-plasma was removed, and preincubated with 4 pM 
fura-2/AM at 37°C for 45 min in a water bath protected from light. The fura-2/AM 
loaded platelet suspension was centrifuged at 680g for 20min to sediment the platelets in 
the presence of 1 pM prostacyclin to prevent aggregation. The platelet pellet was 
resuspended at 2 x 108/ml in HEPES-saline (pH 7.4). 750 pi aliquots of platelet 
suspension were incubated at 37°C in siliconized glass aggregometer tubes and then 
transferred to a Perkin Elmer LS50 fluorimeter (Perkin-Elmer Ltd., Buckinghamshire, 
UK), with a cuvette modified to hold an aggregometer tube for measurement of cytosolic 
calcium concentration.
3.2.5 Measurement of cytosolic Ca2+ concentration
The fura-2/AM loaded platelet suspension was warmed at 37°C and stirred throughout 
the experiment. Ca (1 mM) was added 3 min before addition of ADP alone or in the 
absence or presence of A3P5PS added simultaneously. [Ca2+]i was measured 
fluorimetrically by the method of Grynkiewitz et al. (1985). The fura-2/AM loaded 
platelet suspension was excited alternately with light at 340 nm and 380 nm. The 
intensity of emitted light was measured at 510 nm and the ratio of the emitted light 
intensity on stimulation at these two wavelengths (I340/I380) was plotted against time. 
ADP (in the presence or absence of A3P5PS) were added in a maximal volume of 15 pi, 
20 sec after the start of data collection and the increase in [Ca2+]i was detected as an 
increase in the I340/I380 ratio (figure 3.2). The maximal intensity ratio (Rmax) was 
determined following lysis of the platelets with 0.2% Triton X-100 to expose the trapped 
dye to the saturating concentration of calcium in the suspending buffer, and the minimum 
intensity ratio (Rmiti) was determined by adding 10 mM EGTA in 40 mM Tris, where Tris 
raises the pH of the solution to a value at which EGTA binds calcium optimally and 
EGTA reduces the calcium concentration to the sub-nanomolar range. These
1 0 9
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Figure 3.2 Change of cytosolic calcium concentration of 
human washed platelets stimulated by 100pM ADP (a), 
followed by 0.4% Triton-X (b), and 10mM EGTA (c).
1 1 0
measurements were necessary to calibrate the loaded dye signal for the fluorescence 
ratio, and then were used for calculation of [Ca2+]i. The fluorescence intensity ratios were 
converted to calcium concentrations using the following formula (Grynkiewicz et al., 
1985):
[Ca2+],=KD[(R-R„lm)/(R1„„-R)]p
where: R is the measured intensity ratio,
Kd is the apparent dissociation constant of calcium from fiira-2/AM (225 nM),
(3 is the ratio of fluorescence values for Ca2+-bound/Ca2+-free indicator measured 
at wavelength used to monitor the Ca2+-free indicator (380 nm).
The response was quantified as the difference between the [Ca2+]j at the peak of the 
transient and the baseline value. Log concentration-response curves were obtained in 
triplicate with blood from at least three different donors and the results pooled. The EC50 
values were obtained by regression of the linear parts of the log concentration-response 
curves and concentration ratios for antagonist were calculated from the shift in the EC50 
values in the presence and absence o f antagonist. The apparent Kb values for antagonist 
were calculated from the concentration ratios using the formula KB=concentration of 
antagonist/(concentration ratio-1) and pKB values were calculated as -logioKB.
3.3 Results
The sulfate-containing adenine nucleotide derivative, A3P5PS inhibited ADP-induced 
aggregation in human washed platelets (figure 3.3). A3P5PS produced a parallel 
concentration-dependent shift to the right of the concentration-response curve for ADP 
with no apparent depression of the maximal response. The EC50 of ADP-induced platelet 
aggregation were 1.9 pM and the apparent pKB values in the presence of 10 pM and 100 
pM A3P5PS were 5.2 for both concentrations. This effect was selective as this antagonist 
(1 0 0  pM) did not inhibit the aggregation induced by PGH2 analogue U46619 (figure 3.4).
i l l
ADP concentration (pM)
Figure 3.3 Effect of A3P5PS on aggregation of human washed 
platelets to ADP. Each point is the mean and s.e.m. of the responses 
to ADP alone (■) or in the presence of lOpM (A) or lOOpM (□) 
A3P5PS, taken from experiments using blood from at least three 
donors.
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U46619 concentration (pM)
Figure 3.4 Effects of A3P5PS on aggregation of human washed 
platelets to U46619. Each point is the mean and s.e.m. of the 
responses to U46619 alone (■) or in the presence of lOOpM 
A3P5PS (□), taken from one experiment performed in triplicate .
U46619 alone 
+ lOOpM A3P5PS
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A3P5PS was also able to inhibit ADP-induced platelet shape change (figure 3.5). The 
inhibition was concentration-dependent, producing a parallel right-hand shift of the 
concentration-response curve for ADP. The EC50 value for ADP for the shape change in 
washed platelets were 0.45 pM and the apparent pKB values in the presence of 10 pM 
and 100 pM A3P5PS were 6.0 and 5.8, respectively.
Similar inhibition by A3P5PS was seen for ADP-induced increases in [Ca2+]i (figure 3.6), 
causing a concentration-dependent inhibition of this effect induced by ADP in fura- 
2/AM-loaded human washed platelets. The EC50 value for ADP for this effect was 3.1 
pM and the apparent pKB values for A3P5PS for this effect calculated from the 
concentration ratio for ADP in the absence and presence of A3P5PS were 5.4 and 5.0 for 
10 pM and 100 pM A3P5PS, respectively.
However, A3P5PS (100 pM) had no effect on the ADP-induced inhibition of increase in 
cAMP levels stimulated by 1 pM PGEi in human washed platelets (figure 3.7). The EC50 
value for ADP for this effect was 0.83 pM in the absence and 0.86 pM in the presence of 
this compound.
3.4 Discussion
The increasingly broad class of P2 receptors has been difficult to study, in part because of 
the lack of specific and subtype-selective antagonists. Although certain molecules have 
been found to act as P2 receptor antagonists, these compounds have little selectivity for 
interaction with P2 receptors over various other proteins with which they might interact, 
and these non-selective drugs in general are not able to distinguish among various 
subtypes. For the ADP receptor on platelets, three molecules that were previously used in 
studies of P2Y receptors, i.e. suramin, reactive blue 2 and PPADS, are not direct 
structural analogues of ATP and act in non-specific way (Burnstock and Kennedy, 1985; 
Hourani et al., 1992; Charlton et al., 1996; Vigne et al., 1998). For this reason, the recent 
observation by Boyer et al. (1996) that A3P5PS and A3P5P are selective P2Yi receptor 
antagonists appears to be an
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-A- -t-lOpM A3P5PS 
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ADP concentration (pM)
Figure 3.5 Effect of A3P5PS on shape change of human 
washed platelets to ADP. Each point is the mean and s.e.m. 
of the responses to ADP alone (■) or in the presence of 
lOpM (A) or lOOpM (□) A3P5PS, taken from experiments 
using blood from at least three donors.
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ADP concentration (pM)
Figure 3.6 Effect of A3P5PS on increases in cytosolic calcium 
concentration of human washed platelets to ADP. Each point is 
the mean and s.e.m. of the responses to ADP alone (■) or in the 
presence of lOpM (A) or lOOpM (□) A3P5PS, taken from 
experiments using blood from at least donors.
I- ADP alone 
+10pM A3P5PS
I- + lOOpM A3P5PS
116
ADP alone 
+100pM A3P5PS
ADP concentration (pM)
Figure 3.7 Effect of A3P5PS on inhibition of PGEl-stimulated 
adenylate cyclase. Each point is the mean and s.e.m. of the 
responses to ADP alone (■) or in the presence of lOOpM (□) 
A3P5PS, taken from experiments using blood from at least three 
donors.
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important step for further research, together with the results more recently presented by 
Leon et al. (1997) about the pharmacological characteristics of the human P2Yi receptor 
heterologously expressed in Jurkat cells, with ADP shown to be a selective agonist while 
freshly purified ATP competitively antagonized the action of ADP. As P2Yi receptor 
transcripts were found to be present in human platelets and megakaryoblastic cell lines, 
this group suggested that the P2Yi receptor could be similar to the platelet ADP receptor. 
In the present work, a more detailed pharmacological study of the effects of A3P5PS on 
the responses of human platelets was performed to further investigate the suggestion that 
the P2Yi receptor could be the platelet ADP receptor mediating ADP-induced responses 
in platelets.
The results presented here show that A3P5PS can inhibit the major functional responses 
of platelets, aggregation and shape change, and also the increase in cytosolic calcium 
concentration which appears to cause the former two responses. These results 
demonstrate the critical role of the P2Yi receptor in these events and support the 
suggestion that the receptor by which ADP causes platelet aggregation (the elusive “P2 t ” 
receptor) is in fact the P2Yi receptor (Leon et al., 1997). The pKB values calculated here 
(5.2) are somewhat lower than the pKB value of 6,46±0.17 reported by Boyer et al. 
(1996) in turkey erythrocytes, but this difference may be due to species differences or the 
experimental conditions, as these authors used a longer incubation time (5 min), which 
may allow better equilibration with the receptor but at the same time allow the 
breakdown of the compound. At the two antagonist concentrations used here (10 and 100 
pM), the calculated values of the apparent pKB were in close agreement, suggesting a 
competitive action of A3P5PS at the receptor on platelets. However, these results were 
different from those with previously known other antagonists of ADP, including ATP, 
which inhibited ADP-induced platelet aggregation, intracellular calcium increases, and 
adenylate cyclase inhibition as well (Mills, 1996; Hourani and Hall, 1996). Compared to 
the previously known fact that the ADP receptor on platelets is functionally coupled to 
adenylate cyclase which is blocked by ATP and its analogues, it was surprising to find 
that A3P5PS was not able to antagonize ADP-induced inhibition of PGEi-stimulated 
adenylate cyclase activity. This means that under conditions where the platelet
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aggregation was blocked by A3P5PS, ADP was still able to promote the inhibition of 
adenylate cyclase. This result is in agreement with results reported by Jin et al.(1998) and 
Savi et al.(1998). All these findings suggest that there exists a separate (yet to be cloned) 
P2 receptor coupled to inhibition of adenylate cyclase and resistant to A3P5PS but with 
very similar structure-activity relationships to the P2Y, receptor. However, it remains a 
question as to whether somehow coupling of the P2Yi receptor to this effector 
mechanism possibly by a different G protein in some way changes the structure-activity 
relationships and in particular, reduces its affinity for A3P5PS. As the antagonism by 
A3P5PS has been shown here to be specific for ADP and competitive, from a 
pharmacological view the existence of separate P2 receptor appears to be more plausible 
than the coupling to a different G protein. A P2Y receptor coupled to inhibition of 
adenylate cyclase has also been identified in a subclone of rat glioma cells termed C6-2B 
(Boyer et al., 1993) and in BIO rat brain capillary endothelial cells (Webb et al., 1996c), 
but whether these receptors are the same as that of platelets remains to be determined. 
Investigation of these receptors using compounds such as A3P5PS and ARL 66096 might 
help to answer this question.
To explain the mechanism of platelet activation by ADP, a three-receptor model has been 
proposed by Daniel et al. (1998). According to this model, there exist two separate 
receptors for ADP on platelets apart from the P2Xi receptor that is coupled to rapid 
calcium influx; one coupled to inhibition of adenylate cyclase and the other coupled to 
PLC/Ca2+ mobilization which could be the P2Yi receptor. The finding that the ATP 
analogue, ARL 66096 is a highly potent and selective inhibitor of ADP-induced platelet 
aggregation without any effect on ADP-induced intracellular Ca2+ mobilization and shape 
change (Humphries et al., 1994; Daniel et al., 1998) contributed to the idea of a three- 
receptor model, clearly separating two distinct responses of platelets to ADP. The results 
from using A3P5PS further confirm the existence of two different receptors coupled to 
two different signaling pathway. However, although this model explains what a single 
receptor model fails to explain, the exact mechanism of action of multiple ADP receptors 
still remains obscure until the adenylate cyclase coupled ADP receptor is cloned and 
further characterized.
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The reason why the ADP receptor coupled to inhibition of adenylate cyclase should be of 
the P2Y type is that it is clearly G protein coupled and indeed the Gj2 heterotrimeric G- 
protein involving adenylate cyclase has been found to be activated by ADP in human 
platelet membranes (Ohlmann et al., 1995). This receptor must exhibit a similar 
pharmacological profile to that of the P2Yi receptor, ADP being an agonist and ATP a 
competitive antagonist, but with slight differences in the selectivity of some ligands, for 
example, A3P5PS does not appear to interact with this receptor. The contrary examples 
of compounds which interact with adenylate cyclase coupled ADP receptor but not P2Yi 
receptor can be found not only in ARL 66096 but also in the earlier reported compounds,
2-MeS-AMP-PCP and 2-EtSAMP which selectively and competitively inhibit the effects 
of ADP on adenylate cyclase in platelets while only partially inhibiting ADP-induced 
platelet aggregation (Hourani et a l, 1996; Humphries et al., 1994; Daniel et al., 1998). 
Also, 2-MeSATP from chapter 2 appears to interact with adenylate cyclase coupled ADP 
receptor in preference to the P2Yi receptor. Overall, the current data fit very well a model 
of two P2Y receptors mediating the effects of ADP on platelet aggregation. However, the 
way and the extent in which these two different receptors contribute to the ADP-induced 
platelet activation has not been clearly established yet. It is already known that inhibition 
of adenylate cyclase alone is not sufficient to induce platelet aggregation from the studies 
using adenosine analogues, 2’,5’-dideoxyadenosine and 9-(tetrahydro-2-furyl)adenine 
(SQ 22536) (Haslam et al., 1978). In this previous study, both compounds markedly 
decreased the inhibition by PGEi of platelet aggregation induced by ADP as well as the 
associated increases in platelet cAMP, so providing further evidence that the effects of 
PGEi on platelet aggregation are mediated by cAMP. However, neither 2’, 5’- 
dideoxyadenosine nor SQ 22536 alone induced platelet aggregation. Moreover, neither 
compound potentiated platelet aggregation or the platelet release reaction when 
suboptimal concentrations of ADP were added to heparinized or citrated platelet-rich- 
plasma in the absence of PGEi, showing that cAMP plays no significant role in the 
responses of platelets to aggregating agents in the absence of compounds that increase the 
platelet cAMP concentration above the resting value. Thus, this means that the P2Yi is 
absolutely required for ADP to induce aggregation. Simultaneously, it was reported that
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the cytosolic calcium increase which is the P2Yi-related event, is a necessary but not 
sufficient event in the platelet activation (Rink et al., 1982). In this study, they showed 
that in Ca2+-free medium, thrombin evoked shape change and secretion even when [Ca2+]i 
remained near basal levels, suggesting the existence of alternative triggers for shape 
change and secretory exocytosis. Therefore, the role of the P2Y receptor coupled to 
adenylate cyclase (tentatively called “P 2 Y a c ” receptor) in ADP-induced aggregation 
should be considered to be similar to the role of the P2Yi receptor as both of them are 
essential but neither is able to trigger full aggregation alone.
In addition, the suitability of A3P5PS as a selective P2Y receptor antagonist and possible 
breakdown have been tested in intact tissues by some groups (Bultmann et al., 1998; Park 
et al., 1998). A3P5PS did not always act through P2Y receptor, for example, in the 
guinea-pig taenia coli, it was found to act through a non-P2Y receptor (Biiltmann et al.,
1998). In rat vas deferens, it did not inhibit the responses (contraction) mediated by 
means of the P2Xi receptor, confirming its selectivity for the P2Yi subtype, but it 
behaved as an agonist for the P2Yi-mediated response (relaxation) when it was used 
alone in rat duodenum (Park et al., 1998). Therefore, it appears that there are limitations 
for use of this compound as a selective P2Yi antagonist in whole tissues. Another 
limitation to its use as an antagonist is its rapid degradation. A3P5PS was degraded by 
preparations of the rat vas deferens with a half-life of 14.7+3.6 min although A3P5P was 
the only detectable degradation product (Park et al., 1998). This is why preincubation of 
A3P5PS with platelets was avoided in the present study, although the major breakdown 
product, A3P5P, has been reported to have very similar activity to the parent compound 
(Boyer et al., 1996).
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CHAPTER 4. 
COMPARISON OF THE RESPONSES OF 
WASHED PLATELETS AND UNWASHED 
PLATELETS IN PLASMA
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4.1 Introduction
All the experiments presented here so far have been carried out with washed platelets for 
the purpose of precluding the complication which might be brought by any components 
in plasma, and affect the characterization of agonist or antagonist activity, e.g. enzymic 
degradation, different ion concentrations, as has been shown in the case of suramin. 
Suramin showed its antagonistic activity for ADP-induced platelet aggregation only in 
washed platelets, not in platelets in plasma (Hourani et al., 1992). The study using 
washed platelets presented in chapter 2 not only provided pharmacological evidence in 
favour of a two-receptor model of platelet activation, but also indicated important 
differences between washed platelets and platelets in plasma which can greatly affect the 
results obtained with agonists and antagonists. In washed platelets, ADPJ3S showed very 
weak agonistic activity for aggregation and ADPaS was almost inactive as an agonist. 
However, in previous reports (Cusack and Hourani, 1981a,b), ADPpS and ADPaS acted 
as partial agonists for aggregation achieving a much higher maximal response (about 
75% of the maximal effect of ADP) compared to that seen in washed platelets presented 
here. Also, in the case of 2-MeSATP, ADP-induced aggregation was only inhibited by 
about 50% even at a high concentration of 2-MeSATP (100 pM) in platelets in plasma 
(Cusack and Hourani, 1982c) while 2-MeSATP (100 pM) completely abolished ADP- 
induced aggregation in washed platelets (see chapter 2). Similar differences in the extent 
of inhibition have been reported for 2-MeS-AMP-PCP which abolished ADP-induced 
aggregation with pICso value of -5.5 (Humphries et al., 1994) while behaving as non­
competitive inhibitor of ADP-induced aggregation of platelets in plasma, producing 
maximum inhibition of only 50-60% at 100 pM (Hourani et al., 1986, 1996). What is the 
difference, the washing itself or the suspending medium? All of these results raise the 
question of whether at least one of the ADP receptors of platelets, in particular the P2Yi 
receptor, since this receptor appears to contribute to aggregation more than P2YAc when 
these three compounds are used as agonists or antagonist for aggregation, is in some way 
desensitized during the washing process, showing weaker activity compared to those of 
platelets in plasma. That human washed platelets contain a low reserve P2Yi receptor 
population that mediates ADP-induced increases in [Ca2+]i has been suggested from a
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comparison between bovine P2Yi receptors transfected into Jurkat cells and human 
washed platelets (Fagura et al., 1998). Also, the studies using the CD39, a vascular 
adenosine triphosphate diphosphohydrolase deficient mice suggests that the P2Yi 
receptor desensitizes more than the P2YAc receptor (Enjyoji et al., 1999). It has been 
suggested from experiments using washed platelets that co-activation of two receptors 
(P2 Yi and P2YAc) is required to induce platelet aggregation (Jin and Kunapuli, 1998). 
Alternatively, in platelets in plasma, stimulation of P2Yi receptors alone appeared to be 
able to induce a sub-maximal aggregation, with activation of P2YAc being required for 
full expression of aggregation, suggesting that in platelets in plasma, P2Yi and P2YAc 
receptors contribute in different ways to cause platelet aggregation, P2Yi being involved 
in rapid transient aggregation while P2YAC mediating later sustained aggregation (Jarvis 
et al., 1998). Thus, the role of two different ADP receptors for the platelet aggregation 
can be explained in different ways depending the status of the platelets. Therefore, 
investigating what makes the difference between the responses of washed platelets and of 
platelets in plasma is important for further characterization of ADP receptors on platelets.
In addition to receptor desensitization, another possible factor responsible for a different 
extent of aggregation between washed platelets and unwashed platelets in plasma is the 
influence by plasma on the responses of platelets, which are lost by washing. The 
unknown factors in plasma, e.g. protein binding, different pH, different Ca2+ and Mg2+ 
concentration etc, might significantly contribute to ADP-induced platelet aggregation so 
that the responses o f platelets are affected by the absence of plasma. For example, the 
effects of [Ca2+]i on ADP-induced responses have been well known as the extent of 
platelet aggregation depends on the concentration of Ca2+ in the plasma (Heptinstall, 
1976; Hall and Hourani, 1993). The concentration of Ca2+ in the platelets medium can be 
different depending on the anticoagulant which is used to collect blood. Citrate is usually 
used as an anticoagulant for preparation for platelets in plasma without washing. Citrate 
lowers the level of [Ca2+]i in plasma and has been shown to stimulate the platelet release 
reaction (Mustard et al., 1975; Heptinstall and Mulley, 1977; Heptinstall and Taylor, 
1979). The contribution of the released products including ADP, 5-HT, and thromboxane 
A2, affects the extent of platelet aggregation caused by ADP, showing the secondary
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phase of aggregation which is not naturally caused by ADP itself at physiological 
concentrations of Ca2+ (Mustard et al., 1975; Heptinstall and Mulley, 1977; Packham et 
al., 1989). In addition, increased extracellular Mg2+ has been reported to show inhibitory 
effects on platelet activity including aggregation and dense granular release in blood 
anticoagulated with hirudin (Hwang et al., 1992; Hardy et al., 1995). The different pH 
between washed platelets in buffer and platelets in plasma has been reported to affect the 
P2Xi receptor mediated platelet response. Reduction of the external pH in washed 
suspensions resulted in a marked inhibition of both [Ca2+]i and shape change responses 
mediated by the P2Xi receptor (Rolf and Mahaut-Smith, 1999).
It is also possible that there exist unidentified factors in plasma which directly interfere 
with the original interaction between the ligand and its receptor in non-selective way, 
affecting the net response caused by the ligand.
In the present study, washed platelets were resuspended in their own plasma before they 
were challenged with drugs to see whether the different responses between washed 
platelets and platelets in plasma is caused by some factors in plasma, or by the process of 
washing resulting in receptor desensitization. If the former is the case, the responses 
which have been lost by washing should be restored by replacement of plasma. If 
receptor desensitization during washing is the case, replacement of plasma should not be 
able to restore the responses in washed platelets.
4.2 Materials and methods
4.2.1 Materials
ADP, BSA, prostacyclin, and Tris were purchased from Sigma Chemical Company 
(Poole, UK). ADPaS was obtained from BIOLOG Life Science Institute (Bremen, 
Germany) and ADPpS was from Boehringer Manheim (Germany). 2-MeSATP were 
purchased from Research Biochemicals Incorporated (Natick, MA, USA). Prostacyclin 
was dissolved at 100 |ag/ml in 10 mM NaOH and all others were dissolved in distilled
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water. Fibrinogen was made up freshly for each experiment while the nucleotides were 
stored frozen at -20° C.
4.2.2 Preparation of platelets in plasma
Venous blood from healthy human volunteers, who had not taken any drugs for the 
previous 10 days, was drawn into one sixth of the volume of acid-citrate-dextrose 
anticoagulant (25g/l tri-sodium citrate dihydrate, 15g/l citric acid monohydrate, 20g/l 
glucose) and centrifuged at 260g for 20 min. The supernatant platelet-rich-plasma was 
taken and the platelet count was estimated using a haemocytometer. The platelet density 
was adjusted to 2 x 108/ml by using HEPES-saline (145 mM NaCl, 5 mM KC1, 10 mM 
glucose, 10 mM HEPES, 2 mg/ml BSA adjusted to pH 7.4 with 1 M NaOH) if necessary. 
Up to this point, the pH of the platelet suspension in plasma was normally below 7.4 as 
acid-citrate-dextrose was used as an anticoagulant, so the pH was re-adjusted to 7.4 with 
5M NaOH.
4.2.3 Preparation of washed platelets
Venous blood was taken as same way as described for platelets in plasma and centrifuged 
at 260g for 20 min to get platelet-rich-plasma which was removed and centrifuged at 
680g for 20 min in the presence of 1 |iM prostacyclin to precipitate the platelets. The 
supernatant plasma was removed and kept separately to resuspend the platelets later. The 
platelets were suspended in 10 ml of HEPES-saline, and centrifuged again at 680g for 20 
min in the presence of 1 pM prostacyclin. This time, the platelets were resuspended in 5 
ml of the plasma from which the platelets had been taken. After the platelet count was 
estimated, it was adjusted to 2 x 108/ml with extra plasma and HEPES-saline when the 
amount of plasma was not enough. The plasma still contained ‘acid-citrate-dextrose’, 
which made it acidic, so the pH of the washed platelets resuspended in plasma was re­
adjusted to be same as the unwashed platelets in plasma (7.4) with 5M NaOH.
4.2.4 Platelet aggregation studies
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Aliquots (250 pi) of the washed platelets or unwashed platelets in plasma were added to 
siliconized aggregometer tubes and maintained at 37°C for 3 min with 1 mM final 
concentration of CaCl2 solution before transfer to a Chronolog lumi-aggregometer 
(Chronolog Corp., Havertown, PA, USA), Aggregation was quantified as the maximal 
rate of increase in light transmission (in arbitrary units per min) through the stirred 
sample relative to plasma, on addition of agonist. The platelet suspensions were 
maintained at 37°C within the aggregometer and was stirred at 1,000 r.p.m. Agonists 
were added in 10 pi of water. Antagonists, where used, were added simultaneously with 
the agonist to avoid possible complicating effects of pharmacologically active 
degradation products. Fibrinogen was added to the platelets at 0.3 mg/ml final 
concentration 10 seconds before the agonist. The experiments were carried out in parallel 
in both washed platelets and unwashed platelets in plasma, usually in triplicate, on 
platelets from the same donor.
4.2.5 Data analysis
All values were expressed as mean ± s. e.mean. Log concentration-response curves were 
obtained in triplicate in blood obtained from at least three donors. The E C 50 values were 
obtained by regression analysis of the linear portion of the triplicate concentration- 
response curves and p[A]so values were calculated as the negative logarithms of the EC50 
values with extrapolation of the lines if necessary. The significance of differences 
between mean values of the agonists in the washed platelets and in the unwashed platelets 
was assessed by analysis of variance, followed by Bonferroni’s test using the computer 
package GB-Stat, and P <0.05 was considered statistically significant.
4.3 Results
The apparent p[A]5 o value of ADP for aggregation in washed platelets and unwashed 
platelets in plasma was similar being 5.32 and 5.39, respectively, with the same 
maximum (figure 4.1). ADPaS was almost inactive in causing aggregation in washed
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Figure 4.1 Effects of ADP or ADPaS on aggregation of 
human washed platelets resuspended with plasma and 
unwashed platelets in plasma. Each point is the mean of at 
least three determinations and vertical bars show the 
s.e.mean. Overall, there was significant difference between 
the aggregation induced by ADPaS in washed platelets(A) 
and in unwashed platelets(A), P< 0.001, as determined with 
analysis of variance. * shows a significant difference between 
washed and unwashed platelets at individual concentration as 
determined by Bonferroni's test, P< 0.05.
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platelets even when the washed platelets were resuspended in plasma, achieving at 100 
pM only 25 % of the maximum aggregation induced by ADP (figure 4.1). In unwashed 
platelets in plasma, the maximum extent of aggregation induced by ADPaS was 54 % of 
the maximum aggregation induced by ADP in the same experiments (figure 4.1). The 
apparent p[A]5o values for ADPaS in washed platelets resuspended in plasma and in 
unwashed platelets in plasma were 1.76 ± 0.44 and 3.45 ± 0.3, respectively, when the 
maximum value was presumed to be same as that of ADP (100 pM). Overall, there was a 
significant difference between the aggregation of washed platelets resuspended by plasma 
and of unwashed platelets induced by ADPaS (analysis of variance, n=3, PcO.OOl) and 
comparison at individual concentration showed a significant difference at 100 pM 
(Bonferroni’s test, P<0.05).
ADP(3S induced aggregation of human washed platelets with low potency even when the 
washed platelets were resuspended by plasma (figure 4.2). The aggregation induced by 
100 pM ADPpS in washed platelets resuspended by plasma was 38 % of the response to 
ADP at the same concentration. In unwashed platelets in plasma, ADPpS achieved 65 % 
of the maximal effect of ADP at 100 pM. As in the case of the experiments with ADPaS, 
the apparent p[A]5o value of ADP for aggregation in washed platelets and unwashed 
platelets in plasma was similar being 5.35 and 5.43, respectively. The apparent p[A]so 
values for ADPPS in washed platelets resuspended in plasma and in unwashed platelets 
in plasma were 3.32 + 0.15 and 4.35 + 0.13, respectively, when the maximum value was 
presumed to be same as that of ADP (100 pM). Overall, there was a significant difference 
between the aggregation of washed platelets resuspended by plasma and of unwashed 
platelets induced by ADPPS (analysis of variance, n=3, P 0 .0 0 1 ) and comparison at 
individual concentration showed a significant difference at 100 pM (Bonferroni’s test, 
P<0.05).
The extent of inhibition of ADP-induced aggregation by 2-MeSATP did not appear to be 
markedly different between the washed platelets resuspended in plasma and
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Figure 4.2 Effects of ADP or ADPpS on aggregation of 
human washed platelets resuspended with plasma and 
unwashed platelets in plasma. Each point is the mean of at 
least three determinations and vertical bars show the s.e.mean. 
Overall, there was significant difference between the 
aggregation induced by ADPpS in washed platelets (A) and 
in unwashed platelets (A), P< 0.001, as determined with 
analysis of variance. * shows a significant difference between 
washed and unwashed platelets at individual concentration as 
determined by Bonferroni's test, P< 0.05.
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unwashed platelets in plasma, with both concentration-response curves of ADP-induced 
aggregation in the presence of 2-MeSATP (1 pM, 10 pM, 100 pM) being very close 
(figure 4.3 a,b,and c). 1 pM 2-MeSATP inhibited ADP-induced aggregation by about 30 
% of the maximal response by 100 pM ADP both in washed platelets resuspended in 
plasma and in unwashed platelets in plasma (figure 4.3 a). In higher concentration of 2- 
MeSATP (10 pM, 100 pM), 40 -  50 % inhibition of the maximal response by 100 pM 
ADP was shown in washed platelets resuspended in plasma and 30 -  40 % inhibition in 
unwashed platelets in plasma (figure 4.3 b and c). In all studies, the extent of ADP- 
induced aggregation of platelets was not affected by washing with both concentration- 
response curves being very close (figure 4.1-4.3).
4.4 Discussion
The different effects of some agonists and antagonists on aggregation between washed 
platelets in buffer and unwashed platelets in plasma were noted when the results in 
chapter 2 were compared to those previously reported results in platelets in plasma. 
However, both washed platelets and unwashed platelets in plasma have not been 
investigated using platelets from the same donor under the same experimental conditions, 
which is required for more precise and quantitative comparison. In the present study, the 
effects of ADPaS, ADPpS and 2-MeSATP, which had shown obviously different effects 
on aggregation were simultaneously compared both in washed platelets and in unwashed 
platelets both in plasma.
The washing process means the removal of plasma from platelets as well as physical 
forces applied to platelets during the centrifugation process. Centrifugation can activate 
the platelets to some extent and cause them to release their contents including ADP into 
the medium, which results in the desensitization of their receptors. Since two 
possibilities, receptor (P2Yi) desensitization or loss of some unidentified components in 
plasma, were considered as factors which could cause a reduced extent of aggregation in 
washed platelets compared to platelets in plasma, in this study I tested whether 
resuspension of the washed platelets in plasma can restore the response in washed
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Figure 4.3 Effects of (a) lpM , (b) 10pM, (c) lOOpM 2-MeSATP on 
ADP-induced aggregation of human washed platelets resuspended with 
plasma and unwashed platelets in plasma. Each point is the mean of at 
least three determinations and vertical bars show the s.e.mean.
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platelets. To preclude the effect of the low pH of the anticoagulant used on the activity of 
platelets in plasma, the pH of the platelet suspensions were re-adjusted to 7.4 before use 
in the aggregation studies.
In case of ADPaS and ADPPS, the extents of aggregation induced by them in washed 
platelets resuspended by plasma were not increased to the level of response in platelets in 
plasma although the aggregation induced by 100 pM ADPaS or ADPPS in washed 
platelets resuspended by plasma was slightly higher than the one in washed platelets 
without plasma; ADPPS inducing 38 % (figure 4.2) in washed platelets resuspended in 
plasma and 26 % in washed platelets in buffer (figure 2.8) of the maximal effect of ADP 
at 100 pM, and ADPaS inducing 25 % (figure 4.1) in washed platelets resuspended in 
plasma and being almost inactive in washed platelets in buffer (figure 2.9), In unwashed 
platelets in plasma, the maximum extent of aggregation by ADPPS (65 % of ADP- 
induced aggregation) was slightly lower than the previously reported value (75 %) 
(Cusack and Hourani, 1981a). The maximum value of ADPaS-induced aggregation in 
unwashed platelets in plasma (54 %) was also slightly lower than the previously reported 
value (75 %) (Cusack and Hourani, 1981b). However, the experiment condition here was 
not exactly same as previous one, i.e. addition of extra Ca2+ and fibrinogen to plasma, 
which could affect the responses. Also, acid-citrate-dextrose was used in the present 
study as an anticoagulant instead of citrate as in the previous study. Overall, the 
replacement of plasma to the washed platelets did not appear fully to restore the 
aggregation induced by ADPaS and ADPpS to that seen in platelets in plasma. Thus, for 
the responses to these two ADP analogues, P2Yi receptor desensitization by the washing 
process may explain the reduced aggregation in washed platelets rather than loss of 
uncertain factors present in plasma.
The case of the effect of 2-MeSATP on ADP-induced aggregation is more complicated. It 
does not appear to be consistent with the results from ADPaS and ADPpS. The extent of 
inhibition in washed platelets resuspended with plasma was not obviously different from 
that in unwashed platelets in plasma, and the concentration-response curves were very 
similar. This was the case at all concentration of 2-MeSATP tested, 1, 10 and 100 pM
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(figure 4.3). When the washed platelets were resuspended in plasma, -  30 % inhibition of 
the response to 100 pM  ADP was achieved by 1 pM  2-MeSATP. This is much lower 
than the ~ 50 % inhibition which was achieved in washed platelets in buffer (pH 7.4) 
(figure 2.16). Also, 10 and 100 pM  of 2-MeSATP inhibited -  50 % of maximal response 
by ADP in washed platelets resuspended in plasma in the present study (figure 4.3 b and 
c) while the same concentrations of 2-MeSATP almost abolished the ADP-induced 
aggregation in washed platelets in buffer (figure 2.16). This ~ 50 % inhibition is similar 
to previous results in citrated platelets in plasma (Cusack and Hourani, 1982c). Thus, 
unlike ADPaS and ADPPS, re-adding plasma to washed platelets did appear to affect the 
extent of response to ADP in the presence of 2-MeSATP, restoring the aggregation to the 
level of platelets in plasma. In other words, in these experiments it appears as if the 
plasma restores the ability of P2Yi receptor to induce some aggregation alone.
Overall, the results of the present study demonstrate that the extent of aggregation 
induced by ADPaS or ADPPS, which act as agonists preferentially on the P2Yi receptor, 
is not affected by the presence of plasma, but is decreased by the washing procedure. 
This suggests that the P2Yi receptors are desensitized by washing, resulting in reduced 
aggregation caused by ADPaS and ADPPS. However, the effect of 2-MeSATP on ADP- 
induced aggregation appears to be affected by the presence of plasma rather than by the 
process of washing. This is not consistent with the results for ADPaS and ADPpS. ADP 
is more potent agonist at P2Yi receptor than ADPaS and ADPpS, so when the plasma is 
re-added to the washed platelets, the restored P2Yi receptors alone can induce 
aggregation of washed platelets and the antagonistic effect of 2-MeSATP on P2YAC 
receptor does not result in a complete inhibition of aggregation compared to the case of 
washed platelets in buffer. However, further investigation remains to be defined to 
confirm this presumption.
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CHAPTER 5. 
PRELIMINARY STUDY ON 
EFFECTS OF HUMAN PLATELETS ON 
VASCULAR SMOOTH MUSCLE CELLS
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5.1 Introduction
A variety of vascular injury subtypes, for example, the development of advanced lesions 
of atherosclerosis, restenosis after angioplasty, and the accelerated coronary lesions that 
developed in transplanted hearts, are known to involve marked vascular smooth muscle 
cell proliferation. The repair mechanisms of vascular injury, including proliferation of 
fibroblasts and vascular smooth muscle cells should start at the site of injury, but at the 
same time the thrombus formation and proliferation of smooth muscle cells have been 
proposed to be possible causes for restenosis which limits the therapeutic effect of 
angioplasty (Ross, 1993). In these situations, a number of potent biological mediators are 
released from blood cells, including growth factors, cytokines, and vasoregulatory 
molecules, and may play a role in the proliferation of vascular smooth muscle cells (Ross, 
1993). More information has recently emerged about the interaction between platelets 
and vascular smooth muscle cells and its importance not only for the immediate, primary 
haemostasis but also for the long term consequences of platelet thrombus formation for 
the adjacent vascular smooth muscle cells. In animal models, there is evidence that 
platelet-mediated paracrine mechanisms contribute to smooth muscle cell proliferation 
and intimal migration (Goldberg et al., 1980; Fingerle et al., 1989) and the magnitude of 
platelet aggregation during the acute phase of mechanically created vascular lesions in 
dogs has been shown to correlate with the magnitude of the subsequent neointimal lesion 
(Willerson et al., 1991). In addition, in human and minipig smooth muscle cells in 
culture, platelets and growth factors were shown to have profound proliferative effects on 
these ceils after coronary angioplasty (Unterberg et al., 1996). Although the reports above 
support the importance of platelet modulation of smooth muscle cell growth and 
migration, the function of platelets within the thrombus as possible inducers or 
controllers and the mechanism of these effects are still incompletely understood. Also, 
most of information about this process concerns platelet-containing peptide growth 
factors, including platelet-derived growth factor (PDGF), epidermal growth factor (EGF), 
and TGF-P (Oka et al., 1983; Bell and Madri, 1985; Clegg and Sambhi, 1989, Hwang et 
al., 1992a), but less is known about the role of non-peptide platelet products, including 5- 
HT, ADP, thromboxane A2, noradrenaline, histamine, and PAF, in this process. Recently,
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it has been reported that at sites of vascular injury, 5-HT and thromboxane A2 could 
induce smooth muscle cell proliferation (Pakala et al., 1997) and adenine nucleotides, 
ATP, ADP, and adenosine and UTP also play a role in proliferation of smooth muscle 
cells (Crowley et al., 1994; Erlinge et al., 1993; 1995; Erlinge, 1998; Kishi et al., 1992; 
Harper et al., 1998; Yu et al., 1996; Boarder and Hourani, 1998). Crowley and his 
colleagues have shown that ADP and 5-HT significantly contribute to the platelet- 
induced smooth muscle cell proliferation in synergy with peptide growth factors, and 
proposed that in vivo 5-HT and ADP act as amplification factors for smooth muscle cell 
proliferation at sites of vascular injury (Crowley et al., 1994). The proliferative effect of 
ATP has been reported in vascular smooth muscle cells from rat (Erlinge et al., 1993; Yu 
et al., 1996), pig (Wang et al, 1992), and human (Erlinge et al., 1994).
The objective o f the present study was to investigate further the effects o f platelets on 
cultured human vascular smooth muscle cells. Explant cultures of human saphenous vein 
vascular smooth muscle were used as the experimental material. Firstly, released 
products from activated and non-activated platelets were tested for their effects on [3H]- 
thymidine incorporation into human smooth muscle cells to see their effects on the 
proliferation of smooth muscle cells. To avoid any effect caused by cell-cell contact 
between the platelets and smooth muscle cells, released products from platelets were 
prepared as supernatants after spinning down the platelets. In addition, the Transwell co­
culture system was investigated in an attempt to avoid direct contact between platelets 
and smooth muscle cells. Extracellular ADP and ATP were also applied separately with 
or without PDGF to see any synergetic effect between adenine nucleotides and PDGF on 
proliferation of smooth muscle cells. Secondly, the same experiments were carried out 
with measurement of phosphoinositide hydrolysis to see if the effects on smooth muscle 
cell proliferation involve the phosphoinositide signaling pathway.
5.2 Materials and methods
5.2.1 Materials
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ADP, ATP, 5-HT, and collagen were purchased from Sigma Chemical Co. (Poole, UK). 
Dulbecco’s modified Eagle’s medium (DMEM), foetal bovine serum, L-glutamine, 
penicillin/streptomycin, gentamycin, and PDGF-AB (human recombinant) were 
purchased from Gibco BRL (Gaithersburg, MD, USA) and diluted in Hanks’ balanced 
salt solution (see 5.2.3) containing 0.1 % BSA just before use according to the 
manufacturer’s instructions. Trichloroacetic acid and ethanol were obtained from Fisher 
Scientific (Loughborough, UK). Dowex 1X8-200 ion-exchange resin was purchased from 
Aldrich (Poole, UK). [3H]-Methyl-thymidine (76 Ci mmol'1) and [3H]-myoinositol (15 
Ci mmol'1) were obtained from Amersham International, pic. 24-Well culture plates and 
Transwell inserts (6.5 mm diameter, 0.4 pm pore size) were purchased from Costar. All 
other chemicals were obtained from Sigma. Drugs were prepared in sterile distilled water 
and diluted to a working concentration in serum-free DMEM.
5.2.2 Cell culture
Vascular smooth muscle cells explanted from human saphenous vein and verified as 95% 
smooth muscle cells by immunostaining for actin, were donated by Dr M.R.Boarder, 
Department of Cell Physiology and Pharmacology, University o f Leicester. They were 
cultured in DMEM supplemented with 10% foetal bovine serum, 2 mM glutamine, 50 
pg/mL penicillin, 50 pg/mL streptomycin, and 100 pg/mL gentamycin, at 37°C in a 
humidified 5% C 02, 95% air atmosphere until the cells reached confluence. They were 
then suspended by trypsinization, and split for subculture into 75-cm2 flasks at a ratio of 
1:3 or replated into 24-well culture plates at a density of 5 x 104 cells per well for the 
following assays. Cells from passages 7 through 13 were used for all studies.
5.2 3 Determination of DN A synthesis
Incorporation of [3H]-thymidine into smooth muscle cells was used as a measure of cell 
proliferation. When the cells growing in the 24-well plates reached 80-90% confluence, 
the cells were starved in serum-free medium containing 2 mM glutamine, 50 pg/mL 
penicillin, 50 pg/mL streptomycin and 100 pg/mL gentamycin for 24 hours to induce
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quiescent status. Drugs and platelet supernatants were added and the cells were incubated 
for 1 hour in the C 02 incubator. The medium containing these substances was then 
replaced with new serum-free medium and the cells returned to the incubator. After 19 
hours, [3H]-thymidine (1 fJiCi/pil) was added to the cells at a concentration of 1 pCi/mL 
and incubated for 4 hours. The medium was aspirated, and the cells were washed twice 
with cold Hanks’ balanced salt solution (HBSS) [(mg per L) NaCl 8000, KC1 400, 
Na2H P04 48, KH2P 0 4 60, M gS04*7H20  100, CaCl2-2H20  140, glucose 1000, 
MgCl2-6H20  100, NaHC03 350, pH 7.4], twice with ice-cold 5% trichloroacetic acid, and 
twice with ethanol. The fixed cells were solubilized in 0,5 ml of 0.5 M NaOH at -20°C 
for 1 hour. The contents of the wells were then thawed in a warm water bath and 
transferred to scintillation vials for liquid scintillation counting.
5.2.4 Measurement of phosphoinositide hydrolysis
Phosphoinositide hydrolysis was measured by monitoring the accumulation of IPi in the 
presence of LiCl (10 mM). Lithium acts as an inhibitor for the enzymes inositol 
monophosphatase and inositol polyphosphate 1-phosphatase, resulting in accumulation of 
IPi (Berridge et al., 1982). The protocol described by Toms et al. (1995) was modified. 
When the cells growing in the 24-well plates reached confluence, the cells were pre­
labeled with 2 pCi/ml [3H]-/wyo-inositol for 24 hours. The culture medium was then 
removed and the cells washed extensively with buffer (154mM NaCl, 5.6 mM KC1, 1.0 
mM M gS04, 3.6 mM NaHC03, 5.6 mM glucose, 1.3 mM CaCl2, 10.0 mM HEPES, 10.0 
mM LiCl, pH 7.4). Drugs or platelet supernatants were added to the wells in this buffer, 
and incubated at 37°C for 30 min. The assay was terminated by aspiration of the buffer 
and the addition of ice-cold 500 pi HC104 (7.5 % v/v), after which the platelets were left 
on ice at least for 15 min. The cell extract was then neutralized with Na2C 03 and [3H]-IPi 
was isolated via an ion-exchange column chromatography (Dowex 1X8-200) using 200 
mM NLLCOOH as eluant after washing myo-inositol from column with water, and 
glycerol phosphate with 25 mM NH4COOH. The [3H]-IPi was then quantified by liquid 
scintillation counting.
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5.2.5 Preparation and treatment of platelet-derived products
Blood was taken from healthy volunteers into one sixth of the volume of acid-citrate- 
dextrose anticoagulant (25g/l tri-sodium citrate dihydrate, 15g/l citric acid monohydrate, 
20g/l glucose) and centrifuged at 260g for 20min. The supernatant platelet-rich-plasma 
was removed and washed twice in the presence of 1 pM prostacyclin as described in 
section 2.2.2. The platelets were resuspended in HEPES-saline (145 mM NaCl, 5 mM 
KC1, 10 mM glucose, 10 mM HEPES, 2 mg/ml BSA adjusted to pH 7.4 with 1M NaOH), 
counted and the count adjusted to 2 x 108/ml.
200 pi of the washed platelet suspension was transferred to a siliconized aggregometer 
glass tube containing CaCl2 (1 mM) and maintained at 37°C for 3 min prior to transfer to 
a Chronolog lumi-aggregometer (Chronolog Corp., Havertown, PA, USA). Platelet 
suspensions were then stimulated with collagen (lOOpg) for 2 min in the presence of 
fibrinogen (0.3 mg/ml) to aggregate platelets. To prepare suspensions from non­
aggregating platelets, the same procedure was carried out but without the addition of 
collagen. The aggregated or non-aggregated platelets were removed by centrifugation at 
12,000 rpm for 5 min, and the supernatant collected. The supernatant of the aggregated or 
non-aggregated platelet suspension was added to the smooth muscle cell culture medium 
as described above. When the Transwell system was used, 200 pi of washed platelet 
suspension was laid into the Transwell inserts which sit on the top of the smooth muscle 
cell culture at 37°C, the same concentration of Ca2+, fibrinogen and collagen as above 
were added to the platelet suspension in the Transwell insert and stirred at maximum 
speed with a small magnetic bar until the platelets were observed to aggregate (~2 
minutes).
5.2.6 Data analysis
Results were shown as mean ± s.e.mean, except were otherwise stated. The significance 
of any differences between means were evaluated with analysis of variance, followed by 
Bonferroni’s test. A value of P<0.05 was considered to be statistically significant.
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5.3 Results
The cultured vascular smooth muscle cells showed a marked increase in proliferation, 
with about 250% of [3H]-thymidine incorporation compared to basal level (100%) after 
treatment with 100 ng per well of PDGF-AB (6.7 nM) (n=4, P<0.05). PDGF-AB 25 ng 
(1.7 nM) did not induce an increase in proliferation, only showing an incorporation of 
130% compared to basal level (n=3, P>0.05) (figure 5.1). Neither ATP (100 pM) nor 
ADP (100 pM) alone induced such a large increase in [3H]-thymidine incorporation, the 
incorporation being only 146% and 110% of basal level induced by ATP and ADP, 
respectively (n=3, P>0.05). However, ATP and ADP in the presence of PDGF-AB (25 
ng) evoked a larger increase compared to ATP or ADP alone, and even more than PDGF 
(25 ng) alone. 100 pM of ATP in the presence of 25 ng of PDGF-AB (1.7 nM) gave 
370% of [3H]-thymidine incorporation in the smooth muscle cells compared to the basal 
level and the same concentration of ADP in the presence of 25 ng of PDGF-AB gave an 
incorporation of 309% compared to the basal level. These experiments were only carried 
out twice in triplicate, and when each experiment was analyzed separately, this increase
for both ADP with PDGF and ATP with PDGF was statistically significant (P<0.05) in 
one of the two experiments.
Complete aggregation of washed platelets was observed by aggregometry on addition of 
collagen (100 pg per 4xl07 platelets) (figure 5.2). The supernatants from aggregated and 
non-aggregated platelets caused increases in the proliferation of vascular smooth muscle 
cells, the incorporation of [3H]-thymidine being 166% with the supernatant from non­
aggregated platelets while the supernatant from aggregated platelets caused 223% 
incorporation. These experiments were carried out twice in triplicate and there was a 
significant difference between the incorporation level caused by the supernatant from 
aggregated platelets and the basal incorporation level in one of the two experiments 
(P<0.05) when statistically analyzed for each experiment (figure 5.1). When the platelet 
count was increased to 6x107 or 8x107, the stimulatory effects on smooth muscle cell 
proliferation by the supernatants from aggregated platelets were markedly decreased 
compared to the supernatant from normal platelet count, and they even inhibited [3H]-
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Figure 5.1 Effects of various substances from platelets 
on [3H]-thymidine incorporation in human saphenous 
vein smooth muscle cells. Each bar shows the average 
and s.e.mean from at least three separate experiments 
or average and range of values from two separate 
experiments (+) performed in triplicate. * shows a 
significant difference from the basal level as 
determined by analysis of variance (P <0.05).
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Figure 5.2 Collagen-induced platelet aggregation in the presence of Ca2+ and 
fibrinogen. Washed platelets were stimulated with 100 pg of collagen at the arrow.
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thymidine incorporation (figure 5.3). Indeed, the supernatant of aggregated platelets at 
half o f the normal count (2xl07) caused an increase in the proliferation of smooth muscle 
cells compared to the basal level which was even higher than the increase caused by 
supernatant from aggregated platelets at a normal count (4xl07) (figure 5.3). This result is 
from one experiment in triplicate, and in this experiment, there was a statistically 
significant difference between the basal incorporation level and the increase allowed by 
supernatant from aggregated platelets at 2x107 count (P<0.01), and 4xl07 count (P<0.05), 
but the difference between the incorporation level by supernatant from aggregated 
platelets at 2x107 count and 4x107 count was not statistically significant.
Figure 5.4 shows the effects of ADP, ATP, and platelet supernatants on phosphoinositide 
hydrolysis in the smooth muscle cells. These experiments were carried out twice in 
triplicate. Whereas 25 ng of PDGF-AB per well (1.7 nM) did not cause any marked 
increase in the proliferation of the smooth muscle cells (figure 5.1), the same amount of 
PDGF-AB evoked a great increase in phosphoinositide hydrolysis. This achieved 
statistical significance (P<0.01) in each experiment. ATP and ADP (100 juM) also 
increased the phosphoinositide hydrolysis on their own. In each experiment, there was a 
significant difference between the levels of [3H]-IPi in the presence of 100 jjM ATP or 
ADP and the basal level (P<0.05). Compared to ATP and ADP, lOOpM 5-HT caused a 
smaller increase in phosphoinositide hydrolysis in smooth muscle cells which did not 
achieve a statistical significance. The supernatants from aggregated platelets caused a 
slight increase in phosphoinositide hydrolysis in smooth muscle cells while the 
supernatants from non-aggregated platelets did not cause any marked increase in the 
same experiments, and neither of these was significantly different from the basal level.
When the Transwell inserts were used for the purpose of keeping the platelet suspension 
from directly contacting the vascular smooth muscle cells in culture while at the same 
time hopefully allowing the derived products from platelets to pass through the Transwell 
inserts, the aggregation of platelets was observed in less than 2 minutes after adding 
collagen. However, there was no increase in [3H]-thymidine incorporation compared to 
the basal level whether the platelets were aggregated or not (figure 5.1). The same results
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Figure 5.3 Effects of platelet number on [3H] -thymidine 
incorporation in human saphenous vein smooth muscle 
cells. Each bar shows the average and s.e.mean from one 
experiment performed in triplicate. * shows a significant 
difference from the basal level as determined by analysis 
of variance (P<0.05).
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Figure 5.4 Effects of various substances from platelets on [3H]- 
inositol monophosphate production in human saphenous vein 
smooth muscle cells. Each bar shows the average and range of 
values from two separate experiments performed in triplicate, 
apart from the value for IOOjhM 5-HT (+) which represents one 
experiment performed in triplicae. * shows a significant 
difference from the basal level in each experiment as determined 
by analysis of variance (P<0.05).
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were seen when phosphoinositide hydrolysis was measured with no increase in [3H]-IPi 
being obtained (figure 5.4). When the Transwell system was tested with commercial ink 
being placed in the insert to confirm that derived products could pass through the filter 
into the bottom well during the incubation time which was used for the present 
experiments, it was found to be too slow, with no ink being detectable by eye in the 
bottom well before 2 hours.
5.4 Discussion
The mitogenic effects of platelets on vascular smooth muscle cells and the contribution in 
vivo of platelet accumulation at the sites of vascular injury in local smooth muscle cell 
proliferation has been presented in previous several studies (Ross, 1988a,b; Fingerle et 
al., 1989; Friedman et al., 1977; Willerson et al., 1991). Although the role in this 
proliferation of PDGF and other peptide growth factors present in platelets has been 
proposed by several groups (Ross, 1988a,b; Ross et al., 1986; Ferns et al., 1991; Clegg 
and Sambhi, 1989; Hwang et al., 1992a), little is known about the role of the non-peptide 
products in platelet-induced vascular smooth muscle cell proliferation. Based on the 
recent evidence that platelet-induced vascular smooth muscle cell proliferation is 
modulated by various platelet-derived products including adenine nucleotides (Crowley 
et al., 1994; Erlinge et al., 1995; Erlinge, 1998; Harper et al., 1998; Yu et al., 1996; 
Boarder and Hourani, 1998), the present study extends the previous observations by 
showing that activated platelets release various platelet-derived factors sufficient to 
induce smooth muscle cell proliferation. To fully activate the platelets, collagen was 
chosen because it is the highly potent platelet activator and unlikely to have a mitogenic 
effect on smooth muscle cells by itself. The extent of platelet activation by collagen was 
confirmed by the aggregation profile (figure 5.2). The effects of platelets on smooth 
muscle cell proliferation appeared to depend on the way the platelet-derived products 
were administered to the smooth muscle cells. While most of previous studies have been 
done either by adding the platelet suspension directly to the smooth muscle cell culture or 
by using supernatants from lysed platelets (Crowley et al, 1994; Unterberg et al., 1996; 
Kishi et al, 1992), the present study was carried out in such a way as to avoid direct
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contact between platelets and smooth muscle cells, and to only investigate products 
released physiologically from activated platelets rather than the entire platelet contents.
The Costar Transwell system was originally designed to allow co-culture, in which one 
cell type grows on a permeable membrane in the upper chamber of a co-culture dish and 
the other cell type grows in the lower chamber. This system was investigated as a way of 
keeping the platelets and cultured smooth muscle cells physically separated while 
allowing the passage o f any released products from platelets down to the smooth muscle 
cells in the lower chamber. The 0.4 pm pore size and 6.5 mm diameter Transwell inserts 
which fit into the 24-well plates containing the cultured smooth muscle cells were used 
with the platelet suspensions placed in the top chamber and activated in situ. The pore 
size of the Transwell inserts was considered appropriate to prevent the platelets from 
passing through the membrane while allowing the released substances for platelets 
including adenine nucleotide molecules, 5-HT, thromboxane A2 and PDGF to pass 
through the membrane. However, when the platelets were activated in the Transwell 
inserts, they did not cause any increase in the [3H]-thymidine incorporation into smooth 
muscle cells compared to basal level (figure 5.1). It appears that the derived products of 
platelets are not able to pass through the Transwell membrane within the 1 hour 
incubation time to affect the smooth muscle cells although the pore size should have been 
large enough for this passage. Indeed, even ink could pass through only very slowly.
In separate experiments therefore, the washed platelets were activated in the same way as 
for an aggregation study, and then the supernatants which contained the platelet-derived 
products, were added to the smooth muscle cells. This treatment evoked an increase in 
[3H]-thymidine incorporation into the smooth muscle cells of 166 % of the basal level by 
non-aggregated platelets, and 223 % by aggregated platelets (figure 5.1). The non­
aggregated platelets were treated exactly the same as the aggregated platelets including 
the addition of CaCl2 and stirring, apart from the absence of aggregating agent collagen. 
However, platelets can be activated by centrifugation, and this might explain why even 
the non-aggregated platelets induced a slight increase in proliferation of the smooth 
muscle cells. It is interesting that the effects of platelet-derived products on smooth
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muscle cell proliferation depended on the number of platelets. When more than 6 x 107 
platelets were used to get the platelet-derived products, the supernatant actually lowered 
the [3H]-thymidine incorporation into smooth muscle cells (figure 5.3). Similar results 
have been reported in human and minipig smooth muscle cells (Unterberg et al., 1996). 
The results of this group have shown a bell-shaped platelet concentration-response curve 
when platelet-induced DNA synthesis in human smooth muscle cell was studied and it 
was suggested that the decrease in [3H]-thymidine incorporation into smooth muscle cells 
caused by high numbers of platelets could be caused by a high concentration of TGF-(3 
present in platelets. TGF-p has been known to be released from the aggregating human 
platelets, stimulating the expression of thrombin receptors in vascular smooth muscle 
cells (Schini-Kerth et al., 1997). It has been previously reported to exert an inhibitory 
effect on smooth muscle cells in high concentrations (Gospodarowicz et al., 1988) and 
more recently, Crowley and his colleagues (1994) reported an inhibitory effect on bovine 
vascular smooth muscle cells by T GF - (3 - concentration above 1.5 ng/ml. As well as this 
mechanism to explain the inhibitory effects of high platelet numbers on smooth muscle 
cell proliferation, three other mechanisms in vivo have been proposed (Weber and Schror,
1999): (i) stimulation of endothelial cells via thromboxane A2j 5-HT and thrombin; (ii) 
induction of cyclooxygenase-2 via PDGF and thrombin, and (iii) trans-cellular eicosanoid 
metabolism, all of which could result in smooth muscle cell growth inhibition.
Using the same type of cultured human vascular smooth muscle cells, it has been 
reported that ATP alone (up to 300 pM) does not induce an increase in [3H]-thymidine in 
smooth muscle cells, while it does evoke a significant increase in [3H]-thymidine 
incorporation in the presence of PDGF (1 nM) compared to PDGF (1 nM) alone (White 
et al., 1999). In the present study, no marked effects on smooth muscle cell proliferation 
were shown by ADP or by ATP alone (100 pM), but ADP and ATP (100 pM) increased 
smooth muscle cell proliferation in synergy with 25 ng of PDGF (1.7 nM), causing a 
much higher extent of proliferation than 25 ng of PDGF (1.7 nM) alone. These results are 
in agreement with those of White et al. (1999). The effect of 100 pM ATP with 1.7 nM 
PDGF was much greater than the effect of the supernatant of aggregated platelets, being 
370 % and 166 %, respectively, compared to the basal level.
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The effect of platelet-derived products on smooth muscle cells was not observed when 
phosphoinositide hydrolysis was measured, rather than [3H]-thymidine incorporation, 
whereas the stimulatory effect of PDGF (1.7 nM) on phosphoinositide hydrolysis was 
much higher than its effect on proliferation. ATP and ADP (100 p.M) evoked a marked 
increase in the level of IPi as expected for action at a P2Y receptor (Abbrachio et al., 
1993). The same concentration of 5-HT also caused an increase in IPi levels, but to a 
lesser extent than did ADP or ATP. So, the effect of supernatant of aggregated platelets 
on smooth muscle cell proliferation does not appear to be due to phosphoinositide 
turnover. It might be worth testing a larger amount of supernatant from aggregated 
platelets to see whether the concentration of platelets which was used in the present study 
was too low to induce the effect. However, the inhibitory effects at high platelet density 
may be seen here as in experiments on [3H]-thymidine incorporation.
In summary, activated platelets modulate the proliferation of human saphenous vein 
smooth muscle cells by releasing various products which interact with each other. Further 
studies on the role and comparative contribution of each product to the responses remains 
to be done to elucidate the mechanism of platelet modulation of smooth muscle cell 
proliferation.
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CHAPTER 6. 
GENERAL DISCUSSION
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In this study, four major responses of platelets, aggregation, shape change, intracellular 
calcium concentration, and adenylate cyclase activity were measured using a range of 
adenine nucleotide analogues for further characterization of human platelet ADP 
receptors (Table 6.1, Figure 6.1). Studies on the effects of adenine nucleotide analogues 
on aggregation and shape change induced by ADP in human platelets showed the detailed 
quantitative comparison of the structure-activity relationships of a group of adenine 
nucleotide analogues at the human platelet ADP receptors mediating aggregation and 
shape change in washed platelets. In general, the structure-activity relationships for both 
responses were similar, but for ADPaS, ADPPS, and 2-MeSATP differences were 
observed. ADPaS and ADP|3S were very week or almost inactive agonists for 
aggregation, and showed much more potency for shape change than for aggregation. 
ADPaS even showed an antagonistic effect on ADP-induced aggregation with an 
apparent pKB value of 5.5+0.1. 2-MeSATP was a much higher affinity antagonist of 
aggregation than of shape change with an apparent pKB value of 7.0+0.2 for aggregation 
and 5.2+0.2 for shape change. It had previously been proposed that the ADP-induced 
platelet aggregation is mediated by one receptor and the shape change is mediated by 
another, separate receptor (Gachet et al., 1995). This proposal was based upon the studies 
with antiplatelet compounds, ticlopidine and clopidogrel which inhibited ADP-induced 
aggregation with no affect on shape change. This group suggested that platelet 
aggregation is mediated by a P2Yi receptor coupled to internal calcium mobilization 
while shape change is mediated by a P2Xi receptor causing influx of Ca2+. This 
proposition has been modified at some extent now that we have more knowledge about 
molecular mechanisms for platelet activation. The results from molecular cloning and 
further development of selective antagonists have established a model involving P2Xi, 
P2Yi, and the tentatively named P2YAc receptors for ADP-induced platelet activation. 
Among the ADP-induced platelet responses, aggregation, increases in calcium 
concentration, and inhibition of stimulated adenylate cyclase activity have been 
investigated by other groups (for review, Hourani and Hall, 1996; Mills, 1996; Geiger et 
al., 1998). However, shape change had not been investigated using a range of adenine 
nucleotide analogues and compared to other responses. Thus, the pharmacological 
investigation to assign each of these ADP receptors to their functions had not been
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Aggregation Shape change Increase in 
[Ca2'h
Inhibition o f 
adenylate cyclase
Agonists
ADP 5.7 6.2 6.1 5.5
2-Methylthio-ADP 7.0 7.2 7.4 7.5
AMPCP < 4 <4 n.d n.d
ADPpS < 4 p-» 5.2 5.4 pa 5.3 pa
ADPaS 5.4 ant 5.9 6.3 pa 5.1 ant
Antagonists
ATP 4.9 4.6 5.0 5.2
ApsA 4.8 4.6 5.1 4.8
AMPCPP <4 < 4 4.3 4.2
UTP < 4 <4 <4 n.d
2-Methylthio-ATP 7.0 5.2 5.3 7.2
Suramin 4.6 5.0 4.6 5.1
Table 6.1 p[A]so values for agonists and apparent pKB values for antagonists for ADP-induced 
aggregation, shape change, increases in cytoplasmic Ca2+ levels and inhibition of adenylate 
cyclase in human platelets. Aggregation, shape change, and increases in [Ca2+]i were 
investigated with washed platelets (washed twice for aggregation and shape change, once for 
[Ca2+]i) and inhibition of adenylate cyclase was investigated with unwashed platelets in plasma 
except 2-methylthio-ATP which was done with washed platelets. 
p.a= partial agonist for this effect 
n.d= not determined 
ant= antagonist for this effect
(Data are taken from Cusack and Hourani 1981a,b, 1982a,b, Hall et al., 1994, Hall and Hourani 
1993, 1994, Hourani et al., 1992, and from the present study.)
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Figure 6.1 Comparison between aggregation, shape change, increases in [Ca2+]i and 
inhibition of adenylate cyclase for ADP receptors agonists and antagonists. Data are 
taken from Table 6.1. The lines on the graphs are drawn from the regression analysis 
between responses. A statistically significant correlation was only found for graph b 
(PC0.001).
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completed. At this point, it required to be done to provide a better understanding of the 
role of each receptor and their contribution to platelet responses. The results presented 
here support the suggestion that aggregation and shape change are mediated by multiple 
ADP receptors on human platelets, and are consistent with shape change being mediated 
via one receptor (the P2Yi receptor) and aggregation requiring the activation of two 
receptors (the P2Yi and the P2YAc receptor).
According to previous studies (Hall and Hourani, 1993; Hourani and Hall, 1996), 
aggregation by adenine nucleotide analogues showed a good correlation with [Ca2+]i 
increase, and with inhibition of stimulated adenylate cyclase activity. However, the 
correlation between [Ca2+]i increase and inhibition of adenylate cyclase was reported to 
be less good (Hourani and Hall, 1996). This is not so surprising when one considers that 
these responses are mediated by different ADP receptors, the P2Yi and the P2YAc, 
respectively, according to the current model (Jin et al., 1998; Kunapuli, 1998). The first 
report of a structural adenine nucleotide analogue which shows obviously differential 
effects on the responses of ADP-induced platelets was for 2-MeS-AMP-PCP and 2- 
EtSAMP in 1986 (Hourani et al., 1986, 1996), suggesting the possibility o f two forms of 
ADP receptor, only one of which is coupled to inhibition of adenylate cyclase and at 
which these two compounds are specific competitive antagonists. Afterwards, it was 
followed by ticlopidine (Gachet et al., 1990b) and ARL 66096 (Humphries et al., 1993, 
1994a) which act exclusively on the adenylate cyclase-linked ADP receptor (the P2YAC 
receptor), and A3P5PS and A3P5P which act on the P2Yi receptor coupled to PLC (Jin et 
al., 1998). The molecular cloning of the P2Yi receptor and the P2Xi receptor has further 
completed the previous pharmacological data as it allowed investigation of their 
structure-activity relationship by cloning the receptor genes and exclusively expressing 
them in other types of cells. The P2YAc receptor has not yet been cloned.
In the present study, the results shown in chapter 2 demonstrate that ADPaS and ADPpS 
have a much higher potency on the P2Yi receptor than the P2YAC receptor with ADPaS 
being an antagonist on the P2YAC, while 2-MeSATP has a higher affinity for the P2YAC 
receptor than for the P2Yi receptor. In a previous study, ADPaS was shown to be almost
155
inactive for affecting adenylate cyclase activity by itself and even to act as an antagonist 
for ADP-induced inhibition of adenylate cyclase activity in platelets in plasma (Cusack 
and Hourani, 1981b). ADPpS was a partial agonist both for inhibition of adenylate 
cyclase activity and for aggregation, but with less efficacy for inhibition of adenylate 
cyclase activity than aggregation in platelets in plasma (Cusack and Hourani, 1981a). 2- 
MeS ATP was shown to behave as a non-competitive antagonist for ADP-induced platelet 
aggregation in platelets in plasma (Cusack and Hourani, 1982c), while it appeared to be 
an competitive antagonist for ADP-induced platelet aggregation as well as inhibition of 
adenylate cyclase activity in washed platelets (chapter 2). For the increase in [Ca2+]i, 
ADPaS and ADPpS showed much higher partial agonist activities compared to the 
aggregation (Hall and Hourani, 1993) even though the [Ca2+]i increase was also measured 
in washed platelets as was aggregation in the present study, confirming that the P2Yi 
receptor is not the only ADP receptor required for the full expression of aggregation. 2- 
MeSATP (50p,M) acted as a non-competitive antagonist for increase in [Ca2+]i in washed 
platelets (Hall and Hourani, 1993), but the extent of inhibition was much less than for 
aggregation shown in the present study as 10pM and lOOpM 2-MeSATP almost 
abolished the ADP-induced aggregation. In addition, 2-MeSATP appeared to act as a 
competitive antagonist for ADP-induced aggregation in washed platelets rather than a 
non-competitive inhibitor (figure 2.16). It appears that 2-MeSATP affects its antagonistic 
activity via both P2Yi and P2YAc receptors, although the activity via P2Yi is certainly 
much less than P2YAc, thus apparently showing less effect on the increase in [Ca2+]i 
which is mediated via the P2Yi receptor than on aggregation.
Needless to say, the development of selective antagonists for P2Yi and P2YAc, is crucial 
to characterize further each of the multiple ADP receptors on platelets and to confirm 
pharmacologically the current model for ADP-induced platelet activation. Ticlopidine 
and ARL compounds are known to inhibit selectively the ADP-induced inhibition of 
adenylate cyclase activity in platelets (P2YAc receptor), but unfortunately there is a 
limitation to the use of these compounds to investigate P2YAc receptors because 
ticlopidine is only active in vivo and ARL compounds are not commercially available. 
A3P5PS which has been recently reported as a P2Yi receptor-selective antagonist was
156
useful to delineate the role of multiple ADP receptors in the present study. It inhibited 
ADP-induced aggregation, shape change and increase in [Ca2+]i, but did not affect the 
inhibition of adenylate cyclase activity, confirming that the former responses are 
mediated via the P2Yi receptor, but not the adenylate cyclase activity. Although this 
compound has been found to be degraded very quickly and to act through non-P2Y 
receptors depending on tissue type (Bultmann et al., 1998; Park et al., 1998), it is still 
suitable for use in platelets as the major degradation product, A3P5P, acts in very similar 
way to A3P5PS itself (Boyer et al., 1996).
The washing process can affect any receptors on platelet membranes in two possible 
ways; by desensitizing the receptor and by loss of plasma. Removal of plasma is the aim 
of washing, avoiding any complicating effect caused by any factors in plasma on 
assaying the agonist or antagonist activity on platelet activation. It is interesting that three 
compounds which showed differential effects on aggregation and shape change of 
platelets in chapter 2 also affect platelet aggregation to different extents depending on 
whether the platelets are washed or in plasma. ADP analogues which show similar extent 
of effects on platelet aggregation and shape change as agonists apparently have similar 
affinity for both P2Yi and P2YAc receptors. In this case, even when the P2Yi receptors 
are desensitized by washing, the response can be complemented by the activity of the 
P2YAC, because the full expression of platelet aggregation depends on both receptors on 
platelets. However, ADPaS and ADPpS have much higher agonist potency on the P2Yi 
receptor than on the P2YAc receptor, so that the desensitized P2Yi receptors in washed 
platelets result in a reduced extent of aggregation compared to platelets in plasma. These 
results fit in with the suggestion that both P2Yi and P2YAc receptors are involved in 
inducing full expression of aggregation in platelets (Jin and Kunapuli, 1998; Hechler et 
al., 1998a). However, the way in which 2-MeSATP shows a different extent of inhibition 
of ADP-induced aggregation between washed platelets and platelets in plasma might be 
different from the mechanism for ADPaS or ADPpS. The comparison of inhibition of 
ADP-induced aggregation by 2-MeSATP in washed platelets and in platelets in plasma 
suggests that the multiple ADP receptors which mediate aggregation and shape change, 
might be affected differently by washing so that any analogues which have differential
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affinity for each ADP receptor can affect the aggregation with different extent between 
washed platelets and platelets in plasma. In plasma-resuspended washed platelets, the 
extent of inhibition of ADP-induced aggregation by 2-MeSATP was very similar to that 
in platelets in plasma, suggesting there might be a certain role for plasma in ADP- 
induced aggregation in the presence of 2-MeSATP. Further investigation is required 
using another P2YAc-selective antagonist which is structurally related to 2-MeSATP in 
order to confirm that the presence of plasma in washed platelets compensates for the 
inhibition of the P2YAc receptor and restore the ability of the P2Yi receptor alone to 
induce platelet aggregation.
In conclusion, all the studies presented here provide further support for the current model 
for ADP-induced platelet activation involving firstly the ‘P2Y f receptor coupled to Gq, 
mediating mobilization of Ca2+ from intracellular stores through activation of PLC, 
secondly, the £P2YAc’ receptor coupled to Gi, mediating inhibition of stimulated 
adenylate cyclase, with both P2Yi and P2YAc receptors being required to cause full 
expression of aggregation of platelets. The current model includes a third receptor, the 
‘P2XF receptor, which mediates rapid Ca2+ influx and normally is desensitized in 
experimental conditions, but the studies presented here provides no information on the 
role of this receptor in platelet activation. Although the P2Yi receptor alone can induce 
shape change and increase in [Ca2+]i, the contribution of P2YAc receptor is necessary for 
platelet aggregation. There is an example of a patient who presents a severe deficiency of 
ADP-induced platelet aggregation but in whose platelets P2Yi receptor is expressed and 
normally functional, adding further evidence for involvement of adenylate cyclase- 
coupled P2YAc receptor in ADP-induced platelet aggregation (Leon et al., 1999). Also, it 
has been reported that the platelets of P2Yi-deficient mice partially aggregated at higher 
concentrations of ADP and the ability o f ADP to inhibit cAMP was not altered by the 
lack of P2Yi receptor, indicating that platelets express at least one additional ADP 
receptor (Fabre et al., 1999).
Additionally, the effects of platelets on vascular smooth muscle cells were investigated in 
a preliminary study. Platelets interact with the blood vessel wall, adhering and
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degranulating where the endothelial lining is damaged or lost and affecting the 
underlying smooth muscle cells, and this is considered to be a major event in the 
development of restenosis after angioplasty as well as in the development of 
atherosclerotic lesions (Ross, 1988a,b). The aim of present study was to see how 
activated platelets and platelet-derived products affect the proliferation of human vascular 
smooth muscle cells at the cellular level. For this purpose, [3H]-thymidine incorporation 
into human saphenous vein vascular smooth muscle cells in response to activated 
platelets or to released products from platelets PDGF, ADP and ATP, was measured. 
Also, phosphoinositide hydrolysis by the smooth muscle cells was measured to see if the 
phosphoinositide signaling pathway is involved in the smooth muscle cell proliferation. 
The fact that the proliferative effects of ADP or ATP and PDGF were greater when they 
were administered together compared to their effects alone suggests that the proliferation 
of smooth muscle cell is modulated by interaction of multiple substances derived from 
platelets. The results of phosphoinositide hydrolysis show that phosphoinositide turnover 
does not contribute immediately to the effect of aggregated platelets on smooth muscle 
cell proliferation. That platelets could inhibit the smooth muscle cell proliferation at 
higher concentration means that the platelet-derived products include inhibitory 
substances for smooth muscle cell proliferation such as TGF-|3 as well as stimulatory 
ones. So, platelet-mediated modulation of smooth muscle cell proliferation does not 
result only from the platelet factors which have an ability to stimulate the proliferation, 
but the platelet factors which limit smooth muscle cell proliferation also contribute. 
However, the precise role of platelets in controlling smooth muscle cell proliferation is 
not frilly understood yet. Further investigation of the role of platelets in the control of 
smooth muscle cell proliferation and even differentiation may provide a better 
understanding of the development of atherosclerosis and aid development of novel 
therapeutic approaches to control excessive smooth muscle cell growth.
In conclusion, understanding of ADP-induced platelet activation pathway is important for 
a therapeutic goal, being a target for new antithrombotic drugs. To pursue this goal, the 
P2Yi receptors on other type of cells, e.g. smooth muscle cells, endothelial cells, as well 
as on platelets, should be considered. Also, the further characterization of the P2YAc
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receptor, including cloning of its gene, and identifying its location, remains to be done for 
complete understanding of the mechanism of ADP-induced platelet activation.
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